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Abstract 
Several series of new ferrocenyl-quinoline antimalarial agents have been synthesised and fully 
characterised using standard spectroscopic and analytical techniques. The molecular structure 
of N-(7 -Ch loro-q uinolin-4-yl)-N'-[2 -( Nil, N"-d imethylaminomethyl)ferrocenylmethyl]-ethane-1.2-
diamine has been determined by x-ray crystallography. 
N-(7 -Chloro-q uinolin-4-yl)-N'-[2-( Nil, N"-dimethylaminomethyl)ferrocenylmethyl]-al kyl-1 ,n-diam ine 
compounds were made where n = 2-6. These compounds contain a reactive secondary amine 
centre through which derivatisation to form aryl urea and aryl sulfonamide compounds was 
achieved. 
Complexes of the types: triphenylphosphine(L)gold(l) nitrate, pentafluorophenyl(L)gold(l) and 
chloro(cyclooctadiene)(L)rhodium(l) have been synthesised (where L = chloroquine, ferroquine, 
N-(7 -chloro-q uinoli n-4-yl)-N'-[2-( Nil, N"-dimethylaminomethyl)ferrocenyl methyl]-ethane-1 ,2-
diamine, 3-benzyl-1-[2-(7 -chloro-quinolin-4-ylamino)-ethyl]-1-[2-(N",N"-dimethylaminomethyl)-
ferrocenylmethyl]urea). 
All compounds have been evaluated against chloroquine sensitive and chloroquine resistant 
strains of Plasmodium falciparum. In most cases good activity was found in both strains of the 
paraSite. 
N-(7 -Chloro-q u inol in-4-yl)-N'-[2 -( Nil, N"-dimethylam inomethyl)ferrocenyl methyl]-alkyl-1 ,n-d iamine 
compounds have been made where n = 2-6. It was found that in vitro efficacy against P. 
falciparum diminished with increasing spacer length. The introduction of the aryl urea mOiety 
served to influence efficacy towards P. falciparum and toxicity towards mammalian cells. In 
some cases the toxicity was significantly reduced accompanied by an improvement in efficacy. 
The coordination complexes where L = chloroquine showed improved efficacy in the 
chloroquine resistant K1 strain of P. falciparum. In the heterobimetallic complexes, the ligand L 
showed equivalent or better in vitro efficacy than the coordination complexes of L against both 
chloroquine sensitive D10 and chloroquine resistant K1 strains of P. falciparum 
Preliminary structure-activity studies were carried out on some of the prepared compounds. 
Phenylene analogues of some of the ferrocenyl compounds have been synthesized and it was 
found that the analogues show similar in vitro efficacy to each other in both chloroquine 
sensitive 3D7 and chloroquine resistant K1 strains of P. falciparum. The presence of a 
ferrocenyl moiety in the side chain of chloroquine analogues appears to have a synergistic or 
additive effect on in vitro efficacy. 
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Infra-red spectroscopy (IR) 
br broad band 
m medium band 
s strong band 
v very strong band 
w weak band 
v-s ymmetric stretch 
v-as asymmetric stretch 
o-s symmetric bend 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
A 
Ar 
8 
d 
dd 
iVC 
m 
U 
S 
signal arises from amide or amine group 
signals arise from aromatic group (usually quinoline) 
signals arises from phenylene group 
doublet 
doublet of doublets 
quaternary carbon atom 
multiplet 
signals arise from urea group 
signals arise from sulfonamide group 
triplet 
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Chapter 1 
Introduction 
This project describes the development of new monometallic and heterobimetallic compounds 
as antiparasitic agents. It is necessary to establish a foundation for this project in this chapter. 
Essentially, this foundation requires the development of some understanding of the problems 
faced in the treatment of parasitic diseases today, in particular malaria. In addition to this, it is of 
interest to look at the development of the use of organometallic compounds and coordination 
complexes in medicine. 
Malaria 
Malaria has been one of the major health problems faced by humanity throughout recorded 
history.l It is purported to be the number one killer of people after natural causes2 Even today, 
with the advances of modern medicine, between 400 million and 600 million people are 
diagnosed with the disease annually, resulting in 1.5 to 2.7 million deaths per annum. 1 This 
approximates to three deaths every minute.2 The problem is most prevalent in sub-Saharan 
Africa, where over 90% of the cases of the disease are reported, the majority of which occur in 
young children. 3 It is estimated that two billion people are at risk of contracting malaria.4 
Malaria, also known as 'marsh fever' has long been associated with wetlands. 5 Initially it was 
thought that exposure to the miasmata that rose from swamps and marshes caused the 
disease. The name 'malaria' is, in fact, derived from the Italian for 'bad air,.6 It was only in 1880 
that Alphonse Laveran discovered the parasitic causal agent.5 Sir Ronald Ross established the 
role of mosquitoes in the transmission of the disease shortly before the turn of the century some 
twenty years later.6 
Four species of the Plasmodium parasite are responsible for causing malaria in humans, 
namely, Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae and Plasmodium 
ovale. 5 Of these P. falciparum accounts for up to 90% of the fatalities7 and is the prevalent 
species in sub-Saharan Africa. 2 
In the 1950's and 1960's there was a massive drive to try and eradicate malaria worldwide, 
following the successful eradication of the disease in the United States. This effort resulted in 
the reduction of those potentially at risk to 10% of the world's population.8 Essentially, the main 
idea was to destroy the vector, the female Anopheles mosquito, by the use of DDT and other 
insecticides. Unfortunately, this program was thwarted by financial constraints and the lack of 
trained personnel in affected areas. At the same time, insecticide resistant mosquitoes began to 
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Chapter 1: Introduction 
emerge.' In addition to this, there was mounting evidence of the emergence of the development 
of resistance to chloroquine in some strains of the parasite. 9 Today, malaria is dearly on the 
increase with as much as 40% of the world's population living in so-called 'malaria areas's and 
the efficacy of the current antimalarial drugs is diminishing.'o It is estimated that the annual cost 
of the problem to developing countries is in excess of US$ two billion 8 
In order to understand some of the current chemotherapies of the disease it is necessary to look 
at the life cycle of the parasite. 
Life Cycle of the Parasite 
In order to survive and propagate, Plasmodium parasites require two organisms, the human 
host and the mosquito vector. The parasite undergoes various changes in the bodies of both 
species. The mosquito is unaffected by the presence of the parasite, while humans suffer chills, 
shaking and bouts of intense fever. 1 As treatment of malaria deals only with the parasitiC 
presence in the human host, only this section of the life cycle is of interest with regard to the 
topic of this thesis. 
... 
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Figure 1: A representation of the life cycle of the malarial parasite" 
Sporozoites present in the saliva of a carrier mosquito are injected into the human host when 
the mosquito inserts its proboscis into a human. These travel through the blood stream to the 
liver where they rapidly divide forming tens of thousands of merozoites, which are released into 
the bloodstream again after a period of 7-14 days. The merozoites invade red blood cells and 
again undergo rapid multiplication until the red blood cell bursts, releaSing more merozoites into 
the blood stream. These then invade more red blood cells and the cycle continues . The release 
of the merozoites into the blood stream precipitates a massive immune response, which results 
in an intense fever.' The blood stages of the cycle comprise the ring forms, trophozoites and 
blood sch izonts.'1 
2 
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Chapter 1: Introduction 
Treatment 
The first treatment for malaria in Western medicine was a fine powder made from the bark of 
the cinchona tree. It had been used by the Inca civilisation and was brought back to Europe by 
Spanish Jesuits in 1638.12 Quinine 1, Figure 2, was isolated from the cinchona tree bark in 1820 
and was used as an antimalarial agent.4 Shortly thereafter, the commercial growth of cinchona 
trees started in the islands of the South Pacific.6 Selective breeding of the trees resulted in an 
improvement of the quinine content of the bark of up to 13%.4 The structure of quinine was 
determined in 1908.13 Quinine is not considered to be a 'cure' for malaria because its toxicity to 
the parasite is limited to certain periods of the life cycle of the parasite. 12 Whilst quinine is still an 
effective antimalarial, it has a bitter taste6 and can have severe side effects, which make it 
unsuitable for prophylaxis or use in routine treatment. 4 
Ho~H 
/O~~"!J 
UN) 
1 
Figure 2: Structure of Quinine (1) 
The blockade of Germany by the Allied forces cut off supplies of quinine during World War I and 
thus, precipitated research into the development of synthetic analogues of this drug. 13 The 
production of analogues was favoured as the total synthesis of quinine has proved to be rather 
complicated. The first complete stereoselective synthesis of quinine was only published in 
2001.14 Pamaquine 2 was released in 1932 and quinacrine 3 in 1933, 13 but it was not until 
World War \I that widespread use of the synthetic drugs gained favour as supply of cinchona 
bark was cut off from the Allies by the Japanese presence in the South Pacific. 13 
HN~C 
r7N~) 
~o/ 
2 
HN~C 
I (Y~O, CI~N~ 
3 
Figure 3: Pamaquine (2) and Quinacrine (3) 
Today, there are several classes of antimalarial drugs. 1 Chloroquine 4, primaquine 5 and 
mefloquine 6, Figure 4, are all basically quinine analogues falling within the group of quinoline 
antimalarials. 15 They are thought to have similar modes of action and target the blood stage of 
the parasite i.e. the merozoite. Another class of antimalarials are the antifolate drugs which 
3 
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Chapter 1: Introduction 
prevent the parasite from metabolizing human folic acid, which is necessary for its 
reproduction. 1 The major problem is the development of resistance to the drugs in the parasite.4 
Whilst it is unlikely that any single strain of the parasite will exhibit multiple drug resistance, the 
use of combination drug therapies can be expensive.1 
HN~(---./ 
~ CI~I'JJI 
4 
F 
6 
HN~NH2 
~N~ VJo/ 
5 
Figure 4: Chloroquine (4), primaquine (5) and mefloquine (6) 
There remains much debate as to the mechanism of chloroquine resistance. The focus of this 
thesis has been the development of new compounds that have the potential to act as 
antimalarial agents. If the results obtained herein aid to the understanding of drug resistance in 
the malarial parasites by those better schooled in that particular avenLJe of research it is 
fortuitous. Therefore, it is not within the bounds of this thesis to discuss the varying theories of 
how chloroquine resistance occurs. 
f3-Haematin Inhibition 
Despite the widespread use of 4-aminoquinolines as antimalarial agents, the mode of action of 
this class of drugs has not been unambiguously determined although much research has been 
carried out in this area. 16 There is some debate as to whether their action occurs in the cytosol 
or in the food vacuole of the parasite. Arguments can be made for both extravacuolar17 and 
intravacuolar18 activity of these drugs. 
In 1964 it was suggested that the target of chloroquine could be haematin. 19 In the blood stage 
of the P. fa/ciparum life cycle, haemoglobin is used as the food source for the parasite.2o The 
parasite has enzymes which break down the protein,21 and the haem is autooxidised to 
haematin (aquaferriprotoporphyrin IX, H20-Fe(III)pPIX), this substance is potentially toxic to the 
parasite22 and is converted to haemozoin.7 ~-haematin is the synthetic form of naturally 
produced haemozoin and it has been shown that this substance comprises dimeric subunits of 
ferriprotoporphyrin IX (Fe(III)PPIX) which then combine to form a polymeric chain.23 The mode 
4 
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of formation of haemozoin is still unclear although some in vitro evidence indicates that it may 
be a kind of biomineralisation process.24 
Whilst, the mode of action of chloroquine and other 4-aminoquinolines has not been specifically 
determined, it is known that some of these compounds, most notably, the 4-amino-7-
chloroquinolines, inhibit the formation of ~-haematin.25 This inhibition can easily be monitored by 
infrared spectroscopy as ~-haematin has characteristic bands at 1660 and 1210 cm-\ which are 
not observed if the synthesis of ~-haematin is attempted in the presence of chloroquine. 16 In 
addition to this, there is accumulation of the 4-aminoquinolines in the food vacuole of the 
parasite which has been directly related to the antimalarial activity of these compounds. 26 
The characteristic features necessary for the inhibition of ~-haematin formation by 4-
aminoquinolines has been well established, and there does appear to be a correlation between 
~-haematin inhibition and in vitro efficacy against chloroquine sensitive strains of P. fa/ciparum. 27 
However, it is notable that other compounds having completely different structures such as 
octahedral amine phenol complex of gallium(III), [{1,12-bis-(2-hydroxy-3-methoxybenzyl)-
1,5,8,12-tetraazododecane}gallium(III)], has also been shown to inhibit the formation of ~­
haematin.2B Similar activity has been observed with a ferrocenyl artemisinin derivative.29 
Other Parasitic Diseases 
There is evidence to suggest that compounds that are found to be active antimalarials can also 
exhibit efficacy against the causative agents of other parasitic diseases,3o for' example, 
Leishmania spp., Trypanosoma brucei spp. and Trypanosoma cruzi. Whilst there are several 
classes of parasitic diseases, defined by the causative agent,2 the main focus here is on 
protozoan diseases. The aforementioned protozoa cause Leishmaniasis, African Sleeping 
Sickness and Chagas' Disease respectively. 
Leishmaniasis is a broad term covering a group of vector-borne diseases caused by parasites of 
the genus Leishmania. It is transmitted through female phlebotomine sand flies. 31 There are 
various forms of the disease which have varying degrees of severity. The most severe form, 
visceral leishmaniasis, is fatal and is caused by members of the L. donovani species.2 
Leishmaniasis is essentially a tropical disease, and over 90% of cases of visceral leishmaniasis 
are reported in India, Bangladesh, Nepal, Sudan and Brazil. 31 
Chagas' Disease is the South American form of Trypanosomiasis. It is caused by parasites of 
the species Trypanosoma cruzi. 2 It is transmitted by reduviid insects commonly known as 
'kissing bugs,.32 The disease has an acute phase, which may cause fatalities especially in 
children, but its chronic effects may last decades before resulting in organ failure or the onset of 
cancer.2 
5 
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are responsible for human infection, Trypanosoma brucei gambiense and T. b. rhodisiense. The 
former is prevalent in Central and West Africa and results in a more chronic illness, whilst the 
latter, found in Southern and East Africa causes a far more acute infection.2 The disease can be 
cured if diagnosed and treated in time, but the neuronal damage caused by the disease will 
prove fatal if left untreated.32 
Leishmaniasis, Chagas' Disease and African Sleeping Sickness are all related diseases, as the 
causative agents fall in the same broad class of flagellate protozoa known as 
sarcomastigophora. 2 These protozoa share a common enzyme called trypanothione reductase 
which functions in much the same way that glutathione reductase does in humans. When a cell 
undergoes oxidative stress it produces peroxides which are highly reactive species, unless the 
cell finds a way to break these down they will kill the cell. Glutathione reductase facilitates the 
breakdown of peroxides in humans.33 
R-OOH + GluX-Cys'Gly 
I 
SH 
.. 
G1uX-Cys 'Gly 
I 
S 
I 
S 
I 
GluX-Cys'Gly 
Glutathione Glutathione disulfide 
+ H20 
Scheme 1: Mode of action of glutathione reductase34 
+ ROH 
Trypanothione reductase is therefore a good enzyme to target. If it is possible to inhibit the 
enzyme activity the cell will die, and as the enzyme is present and virtually identical in the 
causative agents of all three diseases, a molecule capable of inhibiting this enzyme could 
potentially be a curative agent for all these diseases. 
GSSR 7 T[S]z 8 
Figure 5: Structures of glutathione disulfide (7) and trypanothione disulfide (8)35 
Whilst the function of glutathione reductase and trypanothione reductase are analogous in 
human and parasite respectively, there is a fundamental difference between the two enzymes. 
Human glutathione reductase is incapable of processing trypanothione disulfide 8 and parasite 
trypanothione reductase is incapable of processing glutathione disulfide 7. This indicates the 
possibility of selective inhibitor design for trypanothione reductaseas The aim then is to achieve 
6 
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a molecule that has high inhibition on trypanothione reductase, but very little effect on the activity 
of glutathione reductase. It is known that the active site of glutathione reductase carries a 
positive charge and is smaller than the active site of trypanothione reductase which carries a 
negative charge. The presence of a protonable nitrogen in a potential drug could aid its 
selectivity for trypanothione reductase. In addition to this, as shown in Scheme 1, the whole 
mechanism of the enzyme is based on a series of redox reactions. The question then arises as 
to whether the presence of a redox active moiety in the drug molecule could interfere with this 
process, especially in vivo. 
The Use of Metals in Chemotherapy 
Metal containing compounds have been used for aeons in traditional medicines for a wide 
variety of complaints. 36 Much of this traditional knowledge was forgotten and no longer in use by 
the late nineteenth century. This coupled with the development of the Food and Drug 
Administration in the late 1800's resulted in less emphaSis on metallo-drugs. Interestingly, one 
of the important factors in the development of the FDA was the egregious abuse of malarial 
remedies. Vendors of quinine-containing cinchona bark powder were mixing the powder with 
alum and clay masked poor wheat powder, amongst other things, to improve their profit 
margin.3? The development and growth of the FDA was, of course, necessitated by the passing 
of the Food and Drugs Act in June 1906.38 Whilst the Act only holds legal standing in the United 
States of America, most countries acknowledge the need for such regulation and have 
developed similar legislation. So, over the last century, there has been a move towards more 
stringent control on the use of substances as medicines. This resulted in the domination of the 
pharmaceutical industry by organic compounds for most of the twentieth century.3S 
The earliest metallo-drugs include iron complexes used in the treatment of hypochronic 
anaemia caused by iron deficiency40 However, the fortuitous discovery of the inhibition of cell 
division by cis-diamminedichloroplatinum(lI) 9, Figure 6, in 196541 and the subsequent discovery 
of the inhibition of tumour growth by the same complex42 stimulated much interest in the field of 
bioinorganic medicinal chemistry. Cisplatin and its analogues have since become the most 
successful drugs for the treatment of testicular and ovarian cancers40 
H3N1', ",CI 
""pr"" 
H3N/ "CI 
9 
Figure 6: Structure of cisplatin (9) 
The use of both organometallic and coordination complexes in a wide variety of medical 
applications has increased significantly in recent years. The use of such compounds covers two 
broad areas of research, that of bioanalysis and biomedical research. 43 
7 
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Coordination Complexes 
Most metallO-drugs are, in fact, coordination complexes. Prior to the discovery of ferrocene in 
1951, there were no organometallic compounds that possessed sufficient stability to be used in 
medicinal chemistry. Cisplatin, as described above, has been one of the major success stories 
of bioinorganic medicinal chemistry. 
Gold complexes were used in chemotherapy in the 1920's against tuberculosis.44 Later 
auranofin, 2,3,4,6-tetra-O-acetyl-1-thio-,B-glucopyranosato-S-triethylphosphine-gold 10, Figure 7, 
was found to be effective against rheumatoid arthritis. More recently the same drug has been 
found to be active against leukaemia P388.45 The efficacy of auranofin against these diseases 
started a trend of testing numerous gold compounds against a variety of microbial agents.46 
Gold complexes have also been used against such varying disorders as syphilis and 
alcoholism.47 
OAc 
AcO- -0 I~ ~I \ .Au-PEt3 AcO . ~_S OAcl 
10 
Figure 7: Structure of auranofin (10) 
Not surprisingly, the success of metallo-drugs in cancer therapy led to investigation into the use 
of coordination complexes in other areas, including their use as antimalarial agents,48,49 anti-
inflammatories50 and antifungal agents.51 In most cases, the new metallo-drug is simply a 
coordination complex of a transition metal and a known commercial drug. This approach has 
had varying success. For example, coordination of gold to chloroquine, Figure 8, results in a 
marked increase in efficacy in the metal complex relative to the free drug in both chloroquine 
sensitive and chloroquine resistant strains of Plasmodium49 
11 
Figure 8: Structure of [Au(CQ)PPh3]PF6 (11) 
The speciation of coordination complexes in the incredibly complex aqueous medium of the 
human body remains a crucial question.4Q Whilst some work has been done in trying to answer 
this question for various well known commercial drugs, such as auranofin52 and cisplatin there is 
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still much work to be done in this field. When developing a new metallo-drug the question of 
speciation cannot be disregarded. 
This is demonstrated well in the case of auranofin 10 in which it is known that acetate groups 
undergo hydrolysis in acidic media and it has been shown that auranofin undergoes 
deacetylation on passing through everted intestinal walls. 53 Thiol exchange is known to occur in 
vivo to form gold-protein-thiol adducts and the triethylphosphine group can undergo oxidation to 
form triethylphosphine oxides4 The question as to what species are active and responsible for 
the efficacy of the drug therefore arises. One stud/2 showed that gold(l) tertiary phosphine 
complexes were more active than gold(l) thiolates against Pseudomonas putida, suggesting that 
the tertiary phosphine plays a role in the activity of the drug. The speciation of cisplatin has 
similarly been the subject of much study. 
Little is known about the speciation of metallo-antimalarial drugs. The reason for this is primarily 
because they are still essentially an area of academic interest, rather than being a real prospect 
of a commercial drug. As a result, the requirement for knowledge of the speciation is limited and 
the question of speciation therefore remains unanswered. However, the implication from studies 
on other coordination complexes used as drugs indicates that the coordination complex is in fact 
a pro-drug. That means that between administration and reaching the site of action, the metal 
complex undergoes some change in vivo and it is the newly formed species that is the active 
drug. 
Organometallic Compounds 
An organometallic compound must contain at least one direct metal-carbon bond. 55 Many of 
these compounds are sensitive to air and moisture, making their synthesis, isolation and 
characterisation difficult and clearly precluding their use as drugs. 
The discovery of ferrocene in 1951 56 opened a new field of transition metal chemistry than could 
not possibly have been imagined from the paradigm of Werner type coordination chemistry.57 
The structure of ferrocene determined in 195258 showed it to contain iron(lI) sandwiched 
between two TJ 5-cyclopentadienyl rings. The n bonding in ferrocene imparts great stability to the 
structure, subliming at 500°C and remains intact in the presence of strong acids or alkaliss9 
Few coordination complexes exhibit such stability, and up until 1951, it was assumed that no 
organometallic compound of a transition metal could exhibit such characteristics. From a 
biological perspective, it is known that in some ferrocenyl compounds, iron can be released from 
the ferrocenyl moiety in the liver.60 However, it is still quite likely that the drug will reach the site 
of action intact, thereby making ferrocenyl compounds ideal candidates for metallo-drugs. 
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Ferrocene 
In recent years there have been several medicinal applicfltions of ferrocene derivatives. Most 
notable is the work done on ferrocenyl derivatives of known antimalarial drugs.52 It has been 
shown, for example, that the introduction of a ferrocenyl moiety into the side chain of 
chloroquine results in a significant improvement in efficacy against both chloroquine sensitive 
and chloroquine resistant strains of the parasite. Whilst the incorporation of the ferrocenyl 
moiety into such molecules seems to have a positive influence on the efficacy of the drugs, the 
role that this moiety plays in the process has yet to be established. It may be that the ferrocenyl 
moiety itself plays a crucial role, or it may be that it is simply a large hydrophobic group. 
However, there is some precedent for assuming that ferrocenyl moiety itself is important. A 
recent study on the differences in efficacy of tamoxifen 12 and ferrocifen 14 exemplify the effect 
ferrocene can have. 53 Tamoxifen is used in the treatment of breast cancer. It acts as a selective 
oestrogen receptor modulator (SERM), meaning that it competes with oestradiol for the 
oestradiol receptor (ER). There appear to be two different types of oestradiol receptors, a-ER 
and !3-ER, which occur in different cell lines. In cell lines that have the a-ER, there is no 
significant difference in the efficacy of tamoxifen and ferrocifen. They appear to have the same 
mode of action, both fitting into the receptor site in a similar manner with no distortion. However, 
in the cell lines having the !3-ER, against which tamoxifen exhibits limited activity, ferrocifen 
shows good activity. There are a number of possible reasons for this, but it has been suggested 
that the redox activity of the ferrocenyl moiety is crucial. It is also noted that ferrocene by itself 
shows no activity. 
R 
12 R = H; Tamoxifen 
13 R = OH; Hydroxytamoxifen 
14 Ferrocifens 
(n = 2, 3, 4, 5, 8) 
Figure 9: Structure of Tamoxifen (12) and Ferrocifen (14) 
Ferrocene in Antimalarial Chemotherapy 
As mentioned previously the use of ferrocene in antimalarial compounds has proved to be 
successful. Ferroquine 15 was developed using a simple 'bait and hook' approach. It is known 
that Plasmodium has an avidity for free iron. It was postulated that the resistance to chloroquine 
could be overcome by the incorporation of a stable iron moiety into the active drug molecule.64 
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This approach has certainly been effective, with ferroquine exhibiting excellent efficacy against 
both chloroquine sensitive and chloroquine resistant strains of Plasmodium in in vitro and in vivo 
studies.62 
15 
Figure 10: Structure of Ferroquine (15) 
Ferrocene has also been incorporated into other known antimalarials such as mefloquine and 
artemisinin.29 However, the presence of the ferrocenyl moiety does not significantly enhance the 
efficacy of the drugs in question. Furthermore, it appears that the positioning of the ferrocenyl 
moiety in the 4-aminoquinolines is crucial to its efficacy. 
Fe 
~ 
16 17 
Figure 11: Alternative positions of ferrocene in chloroquine derivatives65 
It is interesting to note that 16, with ferrocene attached at the quinoline nitrogen shows a 
significant decrease in efficacy with respect to chloroquine. It has been postulated that the 
quaternisation at the quinoline nitrogen prevents the inhibition of ~-haematin formation normally 
characteristic of 7-chloroquinoline compounds.65 The quaternisation of the qUinoline nitrogen is 
also likely to have a significant effect on the weak base properties of the resultaing drug 
complex. This may adversely effect the cellular accumulation of the drug molecule and thereby 
reduce its efficacy. The efficacy of 17 is also interesting to consider. It is known that chloroquine 
is metabolised in the liver to form monodesethylchloroquine (DECO) and didesethylchloroquine 
(di-DECO).66 
HN~~~ HN~NH2 
~ CI~NJl ~ CI~NJl 
18 DECO 19 di-DECO 
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Compound 17 shows enhanced efficacy with respect to chloroquine in both resistant and 
sensitive strains of Plasmodium in in vitro and in vivo studies. This indicates that despite the fact 
that some of the active drug compound may be metabolised to DECQ 18 or di-DECQ 19, 
enough of the drug remains intact or with removal of the ethyl group rather than the 
methylferrocenyl group to have a significant effect on efficacy. This change in efficacy may be 
attributed to the lipophilicity of the ferrocenyl unit resulting in an increased cellular accumulation 
of the drug.64 
It has been suggested that the ferrocenyl unit must be covalently bound to the rest of the 
molecule in order to display improved efficacy against P. falciparum. 63 It has been observed that 
ferroquine is highly active against a wide variety of strains of Plasmodium spp. even in areas 
where chloroquine resistance is as high as 95% and multi-drug resistance is known. 66 In 
addition to this, there is little evidence of toxicological side effects of ferroquine and oral 
administration of the drug appears to be viable, making ferroquine a good candidate for further 
drug trials. 66 Furthermore, there appears to be no difference in activity of the two enantiomers of 
ferroquine which means that costly chiral resolution of the drug can be avoided. 67 
Preliminary studies into the synthesis, characterisation and biological evaluation of novel 
ferrocenyl sugars indicate that the overall structure of the sugar molecule is important to the 
efficacy of the drug.68 This could imply that whilst ferrocene may have an additive or synergistic 
effect when covalently bonded to an biologically active molecule, it has limited efficacy on its 
own. 
The electrochemistry of ferrocene provides an interesting avenue of research. As implied in the 
discussion on ferrocifen and tamoxifen, ferrocene exhibits a characteristic fully reversible one-
electron wave. This means that ferrocene, r{(C5H5hFe, is oxidised relatively easily to the 
ferrocenium ion, I1s-(C5HshFe+,5s which, in turn, is reduced back to ferrocene. In fact, this 
process is often used as a standard in cyclic voltametry experiments. In the human blood 
stream, P. falciparum use haemoglobin as a food source. The haemoglobin is broken down to 
release amino acids required by the parasite. In the process haem is liberated and the iron of 
the haem moiety is oxidised from iron(lI) to iron(III).8 It is possible that the presence of a 
ferrocenyl moiety in a potential antimalarial drug may have some effect on this process as it is 
capable of undergoing redox reactions. 
There is little doubt that the introduction of ferrocene into the field of bioorganometallic chemistry 
opens the door to several possibilities. However, there is stili a great deal of uncertainty as to the 
role played by the ferrocenyl moiety in the efficacy of these drugs. There is therefore, still much 
scope for research in this area. 
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Aims and Objectives 
It should be noted that the focus of the project has been to develop new compounds that have 
the potential to be antimalarial agents. The first priority has been to synthesise, characterise and 
explore the chemistry of new compounds. For the most part, this has required the adaptation of 
known techniques and synthetic pathways in order to make and isolate new compounds. Most 
of the new compounds developed and characterised were then tested for some form of 
antiparasitic activity. 
The second chapter outlines the rationale used for the development of ferroquine analogues. 
This required the development of appropriate synthetic methodology. 
The third chapter outlines the development of ferroquine analogues containing urea and 
sulfonamide substituents in the side chain. Both classes of compounds have been used in 
antiparasitic drugs in the past, and it was thought that combining them with the active ferrocenyl-
quinoline compo!,lnds would be worth examining. 
The fourth chapter outlines the development of coordination complexes of various 4-amino-7-
chloroquinoline compounds. In particular gold and rhodium were used for complexation, and 
chloroquine and ferroquine analogues were used as ligands. Gold and rhodium complexes of 
chloroquine have been shown to be efficacious against both chloroquine sensitive and 
chloroquine resistant strains of Plasmodium in various in vitro and in vivo studies. 
The fifth chapter deals with the biological evaluation of the compounds detailed in Chapters 2, 3 
and 4. Most compounds were tested for in vitro antiplasmodial activity. A few compounds were 
also tested for in vivo antiplasmodial activity. Some enzyme inhibition assays were also carried 
out on the antioxidative enzyme trypanothione reductase. While some compounds were tested 
against the causative agents of Chagas' disease, African Sleeping Sickness and Leishmaniasis. 
The sixth chapter outlines the synthesis of a series of related compounds designed to determine 
the role of ferrocene in the efficacy of ferroquine and its analogues. The in vitro antiplasmodial 
activity of these compounds was also assessed. 
The seventh chapter gives an overview of conclusions from the work carried out for this thesis 
and suggests avenues for future research arising from this work. 
The eighth chapter is the general experimental section. 
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Ferroquine Analogues 
Introduction 
In this chapter the synthesis and characterisation of novel ferroquine analogues is described. 1 A 
rationale is provided for the synthesis of this class of compounds and the use of a variety of 
possible synthetic routes is discussed. The synthesis of the known compound ferroquine, 15, is 
discussed and the synthetic route actually employed is detailed. Several aspects of the 
characterisation of the compounds are then discussed. This is followed by a brief exploration of 
some of the chemical properties of these compounds, for example, cyclic voltametry. The 
biological activity of these compounds is discussed in Chapter 5. 
Rationale 
Whilst there has been a growing emergence of resistance to chloroquine, small variations in the 
structure of the side chain of 7-chloroquinolines have been shown to overcome this resistance. 
Most noteworthy and relevant to this study is the incorporation of a ferrocenyl moiety into such 
molecules.2,3 These types of compounds have been found to be active against chloroquine 
resistant strains of malaria. The incorporation of the ferrocenyl moiety into other known 
antimalarials has also been successful.4 
It has previously been demonstrated that the length of the methylene spacer between the two 
nitrogen atoms in the side chain of chloroquine has a significant effect on the efficacy of the 
compounds For this reason, it was envisaged that investigation into the determination of the 
effect of introducing methylene spacers of various lengths into the side chain of ferroquine was 
a worthwhile endeavour. This led to the design of derivatives 20-24, shown in Figure 1. The 
presence of the secondary amine group in the side chain of 20-24 provides a site for introducing 
chemical diversity which is important for structure-activity studies within this series of 
compounds. 1 
Figure 1: Ferroquine analogues 
n = 2,20 
n = 3,21 
n = 4,22 
n = 5,23 
n = 6,24 
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Possible Synthetic Routes 
1. Reductive amination of 7-chloroquinoline aldehydes and a ferrocene containing amine. 
HNkirCHO 
Clu) + H2N~N/ Fe I ~ 20-24 MeOH 
Scheme 1: Reductive amination from 7-chloroquinoline aldehyde 
This is a simple method from known compounds. The main drawback is that the synthesis of 
the ferrocenyl amine requires a three step synthesis. 2 In total, the process would therefore 
require at least six steps to achieve the synthesis of the desired products (cf option 3). 
2. Displacement of leaving group (L) e.g. iodide or tosylate, by primary amine 
HNk'}L H2N~N/ 
u) + Fe I ~ CI :::::,... :::-"'N ~ 
or 20-24 
HNki-NH2 L~N/ / I 
m + Fe I Q CI :::::,... :::-"'N 
Scheme 2: Use of a Leaving Group, L 
The displacement of a leaving group e.g. iodide or tosylate by the incoming primary amine could 
facilitate the preparation of the required compounds. The leaving group could be incorporated by 
reduction of the relevant aldehyde to the alcohol, followed by substitution of the alcohol group by 
the iodide or tosylate group. The major problem with this route would be over alkylation i.e. the 
secondary amine formed in the first step would readily undergo further alkylation. The reaction 
would, therefore, be difficult to control unless a large excess (4-5 equivalents) of the primary 
amine is used. As all the reagents require initial preparation prior to the reaction and are made 
from starting materials that may not be cheap, the process would be both labour intensive and 
costly. 
3. Reductive amination of 7-chloroquinoline amine and ferrocene carboxaldehyde 
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Scheme 3: 
(ii) NaBH4 
.. 
Reductive amination from ferrocene carboxaldehyde 
20 - 24 
This approach would require a one-step synthesis of both starting materials using known 
methodology.2,s In addition to this, polymer supported borohydride could be used in the 
reduction of the imine to the amine, which could facilitate a simple and quick method of 
preparation of these compounds. This approach had the added advantage that a reduced 
number of steps were required in the synthesis. Although, once again, there were two potentially 
reactive amine centres that could compete, the aniline amine attached to the chloroquinoline 
moiety was deactivated by the mesomeric release of the lone pair of electrons into the 1[ system 
of the chloroquinoline moiety. This is shown in Figure 2 and discussed below. 
(~H2 
elm 
Figure 2: Two of the possible resonance structures of 4-amino-7-
chloroquinoline 25 
4. Use of 4,7-dichloroquinoline and ferrocene amine with methylene spacer 
As shown in Figure 3, if a similar nucleophilic substitution reaction of 4,7 -dichloroquinoline 25 
was attempted in the final step of the reaction, there could be competition between the primary 
and secondary amines present in the ferrocenyl fragment 26. 
The separation of the products, 20 and 27, would ostensibly be fairly simple using silica gel 
chromatography, as the primary amine 27 would have a far greater affinity for the silica gel. 
However, the competition would probably result in lower yields of the desired product 20. The 
conditions of the analogous reaction to form ferroquine2 requires the use of a five fold excess of 
4,7-dichloroquinoline. Given the possibility of the reaction at more than one amine centre, the 
use of an excess of 4,7-dichloroquinoline could result in the formation of a wide variety of 
products. 
19 
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H2N~N~N/ 
m-:Y Fe I ~:-.I~ CI N 
20 27 
F~gure 3: Potential products of formed by using method 4 
Synthesis of Ferroquine Derivatives 
Lithiation of Ferrocene 
The synthesis of the ferroquine analogues required the synthesis of N,N-
dimethylaminomethylferrocenecarboxaldehyde, 30 via ortho-lithiation of the starting material 28 
to give 29 in situ. It is well known that the dimethylamino group has a strongly ortho-directing 
effect in metalation reactions.6 Initially this reaction was carried out as described2 using n-
butyllithium (n-BuLi). A subsequent publication7 detailed the use of tert-butyllithium (t-BuLi) in 
place of n-BuLi. This significantly reduced the reaction time and improved the yield. The 
presence of the lithio-species 29 was easily observed as it formed a bright orange precipitate. 
1/ 
0 N L)J QN/ t-BuLi DMF H~W/ C> ! .. .. C)I 
Fe Et20 Fe Fe Q Q Q 
28 29 30 
Scheme 4: Synthesis of 30 
The difference in the reaction rates between n-butyllithium and tert-butyllithium could result from 
the differences in their structures in solution. In paraffinic or aromatic solvents, the organolithium 
reagents tend to form aggregates. The monomeric species is primarily the species that reacts 
although the dimeric species can also show some activity. The aggregate must, therefore, totally 
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or at least partially break down before any reaction could occur. In diethyl ether at room 
temperature, n-butyllithium exists as a tetramer, whilst tert-butyllithium exists as a dimer. This 
difference in structure can be explained on the basis of the steric bulk of the tert-butyl group 
relative to the n-butyl group. This means that the reaction with tert-butyllithium will be 
Significantly faster, because the deaggregation of the dimer is expected to be more rapid relative 
to that of the tetramer8 The increased rate of reaction using the tert-butyllithium results in a 
higher yield because there is a Significant decrease in reaction time. 7 
In addition to this, the kinetic product appears to be the 1,2-disubstituted product.9 So the 
shorter reaction time reduces the probability of forming either the 1,1'- product or the 
dialdehyde. Furthermore, whilst it cannot be generally stated that a decreased reaction time will 
necessarily result in an increased yield, in this case it holds true because decomposition of the 
product does occur over time. Therefore, if the reaction time can be minimised, the amount of 
decomposition can likewise be reduced thus resulting in an overall improved yield. 
The use of both n-butyllithium and tert-butyllithium resulted in the formation of the 1,2-
disubstituted ferrocene as the major product. There was no obvious evidence of dilithiation or 
the formation of the 1,1 '- derivative. As these species were not the desired product, little time 
was spent on trying to ascertain whether they were forming or not. The preference of the 1,2-
product can be attributed to the stabilising effect of the tertiary amine on the lithiated 
intermediate (Scheme 4). The single carbon linker facilitates and stabilises the formation of the 
1,2-lithiated species which ensures the production of the 1,2-disubstituted ferrocene as the 
major product. It is interesting to note that such preference for the 1 ,2-disubstituted metallocene 
does not extend to the ruthenocene analogues. Work done in our laboratory10 indicates that the 
preference for the production of the 1,1 '-disubstituted ruthenocene over the 1,2- isomer or vice 
versa, can be controlled to some degree by variation of the solvent and base used. 
The ortho-lithio species 29 was reacted in situ with N,N-dimethylformamide (OM F), 11 forming the 
desired product 30 in good yield (84%). The product was characterised using NMR and IR 
spectroscopy and the results compared well with literature results. 2 
Synthesis of Ferroquine 
The synthesis of ferroquine 15 was carried out according to literature procedures.2 
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HN~~N/ 
LiAIH4 .2  I 
THF Fe 
~ 
32 
Scheme 5: Formation of ferroquine from ferrocenecarboxaldehyde 
The conversion of 30 to 32 via the oxime 31, shown in Scheme 5 is relatively straightforward 
and each step has a yield of greater than 95%. The coupling of the ferrocenyl amine 32 to the 
4,7-dichloroquinoline 25 gives 15 in 53% yield. The use of N-methyl-2-pyrrolidinone (NMP) as a 
solvent is necessary to achieve dissolution of the starting materials, but requires numerous 
washings of the organic phase with brine in order to isolate the product. It was found that the 
use of the less dense, ethyl acetate was preferable to dichloromethane because the organic 
layer could then be retained in the separating funnel while the brine is repeatedly added and 
removed. This seemed to have little effect on the overall yield of the reaction, but made the 
work-up far less tedious. It was observed that the yield of ferroquine, 15, was adversely affected 
by the storage of NMP over molecular sieves. 
A five-fold excess of 4,7-dichloroquinoline was used to drive the reaction to completion. The 
possibility of formation of the disubstituted product is unlikely as the presence of the quinoline 
system significantly diminishes the available charge on the newly formed aniline nitrogen due to 
a resonance or mesomeric effect shown in Figure 2. This effect also means that this amine 
centre is unlikely to act as a site of metal co-ordination. This consideration will be elaborated 
upon in Chapter 4. 
Synthesis of Ferroquine Analogues 
It is apparent from Scheme 3 that 4,7-dichloroquinoline required modification to the 
alkyldiamine, before use in the reaction. The formation of the diamines, 33-37 are all simple 
reactions that can be carried out in relatively high yield. The neat 1,n-alkyldiamine is reacted 
directly with 4,7-dichloroquinoline, in the melt, to form the desired products. 12 Reported 
procedures 12 favour the use of ethyl acetate in the work-up, but it was found that 
dichloromethane was more convenient to use. The aqueous layer tended to form an emulsion 
and a better separation was achieved by using the more dense dichloromethane, although this 
had no marked effect on the yield. As the compounds are all primary amines, purification by 
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silica gel chromatography is not an easy option, albeit possible. The presence of the product 
was determined by TLC. The product remains on the base line whilst 4,7-dichloroquinoline 
moves close to the solvent front. The compounds 33-37 were used without further purification. A 
proton NMR spectrum was run on the crude product to ensure the formation of the desired 
product had indeed occurred. This was compared with literature values. 12 
CI 
N) CI~N 
25 
+ 
HCI 
n 2,33,84% 
n 3,34,44% 
n = 4,35,67% 
n = 5, 36, 80% 
n = 6, 37, 89% 
Scheme 6: Synthesis of 7-chloroquinolinyl-1 ,n-alkyldiamines 
It should be noted that in 4,7 -dichloroquinoline, the relative positions of the chlorine atom at the 
carbon 4 position and the quinoline nitrogen is crucial to the leaving group ability of this chlorine 
atom, Scheme 7. The quinoline nitrogen acts as an electron 'sink' which allows the nucleophilic 
attack of the incoming amine at the closer carbon 4. The resulting resonance stabilisation and 
proximity of the 4-chloro to the quinoline nitrogen are a major driving force. There is absolutely 
no competition from the chlorine atom at the 7 position in this reaction. Substitution at the 7 
position, though possible, requires specialised conditions, such as palladium-catalysed 
aminations with appropriate catalysts. 
Scheme 7: Attack of 4,7 -dichloroquinoline by primary amine 
Having made the required 7-chloroquinoline-1,n-alkyldiamines, the reductive amination with 
ferrocenecarboxaldehyde, 30, could then be carried out, Scheme 8. Initially it was hoped that the 
work-up and isolation of the product could be simplified by using polymer supported borohydride 
to reduce the imine Schiff base. However, despite the use of the polymer supported reagent it 
was still necessary to purify the product by silica gel chromatography. Sodium borohydride was 
then used as a reducing agent as there was deemed to be no real advantage to using the 
polymer supported reagent. 
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MeOH 
+ 
33 
Scheme 8: Synthesis of 20 
The synthesis of the ferroquine analogues was achieved in moderate yield . It was found that the 
yield was improved by using freshly prepared ferrocenylcarboxaldehyde. The compounds were 
all fully characterised using standard methods. The results were compared as far as possible 
with known compounds e.g. ferroquine2 and 7 -chloroquinoline-1 ,n-alkyldiamines 12 in order to 
validate their structures. 
Chirality 
At this point, it is important to establish the fact that 1,2-disubstituted metallocenes are chiral. 
They exhibit planar chirality and are subject to a modification of the (R, S) nomenclature. The 
ferrocenyl moiety is viewed from above along the Cs axis whereby the disubstituted ring is 
uppermost. In moving from R to R' in a clockwise direction through the smallest possible angle, 
if R' has a lower priority than R, the metallocene is deSignated R configuration. If R' has a 
greater priority than R, the metallocene is designated S configuration .13 
Figure 4: Illustration of assignment of stereochemistry of compounds 
exhibiting planar chirality 
Ferroquine analogues are therefore chiral. The method of preparation outlined above results in 
the formation of the racemate. The racemate can be resolved using L-tartaric acid. Both 
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ferroquine 15 and 20 were resolved in this manner to form the respective tartrate salts. The 
compounds were characterised by NMR spectroscopy. 
HN~N/ OH 0 
m-:?" Fe I 2. H°0rOH ~ ~ I ~ 0 OH CI N 
Figure 5: Tartaric acid derivative of 15 
X-ray Crystal Structure 
The crystal structure of 20 has been determined. The compound crystallises in the monoclinic 
crystal system with a P2 1/c space group. There are four repeating units per unit cell. As implied 
by the space group, the crysta~ structure of 20 was determined as a racemate. 
Figure 6: ORTEP diagram of 20 
The distances from the iron to the centre of the Cp rings are not equal (1 .643 and 1.652 A) with 
the shorter bond to the substituted Cp ring . However, this slight difference is unlikely to be of 
significance. The crystal structure confirms the ortho-substitution of the Cp ring . The position of 
the unsubstituted ring is well defined in this structure, this means that it occupies the same 
eclipsed orientation throughout the crystal lattice (Figure 6) . There is one strong intramolecular 
hydrogen bond between N4 of the tertiary aliphatic amine and the H1 atom of the secondary 
amine with an N .. ·H bond distance of 2.190(4)A. There is an intermolecular hydrogen bond 
between the H2 of the secondary amine and N1 of a neighbouring molecule, resulting in 
hydrogen bonded dimers (Figure 7). The angle of this intermolecular hydrogen bond is 160°. 
There is a weaker intermolecular hydrogen bond between the quinoline Nand H17 belonging to 
a neighbouring quinoline ring (N3" 'H17, 2.419(4)A). 
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Figure 7: Hydrogen bonded dimers of 20 
Figure 7 shows the hydrogen bonding between the two enantiomers of 20 to form a loosely 
associated dimer. The dimers then pack together as shown in the packing diagram Figure 8, to 
give four molecules per unit cell . 
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Figure 8: Packing diagram of 20 
NMR Spectroscopy 
All compounds were characterised using 1H and 13C NMR spectroscopy and assignment of 
peaks was facilitated by use of COSY and HSQC two-dimensional NMR spectroscopy. The full 
detail of the NMR data can be found in Chapter 8. The x-ray crystal structure of 20 was crucial 
to the interpretation of the NMR data. As the structural conformation was known, any ambiguity 
in the assignment of the data arose from the inability to distinguish between similar signals and 
not from different possible structural conformations. 
1H NMR Spectroscopy 
The proton NMR data of ferroquine is consistent with literature values.2 The proton NMR data of 
the ferroquine analogues that we have prepared is also consistent with literature values for 
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similar compounds i.e. ferroquine2 and other related chloroquinoline derivatives,12 in as far as 
reasonable comparison could be made. 
The chirality of these molecules is clearly evident in the 1 H NMR spectra, Figure 9. For example, 
if one considers the diastereotopic 2' protons this is demonstrated as follows: in a non-chiral 
environment the two protons would appear as a singlet. In these compounds there are two 
signals separated by a chemical shift of 1 ppm. This is because the environment above and 
below the plane of the cyclopentadienyl ring is different, as one proton will be in close proximity 
to the iron centre, whilst the other will not. These protons are therefore diastereotopic and 
couple to one another. Hence the two signals are both doublets having a coupling constant of 12 
- 13 Hz. The 3' protons show similar behaviour. 
The 3' protons in the ferroquine analogues show a significant upfield shift with respect to 15. 
This is consistent with the fact that in 15 the electron density on the adjacent aniline amine is 
reduced by the partial incorporation of the electrons on the nitrogen into the quinoline ring. This 
results in a deshielding of the 3' protons and hence in 20, 3'a and 3'b appear at 4.09ppm and 
4.35ppm respectively. In the ferroquine analogues there is some variation in the positioning of 
the 3' protons, but they consistently appear below 4ppm. 
The quinoline protons of all compounds, 20-24, occur in expected positions with regular 
coupling patterns. The alkyl protons adjacent to amine centres are observed downfield relative 
to those in the centre of the alkyl chain as would be expected. 
2 
'I 
N 
CI 
3 
H 4' 3' 2' 
N~N~~N/ 
5' H ~ I 
5 Fe 
~ l' 
Cp' 
Cp' 
l' 
3'a 3'b 4' 
12'a 15' I 2'b 
~~,--L~~I.~_l __ J~ ___ --"-".v ."-fiUUJ"--J~" 
5 8 6 3 NH 2 Cp 
I I I I ' . : I I I I j i ll 
8 .5 8.0 7.5 
I I I 
7.0 
I I J , i ! . ! ~ , I ! 
6.5 6.0 5.5 5.0 · 4.5 4.0 3.5 
Figure 9: 1H NMR spectrum of 20 in CDCI3 
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The lH NMR spectra of the resolved salts showed a distinct shift in the 2' protons from 3.80ppm 
and 2.89ppm to approximately 4.2ppm. The l ' protons, normally observed as a 6 proton singlet, 
split into two 3 proton singlets, so 1 'a and 1 'b become distinguishable. This is seen quite clearly 
in Figure 10. 
2' 1'a 
HN~N/ 
m~ Fe 11'b ~ ~ I~ CI N 
OH 0 1'a1 'b OH 
HO 1...,. Jl 
2. Y I' -OH 
o OH 
I II j 11'11' I i i I ii 1' 1 j ' I ' l l I j I I I I I I I I I t i ! I I ) Ii 1, , I i " i i' I j i I i I' i l ' iii' i i i i I i 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 
Figure 10: 1H NMR spectrum of the resolved L-tartrate salt of 15 
13C NMR Spectra 
The carbon-13 NMR data for compounds 20-24 found to be was consistent with data found in 
the literature for similar compounds,2 in as far as reasonable comparison could be made. Figure 
11 shows the 13C NMR for 20, the only changes on increasing spacer length was the increment 
of one signal below 50ppm for each additional methylene group. It appears that the chemical 
shifts of carbon signals are far less susceptible to shielding and deshielding as there is little 
change in the positions of any of the signals irrespective of the length of the carbon spacer. 
HSQC was an invaluable tool in the assignment of the spectra. It was most useful for the 
unambiguous assignment of 2' and 3' protons, and assignment in the aromatic region. 
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2 3 b," 4 3 2 N N~N~N/1 Cp' 
5' H I 
8 f ~ 5 Fe l' 
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2 8 6 5 3 CI Cp 2' 3' 5' 
4' 
I, I J I I 1 
ill , , , 11 , II , ,. It , il l 
' ''I' ""I"" I" 'I I i ( III II i i i i I II, Ii I I Ii i ill i 111 111 I , Iii , , , , , Ii Ii " I , Ii 11111 IIIII III[ fl , I I I II Ifl 
1~ 1~ 1~ 1m 110 100 90 00 ro 00 ~ ~ 
Figure 11: 13C NMR Spectrum of 20 in CDCI3 
Mass Spectrometry 
High resolution mass spectrometry (HRMS) was used principally to determine and confirm the 
accurate molecular mass of the compound. In all cases the accurate mass of the parent ion was 
determined within acceptable limits of error. In addition to this, the isotopic distribution of the 
parent ion was checked to determine whether it was consistent with calculated values . 
Furthermore, some attempt was made to ascertain the identity of the major fragments given that 
the structure of 20 was known. All these factors were used simply to determine whether the 
propose~ compound had been formed or not. Together, these data provided further support that 
the desired compounds had indeed been successfully synthesised. 
Infrared Spect roscopy 
As with mass spectrometry the infrared spectra were very complex and it was not possible to 
assign all the absorption bands unambiguously. Some groups present in the molecules exhibit 
characteristic absorption patterns that were relatively easy to identify. For example, the 
presence of the ferrocenyl moiety may be ascertained by four clear bands at 1104, 1000, 830, 
490 cm-1. The 7 -chloroquinoline moiety similarly showed three characteristic strong bands at 
approximately 1610, 1580 and 1540 cm-1. Once again , this technique was used simply to 
confirm the proposed structures as far as possible and to provide the unique fingerprint for each 
compound. 
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Studies into Activity of the Compounds 
Cyclic Voltametry 
Ferrocene derivatives have been investigated as potential electrochemical probes because they 
are stable and relatively easy to synthesise. 14 
4.E-OS 
~ 3.E·OS 2.E-OS 1.E·OS 
/ O.E+OO :: 
! ·1.E·OS C ~ -2.E·OS " u ) ·3.E-OS ·4.E·OS 
·S.E·OS 
·6.E·OS 
600 400 200 ·200 ·400 -600 
Voltage I mV 
Figure 12: Cyclic voltamogram of ferrocene 
In a cyclic voltametry experiment, ferrocene exhibits a characteristic fully reversible one-electron 
wave, Figure 12. In fact, ferrocene is usually used as the standard for cyclic voltametry. As 
these compounds all contain a sUbstituted ferrocenyl moiety it was of interest to examine the 
redox activity of these complexes. The picture obtained was far more complex than anticipated. 
In general, it is accepted that a fully reversible one-electron wave will have a peak separation 
(L~Ep) within the range of 70-90 mV. Furthermore, it is required that the anodic and cathodic 
peak current values should be approximately the same. This can be seen in Figure 12. 
Table 1: Cyclic Voltametry Data for Ferroquine Analogues 
Compound Epa Epc E1/2a !l.Ep b 
Ferrocene 123 34 79 89 
15 181 113 147 70 
20 150 (30) 120 
21 120 (13) 107 
22 106 (14) 92 
23 92 (12) 80 
24 Indistinct (12) 
a 
-
. 0 
-
Ferroquine, 15, exhibited a fully reversible one electron oxidation but it is far more difficult to 
oxidise than ferrocene, as indicated by the significant increase in E1I2 value. 
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Figure 13: Cyclic voltamogram of Ferroquine 
The ferroquine analogues all show, at best, quasi-reversible oxidation of the ferrocenyl moiety. 
The ease of reversibility of the reaction increased with increasing spacer length, as indicated by 
the decrease in peak separation (tlEp). While the value of the peak separation of the ferroquine 
analogues with longer chain length does fall within the required range, the cathodic peak current 
is consistently significantly smaller than the anodic peak current, so these cannot be regarded 
as fully reversible redox reactions, thus, no half-wave potential is calculated. 
1200 1000 800 800 400 
Voltage I mV 
200 ·200 
Figure 14: Cyclic voltamogram of 20 
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The oxidation of all compounds resulted in the deposition of some species on the electrode. 
This was observed by the decrease in peak currents on each successive sweep cycle in a single 
experiment. 
While there are still a number of questions surrounding the cyclic voltametry of these 
compounds, several points have been established. 
• 4,7-dichloroquinoline does not exhibit any redox behaviour in the solvent window. 
• Chloroquine shows an irreversible oxidation curve at 750mV which results in deposition on 
the electrode. This suggests that the redox activity exhibited by chloroquine is a function of 
the side chain rather than the 7 -chloroquinoline system. 
• Ferroquine 15 shows a fully reversible one electron oxidation. 
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• Whilst the I1Ep values of the longer chain ferroquine analogues fall within the range required 
for a fully reversible oxidation, the cathodic peak current is significantly smaller than the 
anodic peak current and therefore these can only be regarded as quasi-reversible 
oxidations. 
• The ease of reversibility increases with increasing spacer length, shown by the lower LiEp 
values. 
• The ferroquine analogues all cause deposition on the electrode. This is shown by running a 
single experiment with several sweeps. Each successive sweep shows diminished peak 
currents. 
• The ferroquine analogues also exhibit a second redox event at about 300mV. 
• The anodic peak current of the second redox event diminishes with respect to the ferrocenyl 
oxidation on increasing the scan rate. 
These results, when considered alongside the cyclic voltametry results discussed in Chapters 3 
and 4, indicate several possible explanations. 
1. The irreversible oxidation is related to the aniline amine. This event is observed in all 
compounds that have the 7-chloroquinoline system we have tested with the exception of 
4,7 -dichloroquinoline. Deposition on the electrode appears to be related to this event. 
2. The reversibility of the oxidation of the ferrocenyl moiety is impaired by the presence of the 
NH p to this entity. 
3. The aniline amine and the secondary amine p to ferrocene exhibit different redox activity. 
This is demonstrated by the reversibility of the oxidation of the ferrocenyl moiety in 
ferroquine, 15, and the lack thereof in the ferroquine analogues. 
It should also be observed that the electronic effect of the side chain is known to have an impact 
on the redox behaviour of ferrocene. In particular, the oxidation potential increases with 
increasing electon acceptor strength of the substituent. 15 This is clearly demonstrated in the 
significant increase in the cathodic peak potential in moving from ferrocene to ferroquine, 15. 
Whilst it is of interest to look at the cyclic voltametry of these compounds in itself as part of their 
characterisation, it was suggested that there may be a correlation between the electrochemical 
behaviour of these compounds and their in vitro biological activity. Some correlation could be 
drawn between potency of trypanothione reductase inhibition (results given in chapter 5) and 
ease of oxidation, following increasing methylene spacer length. However, no such correlation 
was observed with glutathione reductase inhibition. 
Molar Conductivity 
The molar conductivity of some of the compounds was determined and, as expected, these 
compounds were found to be neutral. This is consistent with the structure of the compounds as 
determined by x-ray crystallography. 
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Conclusions 
The x-ray crystal structure of 20 was determined and thus provided the basis for interpretation of 
the spectroscopic data obtained. In all cases the NMR data was clear and simple to interpret. As 
the methylene spacer increased in length some ambiguity arose as to the absolute assignment 
of methylene groups in both 1H and 13C NMR. This was not deemed to be a problem as the rest 
of the data was consistent across the series of compounds and consistent with the literature as 
far as reasonable comparison could be made.2.12 Data from mass spectrometry and infra-red 
spectroscopy was used to support the other analytical data obtained, and to provide further 
characterisation data for the new compounds described. 
Ferrocene exhibits a fully reversible one-electron redox wave in acetonitrile. Ferroquine exhibits 
similar behaviour, but it is far more difficult to oxidise than ferrocene. The ferroquine analogues, 
20-24 do not display such fully reversible events. The ease of reversibility increases with 
increasing spacer length. 
References 
K Chibale, JR Moss, M Blackie, D van Schalkwyk and PJ Smith, Tetrahedron Lett., 2000,41, 
6231 
2 C Biot, G Glorian, LA Maciejewski, JS Brocard, 0 Domarle, G Blampain, P Millet, AJ 
Georges, H Abessolo, D Dive and J Lebibi, J. Med. Chem., 1997,40,3715 
3 a) C Biot, L Delhaes, CM N'Diaye, LA Maciejewski, D Camus, D Dive and Js Brocard, 
Bloorg. Med. Chem., 1999, 7, 2843; b) C Biot, L Delhaes, H Abessolo, 0 Domarle, LA 
Maciejewski, M Mortuaire, P Delcourt, P Deloron, D Camus, D Dive and JS Brocard, J. 
Organomet. Chem., 1999,589,59 
4 L Delhaes, C Biot, L Berry, LA Maciejewski, D Camus, JS Brocard and D Dive, Bioorg. Med. 
Chem.,2000, 8,2739 
5 a) D De, FM Krogstad, FB Cogswell and D.I Krogstad, Am. J. Trop. Med. Hyg., 1996, 55, 
579; b) RG Ridley, H Hofheinz, H Matile, C Jacquet, ADorn, R Masciadri, S Jolidon, WF 
Richter, A Guenzi, MA Girometta, H Urwyler, W Huber, S Thiathong and W Peters, 
AnUmicrobial. Chemotherap., 1996,40, 1846 
6 a) FN Jones and CR Hauser, J. Org. Chem., 1962, 27, 701; b) ME Wright, Organometallics, 
1990, 9, 853 
7 S Picart-Goetgheluck, 0 Delacroix, L Maciejewski and J Brocard, Synthesis, 2000, 10, 1421 
8 M Schlosser, in Organometallics in Synthesis, ed. M.Schlosser, John Wiley & Sons, England, 
1994, Ch. 1, pp.16. 
9 DW Slocum, BW Rockett and CR Hauser, J. Am. Chem. Soc., 1965,87 (6),1241 
10 P Beagley, MAL Blackie, K Chibale, C Clarkson, JR Moss and PJ Smith, manuscript 
submitted, May 2002 
34 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 2: Ferroquine Analogues 
11 B Delavaux-Nicot, Y Guari and R Mathieu, J. Organomet. Chem., 1996,512,219 
12 0 De, LD Byers and OJ Krogstad, J. Heterocyclic Chem., 1997,34,315 
13 0 Marquarding, H Klusacek, G Gokel, P Hoffmann and I Ugi, J. Am. Chem. Soc., 1970, 92 
(18),5389 
14 CJ Yu, H Yowanto, Y Wan, T J Meade, Y Chong, M Strong, LH Donilon, JF Kayyem, M Gozin 
and GF Blackburn, J. Am. Chem. Soc., 2000,122,6767 
15 B Bildstein, A Hradsky, H Kopacka, R Malleier, K-H Ongania, J. Organomet. Chem., 1997, 
540, 127 
35 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 3 
Urea and Sulfonamide Derivatives of Ferroquine 
Introduction 
This chapter deals with the synthesis and characterisation of various organic derivatives of the 
ferroquine analogues detailed in Chapter 2. Part of the rationale for the design of the ferroquine 
analogues was the inclusion of a reactive secondary amine centre as a site for introducing 
chemical diversity. This was used specifically in this work for the functionalisation of the 
ferroquine analogues to make urea and sulfonamide derivatives. 
The purpose of this study was to ascertain whether potential high throughput synthetic 
methodologies could be applied to these systems in order to rapidly obtain modest libraries of 
compounds that could then be screened for biological activity. It is well known that small 
differences in the structure of potential drug candidates can have significant effects on the 
efficacy. 1 
Rationale 
The aim here was to functionalise the ferroquine analogues using the reactive secondary amine 
centre. In particular, urea and sulfonamide derivatives were targeted. The use of ureas and 
sulfonamides2,3 in compounds that exhibit antimalarial activity has been established.4 In addition 
to this, the possibility of using appropriate quenching reagents and resin bound substrates5,6 
could facilitate the synthesis of modest libraries of these compounds relatively quickly. 
n = 2; 37 
n = 3; 38 
n = 4; 39 
n = 6; 40 
Figure 1: Benzyl ureas with varying spacer length 
A series of benzyl ureas, Figure 1, with varying methylene spacer lengths7 would serve to 
determine the effect, if any, of the length of the methylene spacer on the efficacy of the 
compounds as antimalarial agents.8,g This effect was also examined with regard to the 
ferroquine analogues (Chapter 5). 
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Figure 2: Urea derivatives of 20 with varying side chains 
The effect of aromatic substituents in the urea compounds was examined (Figure 2). Here the 
methylene spacer length was kept constant, in order to determine the effect due to the 
substituted aromatic ring alone. 
R= 
, 
""-No.. 
d 
46 
, , 
¢oo 
CI 
47 48 
Figure 3: Sulfonamide derivatives of 20 with varying side chains 
The introduction of the aromatic sulfonamide moiety was carried out for two purposes. Firstly, to 
further determine the effect aromatic substituents, Secondly, to determine whether there was 
any major difference in efficacy in moving from the urea series to sulfonamide series, Again, the 
methylene spacer was kept constant, in order to minimise the number of changes. 
General Synthesis of Ureas 
There are many possible synthetic routes for the synthesis of urea compounds, only two are 
examined here. 
1, Synthesis from isocyanates and amines 
Using this method, urea compounds can be made quickly and under ambient conditions to give 
the product in high yields. The main drawback of this approach is the limited range of 
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commercially available isocyanates. Although isocyanates can be synthesised from phosgene 
and amines, this diminishes the advantages of using this particular methodology by introducing 
an extra step in the synthesis. 
2. 
R 
I 
R,/NH 
+ 
Ar-N=C=O 
Scheme 1: Synthesis of ureas from amines and isocyanates 
Synthesis from a carbamate intermediate 
R-NH2 
+ 
o A-o CI 0 ~ /;
o A-o R-~ 0 ~ /; 
o 
A R" -0 R-N N' + HO ~ /; 
H R' 
Scheme 2: Synthesis of urea compounds via carbamate intermediate 
The reaction of amines with chloroformates, exemplified in Scheme 2, in the presence of a base 
such as triethylamine gives carbamate intermediates. These intermediates are then reacted 
with a range of primary and secondary amines. As both primary and secondary amines can be 
used and a wide variety of these reagents are commercially available, many different urea 
compounds can be synthesised. 
Formation of Ferroquine Urea Derivatives 
The synthesis of the urea compounds was relatively simple and was achieved in high yields (up 
to 90%). The ferroquine compounds were reacted with the relevant isocyanate to form the 
corresponding ureas. 
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ND-~ N~N~~N/ 
H H ~ I O~ Fe - ~ 
CI I 
Ar-N=C=O 
+ 
Scheme 3: Synthetic route employed to produce substituted ureas 
The use of solid phase quenchers in the synthesis of urea compounds is known.s The product 
could be isolated by filtration and removal of the solvent. This would mean that a variety of 
products could be made simply and rapidly, allowing for the development of a modest library of 
compounds. It was hoped that (aminomethyl)polystyrene could be used to trap the excess 
isocyanate used in the reaction leaving the pure product in solution, Scheme 4. However, it was 
found that purification by silica gel chromatography was still necessary. Decomposition of the 
starting isocyanates under the reaction conditions was the major problem. The use of the 
pOlymer-supported reagent was therefore superfluous and so it was not used for most of the 
syntheses. 
+ 
Ar-N=C=O 
1.2 eq 
Ar-N=C=O 
(excess) 
+ 
polymer bound 
+ 
Ar-N=C=O 
(excess) 
polymer bound 
Scheme 4: Synthesis of ureas using trapping agents. 
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The synthesis of ureas depicted in Scheme 3 worked consistently well. However, as the 
reaction still required purification by silica gel chromatography, it was reasoned that exploration 
of an alternative synthesis of the benzyl urea derivatives via the carbamate intermediate route, 
Scheme 5, was worthwhile. The reason being, the synthesis of several benzyl urea analogues 
was required for the structure-activity relationship studies described in Chapter 6. 
° )l~ X=H; 50 
CI O~X X=N02;51 
49 
1
1 eq Et3N 
Acetonitrile 
30min 
O~X 
_ HN-{ OJ ° 
x = H; 52 
X = N02; 53 
37 
+ 
j THF 50°C 16 h 
20 
HO-\ i-x 
X = H; 54 
X = N02; 55 
Scheme 5: Formation of urea compounds via carbamate intermediate 
The carbamate intermediates (X = H and X = N02) were prepared in high yields (80-85%) from 
the corresponding chloroformates by reaction with benzylamine in the presence of 
triethylamine. The difference between use of the nitrophenylchloroformate- and the 
phenylchloroformate- derived carbamates was significant in the synthesis of the benzyl urea. 
The presence of the electron-withdrawing nitro group renders the carbonyl group highly 
electrophilic. Coupled with the resonance stabilisation of the nitrophenoxide anion, the reaction 
proceeded at a faster rate and could be carried out at a lower temperature. This was important 
because prolonged heating of 20 results in decomposition and therefore significantly reduces 
the yield of the reaction. The yields with respect to 20 obtained by this methodology were 
similar to those found with the isocyanate methodology. 
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General Synthetic Routes for Sulfonamides 
The chemistry of RS02X is similar to that of RCOX (X = CI), In the same way as carboxylic acid 
amides can be made by a substitution reaction between the acid chloride and an amine, so 
sulfonamides can also be made from the corresponding sulfonyl chloride. However, it should be 
noted that the sulfonyl halides are less reactive than the carboxylic acid halide analogues. 10 
Only one synthetic route was explored using trapping reagents and polymer supported reagents 
to provide an efficient synthesis of sulfonamide derivatives of ferroquine analogues. 
R CI 
I I 
NH + O=S=O R'/ I 
Ar 
R 
I 0 N II R'/ "s 
II 'Ar o 
Scheme 6: Synthesis of sulfonamides from amines and sulfonyl 
chlorides 
This methodology requires the use of readily available starting materials under mild conditions 
to give the product in high yield. This type of reaction is well suited to the use of trapping 
reagents. An excess of sulfonyl chloride in the presence of a suitable base is used to ensure as 
much of the amine reacts as possible.6 The base removes the hydrochloric acid formed in 
solution and is best achieved using a polymer supported base exemplified by poly(4-
vinylpyridine). Triethylamine can also be used, but the removal of this reagent can sometimes 
prove difficult, whereas the polymer supported reagent can be removed by filtration. In on of the 
protocols, pentaethylenehexamine is then used to react with the excess sulfonyl chloride. 1,4-
phenylene diisocyanate is then added to form a polymeric product with the 
pentaethylenehexamine through the formation of a polyurea,6 
Scheme 7 shows representative reactions with the three reagents. It is clear that there are 
many potential reactive sites on the pentaethylenehexamine, and two reactive sites on the 1,4-
phenylene diisocyanate, This facilitates the formation of the polyurea which can be removed by 
filtration,6 
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CI 
I H H 
O=S=O 
I 
Ar 
+ H2N~N~N~N~N~NH2 
H H 
H H 
H2N~N~N~N~N~NH2 
0=8=0 H 
I 
Ar 
o 
" C 
" N~ 0 H H V'N)(N~N~N~N~N~NH2 
H H 0=8=0 H 
I 
Ar 
Scheme 7: Trapping of excess sulfonyl chloride 
Formation of Ferroquine Sulfonamide Derivatives 
CI 
+ I o=s=o 
I 
Ar 
CI 
Scheme 8: Synthetic scheme for the formation of the sulfonamide 
derivatives 
The aforementioned use of trapping agents was attempted. Pentaethylenehexamine was added 
to trap any remaining sulfonyl chloride. The excess pentaethylenehexamine was then trapped 
by the addition of 1,4-phenylenediisocyanate. Both these reactions resulted in the formation of 
insoluble products which could then be removed by filtration. However, once again the use of 
silica gel chromatography was necessary to obtain a pure product, so the use of trapping 
agents was superfluous. 
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Characterisation 
1H NMR Spectroscopy 
The proton NMR data is consistent with the proposed structures of the new compounds Figure 
4 and Figure 5 show the 1 H NMR spectra of 37 and 20, respectively. Only the significant points 
of difference are labelled. There are several points to note: 
• The presence of the aromatic protons originating from the isocyanate fragment (7.13-7.07 
ppm) 
• The absence of the broad triplet of the NH (5.9ppm) 
• The presence of the 1" protons (4 .24-4.16ppm) 
• The upfield shift of the 3'a, 3'b in the urea derivative, which shift from the left of the Cp peak 
in 20 to the right of the Cp peak in the urea. 
• The upfield shift of the 4' protons. 
The latter two points are consistent with the close proximity of the electron withdrawing urea 
group causing deshielding of the 3' and 4' protons and hence the upfield shift. 
CI 
l 
Cp, 
3' 
1" 
. , ~ 
I I , I ii' I I I I I I I I I ' I , I I I I I I I I I I . I I I I I I I ' I ri I I I I I I I I I I I I Iii i I I I I I I I I , I i I I I I 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4 .5 4.0 3.5 3.0 2.5 2.0 1.5 
Figure 4: 'H NMR Spectrum of 37 in CDCI3 
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~H 4' 3' Np N~ ~~~ /' 
f ~ ~ ~ ~ 
Fe 
- ~ 
CI 
NH 3'a 3'b 4' 
I 
---"'_->'--"'-----J'Ii...--_----''-~ ~ ____ ,,·v "--""-~ · ~Jl_ 
, j I II iii I i j I I I I I , ! I t [ j 1 ! I I . I Iii I I ! I ii' , I r I I , I I 1[1 ! 1 i I I ' , , I Ii i ' , t ' i ii I ' I I 
8.5 8~ 7.5 ~o 6.5 6.0 5.5 5.0 4.5 4.0 3.5 ao 2.5 ~o 
Figure 5: 1H NMR Spectrum of 20 in CDCI3 
The data for the sulfonamide derivatives show a similar trend in the 1H NMR spectra. A 
comparison can therefore be drawn between the benzyl urea derivative 37 and the benzyl 
sulfonamide derivative 45. Again the downfield shift of 3' and 4' protons is observed, once more 
consistent with the deshielding by electron withdrawing effect of the sulfonamide group. 
13C NMR Spectroscopy 
The carbon-13 NMR data of all compounds was consistent with expected values. There was no 
significant change in the chemical shifts of carbon atoms in the ferroquine analogue scaffolds. 
There were new signals arising from the urea or sulfonamide groups, but their values were all 
found to be consistent within the group when reasonable comparison could be made. 
Mass Spectrometry 
In all cases the accurate mass of the parent ion was determined within acceptable limits of error 
using HRMS. In addition to this, the isotopic distribution around the parent ion was checked to 
determine whether it was consistent with calculated values. Furthermore, some attempt was 
made to ascertain the identity of the major fragments. These compared well with the data 
obtained for the ferroquine scaffolds. Together these data provided further support that the 
desired compounds had indeed been successfully synthesised. 
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Infrared Spectroscopy 
As in Chapter 2, infrared spectroscopy was used principally to ascertain the presence of the 
major functional groups in the molecules. In all cases, characteristic ferrocenyl (1104, 1000, 
830,490 cm-1) and 7-chloroquinoline bands (1610, 1580 and 1540 cm-1) were observed. 
In the urea compounds the carbonyl stretching frequency occurs at about 1640cm-1. In some 
cases a distinct peak was observed, but in other cases, the presence of this absorption band 
was noted only by a distinct broadening of the strong C=C stretching frequency present at 
about 1610 cm-1. 
The methoxyphenylurea shows most characteristic strong R-O-R' symmetric and asymmetric 
stretching bands at 1032cm-1 and 1232 cm-1 respectively. 
The trifluoromethyl groups, CF3 , show distinctive strong symmetric and asymmetric stretching 
bands at 1323cm-1, 1166cm-1 and 1136cm-1 as well. 
Cyclic Voltametry 
Cyclic voltamograms were obtained for the compounds in acetonitrile solution. It is noted that a 
fully reversible one-electron wave will have a peak separation within the range of 70-90mV. In 
addition to this, it is required that the anodic and cathodic peak currents are of similar 
magnitude. The benzyl urea series can all be considered to show such reversible redox events, 
Figure 6. 
NK~~N/~/V 
Y HN~O~ I 
CI d 
- 0 . 500 
E(VOLTl 
Figure 6: Cyclic vOltamogram of 37 
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Figure 7: Cyclic voltamogram of 20 
These results are remarkably different from the parent amines (see Table 1, Chapter 2) . The 
presence of the benzyl urea moiety seems to have two effects. Firstly, the ferrocenyl moiety is 
far more difficult to oxidise, shown by the high half wave potentials. This is consistent with the 
increase in electron acceptor strength of the side chain relative to hydrogen.11 Secondly, the 
redox event is fully reversible in the benzyl ureas, Figure 6, whilst in the parent ferroquine 
analogues it is, at best, quasi reversible, Figure 7. (NB - the differences in appearance of the 
diagrams are simply due to the acquisition of more user friendly software for processing data. 
The CV experiments were performed using the same instrumentation) 
Table 1: Cyclic Voltametric Data of Selected Compounds 
Compound n Ea (mV)a Ec (mVt E1I2 (mV( 6Ep (mV)" 
37 2 198 115 158 83 
38 3 171 91 131 80 
39 4 149 82 116 67 
40 6 164 81 123 83 
a . u . C .0 
-anodic potential, cathodic potential, half wave potential (Ea + Ec)/2 , l:lEp - Ea-Ec 
Table 2 shows the results of the cyclic voltametry experiments performed in the urea series with 
varying side chain. With the exception of 42 and 45 all the compounds showed similar redox 
behaviour to that exh ibited by the benzyl ureas. 
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Table 2: Electrochemistry of urea derivatives of 20 
Compound Side chain Ep~ (mV)1I Epc (mV)P E1I2 (mV)c AEp (mV)" 
37 (Y~ 198 115 157 83 
• 41 ~ 195 115 155 .80 
42 Meo-Q-i 170 5 160 
43 CF3 F3C~ 204 125 165 79 
44 I CF, ~ 218 • 139 179 79 
CF3 
• 45 ~1214 111 103 CI ~ Ii 
a • D. • • C .0 
-anodic potential, cathodic potential, half wave potential (Epa + Epc)/2, IJ.Ep - Ea-Ec 
Overall, it is noted that there seems to be little correlation between the half wave potential and 
the biological activity (detailed in Chapter 4).Note that the half wave potentials of 42 and 45 
were not calculated, because LlEp > 90, so these curves were not fully reversible and thus it is 
misleading to quote an Em value. 
Conclusions 
A limited series of urea and sulfonamide compounds have been synthesised. The synthetic 
strategy employed was relatively simple for each series and in most cases the desired product 
was obtained in good yield. Unfortunately, the use of high throughput methodology, such as 
polymer supported reagents or trapping agents, was found to be superfluous. This was as a 
result of the decomposition of starting materials and/or reaction products particular to the given 
system rather than a problem with the general methodology. 
All of the compounds made have been fully characterised. In all cases the characterisation data 
was consistent with the proposed structure of the compounds. The cyclic voltametry of the 
compounds was interesting. It was found that these compounds show fully reversible one-
electron redox curves. As discussed in Chapter 2, the ferroquine analogues do not show such 
activity. It is proposed that the lack of reversibility in the ferroquine analogues is due to the 
presence of the reactive secondary amine centre. Further studies would need to be done to 
substantiate this theory. 
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Chapter 4 
Metal Complexes of 4-Amino-7-chloroquinoline 
Compounds 
Introduction 
The synthesis and characterisation of metal complexes of various 4-amino-7-chloroquinoline 
ligands is detailed in this chapter. The ligands used in this work were chloroquine, ferroquine, 20 
and 37. (Note in the metal complexes 20 is referred to as F2Q and 37 as eU) 
Figure 1: 
CQ 
20 (F2Q) 
HN~N/ 
ro"" I Fe I , ~ ~ CI '" N 
FQ 
t='\ H Nr-<-N~N~N/ 
";-J HN)"O Fe I 
CI d Q 
37 (eU) 
4-Amino-7-chloroquinoline ligands used for complexation 
Three series of metal complexes have been made using the ligands shown in Figure 1. Firstly, a 
series of ionic gold complexes of the type [Au(L)PPh3tN03-; secondly, a series of neutral gold 
complexes of the type [Au(CeFs)L]; and thirdly, a series of neutral rhodium complexes of the 
type [RhCI(COD)L], (where L = 4-amino-7-chloroquinoline ligand). 
Rationale 
The concept of coordinating metal complexes to existing antimalarial drugs is known. 1 There 
have been several publications regarding the complexation of metals to chloroquine in 
particular2 ,3 ln these papers, it is clearly demonstrated that the introduction of the metal complex 
has a positive influence on the efficacy of chloroquine. The biological evaluation studies were 
carried out in vitro and in vivo on various chloroquine sensitive and chloroquine resistant strains 
of the parasite. 2.3 
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The advantages of incorporating ferrocene into 4-amino-7-chloroquinoline derivatives have 
already been established in previous chapters. The question posed here is whether the 
incorporation of the second metal centre to form heterobimetallic complexes could provide 
synergistic, additive or antagonistic effects. Taking [Au(FO)PPh3]N03 as an example, ferroquine 
15 shows good efficacy against chloroquine resistant P. falciparum, exhibiting a 100 fold 
improvement4 in efficacy versus chloroquine. Similarly, the [Au(CO)PPh3]PF6 is reported to 
show a 22 fold improvement in efficacy.3 
In order to establish whether the aforementioned effects exist, a series of compounds were 
targeted for preliminary investigation. Compounds of the type [Au(CO)PPh3]PF63 and 
[Rh(COD)CI(CO)f have been shown to be more effective than chloroquine against chloroquine 
resistant strains of P. falciparum and are thought to have simple well-defined structures. 
Therefore, these complexes provide a good basis for investigation of the type described. In 
addition to this, a neutral series of gold complexes was also targeted. 
Ionic Gold Complexes 
Synthetic Routes to Ionic Gold Complexes 
The most convenient starting point for the synthesis of these types of complexes is 
chloro(triphenylphosphine )gold( I). The (4-amino-7 -chloroquinoline )(triphenylphosphine )gold 
complexes could then be synthesised using two different routes. 
1. A one-pot synthesis from chloro(triphenylphosphine)gold(l) with potassium 
h exafl uorop hosp hate. 
CI-Au-PPh3 + KPFa 
Reflux 
30 min 
MeCN 
,.. 
HN .... R 
I Reflux 
r7Y) 48h CI~NJJ 
R 0 e 
HN' PFa 
Clm +KCI 
I 
Au 
I 
PPh3 
Scheme 1: Synthesis of quinoline-gold complexes from [Au(CI)PPh 3] and 
KPF6 
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This method of synthesis has been used to prepare chloroquine(triphenylphosphine)gold(l) 
hexafluorophosphate.3 While this method does not require isolation of the gold 
hexafluorophosphate salt, the conditions used are rather vigorous. It has already been 
established (Chapter 2) that prolonged heating of ferroquine derivatives results in some 
decomposition, so heating the reaction mixture under reflux in acetonitrile (bp 82°C) for 48 
hours was not deemed to be a suitable route for the synthesis of these compounds. 
2. A two step synthesis from 
(triphenylphosphine)gold(l) nitrate 
CI-Au-PPh3 + AgN03 
+ 
chloro(triphenylphosphine )gold(l) 
HN"R 
CIW 
I 
Au 
I 
PPh3 
via 
Scheme 2: Synthesis of gold triphenylphosphine complexes using a two step synthesis 
The isolation of the gold nitrate salt could easily be achieved as silver chloride precipitates out of 
solution. The gold nitrate salt can therefore be isolated by a well known simple filtration and 
crystallisation protocoLS This is then reacted with the 4-amino-7-chloroquinoline derivative under 
mild conditions to form the desired gold complex.s 
Formation of ionic gold complexes 
The synthesis of the 4-amino-7-chloroquinoline-gold complexes was achieved in relatively high 
yield using the second methodology outlined above. Chloro(triphenylphosphine)gold(l) 58 was 
synthesised from sodium tetrachloroaurate(lIl) 56. 7 
Na[AuCI41 
acetone/ethanol 
56 
+ 
chloroform 
57 
3h ,.. [Au(CI)PPh31 
58 
Scheme 3: Synthesis of chloro(triphenylphosphine)gold(l) 
Chloro(triphenylphosphine)gold(l) 58, was then converted to (triphenylphosphine)gold(l) nitrate 
59,5 Scheme 2. (Triphenylphosphine)gold(l) nitrate 59 was then reacted with the relevant 4-
amino-7-chloroquinoline ligand to give the desired products 60 - 63 in moderate yields under 
mild conditions. 
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R ® 0 
HN; N03 ~ CI~NjJ 
I 
Au 
I 
PPh3 
:t./"N~N'" 
H I 
Fe 
~ 
62 
)>'./"N~N'" 
HN~O Fe I (iQ\ 
I h 63 
Scheme 4: Synthesis of (4-amino-7-chloroquinoline) 
triphenylphosphinegold complexes 60 - 63 
Neutral Gold Complexes 
There was no obvious literature precedent for making neutral gold complexes of known 
antimalarial drugs. It was decided, therefore, to use some of the expertise available in our 
laboratory.s There is also some literature available on ferrocene containing complexes of this 
type. 10 
There were two classes of neutral gold complexes which could possibly be synthesised viz., 
[Au(CI)L] and [Au(C6FS)L]. 
1. [Au(CI)L] 
These complexes had the advantage of requiring fewer steps in the synthesis. However, it has 
been observed that compounds of this type are light sensitive.9 Given that the compounds were 
being synthesised with a view to evaluating them in a biological testing protocol, stability is an 
important criterion to consider. 
2. [Au(CsFs)Ll 
These compounds required a more lengthy preparation, as the precursor, [Au(C6Fs)tht], is made 
from [Au(CI)tht]. However, the pentafluorophenyl complexes are generally more stable that the 
corresponding chiaro complexes. This can be attributed, in part, to the lower stability of the CsFs-
ion when compared to the chloride ion. In addition to this, the presence of the Au(C6FS) unit 
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could be detected by 19F NMR spectroscopy whereas Au(CI) cannot be detected directly by 
NNiR spectroscopy. 
Synthetic Route to Neutral Gold Complexes 
A well established methodology for the synthesis of these type of compounds requires 
pentafluorophenyl(tetrahydrothiophene )gold(l) 64 as a starting material. 10 The 
tetrahydrothiophene (tht) is known to be a labile ligand, and the 4-amino-7-chlorochloroquinoline 
derivatives would be expected to displace it relatively easily. The reaction can therefore be 
carried out under mild conditions. The tht is volatile and can be removed in vacuo, thereby 
providing a simple route to a pure product provided the synthesis goes to completion. 
HN~R 
HN~R 
F F 
I CS-AU-O-F CH2CI2 m Cs U) + ... CI ~ ":::::-N + CI ~ ~N I \ 2h,25°C I Au F F I 
64 C6F5 
~,~(~ R= -;/~N~N/ R= H I Fe 
65 67 ~ 
R= ;'tJo('~/ 
1~N~N/ 
R= HN~O Fe I 
Fe (iQ ~ Ih 
66 68 
Scheme 5: Synthesis of neutral gold complexes 65 - 68 
The synthesis of the 4-amino-7-chloroquinoline(pentafluorophenyl)gold(l) complexes 65 - 68 
required a multistep synthesis. The available starting material was sodium tetrachloroaurate(III). 
Chloro(tetrahydrothiophene)gold(l) 70 was prepared from sodium tetrachloroaurate 56 
according to a literature procedure. 11 The product was obtained in over 90% yield (Scheme 6). 
Scheme 6: Synthesis of chloro(tetrahydrothiophene )gold(l) 
Chloro(tht)gold(l) 70 was then converted into pentafiuorophenyl(tht)gold(l) 64 as reported. 12•13 
This reaction requires a two step synthesis as shown in Scheme 7. 
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C6F 5Li + [Au(CI)(tht)] 
70 
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__ E-,t2~O_--i"'''''' [Au(C6F5)(tht}] + LiCI 1 h* 64 
* Mixture allowed to warm from -7SoC to 25°C over this time 
Scheme 7: Synthesis of pentafluorophenyl(tht)gold(l) (64) 
The reaction progress could be monitored quite easily using TLC (10% MeOH in CH2Cb). The 
crystalline product was quite stable if isolated as a pure product, but the presence of impurities 
resulted in fairly rapid decomposition. The product was stored at 4°C to minimise decomposition 
and was always used in the complexation reaction with the 4-amino-7-chloroquinoline ligands 
within a few days. The product was characterised using lH and 19F NMR spectroscopy. 
The complexation to the 4-amino-7-chloroquinoline ligands was achieved in reasonable yield 
under fairly mild reaction conditions as shown in Scheme 5. The volatile tht was removed in 
vacuo. The purification of the products was achieved either by preparative TLC or by 
recrystallisation. The latter technique was found to be far superior both qualitatively and 
quantitatively. 
It was observed that the reaction did not go to completion. The TLC (10% MeOH in CH2Ch) of 
the final reaction mixture consistently showed a mixture of product and the two starting 
materials. The reaction time was increased to 24 hours, but the TLC showed little change in the 
reaction mixture composition. The tht was removed in vacuo and further solvent added to 
ensure that the problem was not associated with an equilibrium reaction. Again, there was no 
noticeable difference in the reaction mixture composition. The use of toluene was attempted in 
order to facilitate raising the temperature of the reaction. However, at room temperature, the 4-
amino-7-chloroquinoline ligands are sparingly soluble in toluene and at elevated temperatures 
decomposition of the gold complexes occurred. The net result was a lowering in the overall yield 
of the reaction. The use of dichloromethane was continued despite the relative instability of gold 
complexes in chlorinated solvents. In order to minimise decomposition the reaction vessels 
were protected from light. There were two reasons for this; firstly, it is possible that these 
compounds are sensitive to light, as it has been demonstrated for chloro(quinine)gold(l).9 
Secondly, it is known that chlorinated solvents form radicals when exposed to light. These 
radicals could then react with either reactants or products resulting in diminished yields. 
It is possible that increasing the ratio of pentafluorophenyl(tetrahydrothiophene)gold(I} 64 might 
drive the reaction to completion. This approach was not attempted because of the number of 
potential nitrogen donor sites on the 4-amino-7-chloroquinoline derivatives. As it was, despite 
the fact that the reaction did not go to completion, yields as high as 75% were obtained and it 
was decided not to attempt to increase the yield further by using excess ligand. 
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Rhodium Complexes 
A rhodium cyclooctadiene complex of chloroquine has been prepared previously.z The method 
used starts from di-/-L-chloro-bis(Il4-1 ,5-cyclooctadiene)dirhodium(I), [RhCI(COD)lz 78 which is a 
well established route to the preparation of complexes of the type [Rh(CI)(COD)L], where L is a 
nitrogen or phosphorus donor Iigand,14 The required reaction conditions were mild and the yields 
reasonably good. 
Synthetic Routes to Rhodium Complexes 
The complexes were prepared as outlined above. This required the preparation of 
[RhCI(COD))z, 78, The available starting material was hydrated rhodium trichloride, and the 
synthesis was carried out according to a literature procedure. 14 A yield of 83% was obtained and 
the lH and 13C NMR spectra were found to be consistent with literature values. 15 
2RhCI3.xH20 + 2CaH12 + 2CH3CH20H 
76 77 
EtOH/H20 
---..... ~ + 4HCI + 2CH3CHO 
reflux,4h 
78 
Scheme 8: Preparation of [RhCI(COD)h 78 
The syntheses of the 4-amino-7-chloroquinoline-rhodium complexes 79 - 82, Scheme 9, were 
carried out according to a literature procedure,z with the only change being the choice of solvent. 
Dichloromethane was used instead of 2-methoxyethanol. 
There was no significant difference in the yield or the lH and 13C NMR spectra of the 
chloroquine-rhodium complex 79 formed and the reported literature values,z so all other 
reactions were carried out in a similar manner, using the appropriate 4-amino-7-chloroquinoline 
starting material. In all cases, a yellow/orange crystalline complex was formed. 
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HN,R 
HN,R 
I o /CI, ~ CH2CI2 m ~:) Rh Rh + \:¥ ·c( ;) .. CI :::::-.. ::-"N 4h, reflux CI :::::-.. "::::::'N I 
78 CI-Y I . 
'/-
~l~(--/ R= i../'N~N/ R= H I Fe 
79 80 ~ 
~~~/ i~N~N/ R= R= HN"!:::.O Fe I 
Fe d Q ~ I h 82 81 
Scheme 9: Synthesis of rhodium complexes of 4-amino-7-chloroquinolines 
NMR Spectroscopy 
All complexes were characterised using 1H and DC NMR spectroscopy, using COSY and HSQC 
two dimensional NMR spectroscopy to assign the spectra. In addition, the complexes of the type 
[Au(L)(PPh3)]N03 were characterised using 31 p NMR spectroscopy and complexes of the type 
[Au(CsF5)L] were characterised using 19F NMR spectroscopy. The full assignment of data is 
given in the general experimental (Chapter 8) 
1H NMR Spectroscopy 
For the gold complexes, 1H NMR spectroscopy could not provide a direct method of establishing 
whether the complex has in fact been formed as opposed to having a mixture of starting 
materials. The reason for this is that while there is a change in chemical environment of both the 
incoming [Au(PPh3)] fragment of the 4-amino-7-chloroquinoline ligand, these changes do not 
have a significant effect on the chemical shifts of the proton signals in either of the gold ligands. 
Figure 2 shows the protons which would be expected to show the greatest change in chemical 
shift on complexation. 
56 
Un
ive
rsi
ty 
of 
Ca
pe
 T
wn
Figure 2: 
Chapter 4: Metal Complexes 
I ( 
HN~N---./ 
~ CIA(~~A.H 
..?J H Au ~ ArH 
",/' I 2 
ArHa ~oP~o~ 
VP"I ~ 
:::::..... 
[Au(CQ)PPh3t showing protons expected to be most affected 
by complexation 
There appears to be little long range electronic disturbance within either fragment on 
complexation. This means that the through-bond effect of the complexation reaction may not 
necessarily be evident in the 1H NMR spectrum. In both the ionic and the neutral series of gold 
complexes small changes (> O.6ppm) in the chemical shift of ArHa were observed. The chemical 
shifts of the protons of the remainder of the ligand were largely unchanged. In analogous 
[Au(L)(PPh3)] complexes having pyridyl ligands, it is observed that only the proton in position 4, 
para to the nitrogen, shows significant changes in the chemical shift between the free ligand and 
that which is complexed to gold triphenylphosphine. 16 
In the gold triphenylphosphine complexes the presence of the triphenylphosphine is evidenced 
by the 15 proton signal between 7.6 and 7.5 ppm. This is consistent with literature values 
observed for similar complexes.3, 16 The 1H NMR spectrum of [Au(CQ)PPh3]N03 60 was similar 
to that of [Au(CQ)PPh3]PF6 11.3 The remaining three complexes of the series i.e. 61 - 63 
showed changes that were reasonably consistent with those observed between chloroquine and 
[Au(CQ)PPh3]PF6 in as far as reasonable comparison could be made.3 
In the pentafluorophenylgold complexes 65 - 68, there were no additional protons observed due 
to the incoming [Au(C6FS)] group, although the presence of the group was detected by 19F NMR 
spectroscopy. It should be noted though, that there was no evidence of the tht group in the 1H 
NMR spectrum. This suggests that the 4-amino-7-chloroquinoline ligand has replaced the tht. 
The 1H NMR spectral data of the rhodium complexes 79 - 82 showed the formation of the 4-
amino-7-chloroquinoline-metal complexes far more clearly. The reason being that the chemical 
environment experienced by the cyclooctadiene protons changes significantly on complexation, 
Figure 3. 
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78 
Figure 3: Significant difference in chemical environment of COD 
protons between the dimer 78 and the chloroquine complex, 79 
HN~~N/ 
I~I 
~~) Fe CI~~N ~ 
I 
ArHs 
ArHs 
i , Ii i ' I I' i I I I i I t I Iii ttl i I I 'I' , jill iii II I I I 1'1 I I II I 1'1 i I I i i' ,I I I' r i ii' I I I I' I 
9.0 8.5 8.0 7.5 7.0 6 .5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 
Figure 4: lH NMR spectrum of 15 in CDCI3 
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COD COD COD 
.~-~---
iii i I I i I 
3 2 
, I 
o 
Figure 5: 1 H NMR spectrum of 80 in CDCI3 
~ CI ~ / , Rh Rh Q( "C( \ 
) 
, I I , r , I , I I I , , I , I I , I I , , I i I i I I I I I , i ! I 
5.5 5.0 4,5 4,0 3.5 3,0 2,5 2,0 1.5 1,0 0,5 
Figure 6: lH NMR spectr'um of [Rh(CI)(COD)h 78 in CDCI3 
Figure 4, 5 and 6 show the shifts in proton signals on complexation of ferroquine and rhodium 
cyclooctadiene. Only those protons of particular relevance have been labelled. It is clear that 
there is a significant change in the position of ArHs of the ferroquine ligand (Ll~ 1.6ppm). The 
other point to note is the change in position of the cyclooctadiene protons. In particular the 
methylene protons; in [Rh(CI)(COD)b 78 these are indistinguishable and appear at 4,25ppm. In 
the complex, the methylene protons now exist in different chemical environments, and hence 
two distinct signals are observed at 4,8 and 3.5ppm. The observed changes in the 
cyclooctadiene chemical shifts are consistent through the series and in agreement with reported 
values for 4-amino-7-chloroquinoline complexes2 The splitting of the methylene cyclooctadiene 
protons is also consistent with the lH NMR spectra obtained for a variety of rhodium complexes 
with nitrogen donor ligands.17 
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13C NMR Spectroscopy 
In the gold complexes, 60 - 63 and 65 - 68, there is no significant difference in the 13C NMR 
spectra between the complex and the free ligands. In the triphenylphosphine complexes, the 
resonances due to the phenyl carbons are observed in positions similar to those reported 
previously.6,16 In the pentafluorophenyl complexes, however, no new signals are seen. This is 
because the relaxation time of the carbon-fluorine coupling is of greater duration than the NMR 
time scale. Again this observation is consistent with literature reports. 10 
In the rhodium complexes, 79 - 82, the presence of the [Rh(CI)(COD)] fragment is clearly seen. 
There are four new signals in the spectrum as the eight cyclooctadiene carbons exist in four 
different environments when complexed to an asymmetric nitrogen donor ligand. 
31 p NMR Spectroscopy 
The 31 P NMR spectra consistently show a singlet at approximately 30 ppm for all complexes. 
Again this is consistent with values reported for similar complexes. 6.16 There seems to be no 
significant shift in the signal in changing from chloro(triphenylphosphine)gold(l) 58 to the 4-
amino-7-chloroquinoline(triphenylphosphine)gold(l) complexes 60 - 63. 
19F NMR Spectroscopy 
The 19F NMR spectra of all complexes, 65 - 68, clearly show the presence of the 
pentafluorophenyl group. There are slight changes in the chemical shifts observed between the 
gold tetrahydrothiophene complex 64 and the 4-amino-7-chloroquinoline complexes 65 - 68 (± 
1ppm for all signals). The fluorine atoms may seem relatively remote from the site of 
complexation to be so affected, but it must be noted that there is a change from a sulfur donor 
ligand (tht) to a nitrogen donor ligand (quinoline). There is a large difference in the electron 
donor properties of sulfur and nitrogen. 18 This could have a large effect on the electron density 
of the phenyl moiety and hence cause a change in the chemical shifts of the fluorine atoms, 
While these shifts are small, they are Significant. This is shown by the fact that the spectrum of 
the crude reaction mixture clearly shows the presence of the two different species. The 19F 
spectra show two mulitplets corresponding to fluorine atoms in ortho and meta positions, whilst 
the fluorine atom in the para position forms a triplet with a coupling constant of approximately 
20Hz. 
Infrared Spectra 
The bands corresponding to the 4-amino-7-chloroquinoline ligands do not change significantly 
on complexation to gold or rhodium and have already been discussed in chapters 2 and 3. 
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The infrared spectra are also useful in identifying the presence of the complexes. The nitrate ion 
of the gold triphenylphosphine complexes is clearly observed by a strong absorption band at 
1369 cm-'. The phosphorus-carbon stretching frequency is also observed with a weak band at 
998 cm-1. Two bands at 750 and 700 cm-1 correspond to C-H aromatic bending frequencies with 
5 adjacent protons, arising from the phenyl group. Several strong absorption bands resulting 
from the pentafluorophenyl group are observed in the spectra of the gold pentafluorophenyl 
complexes at approximately 1500, 1460 and 960 cm-1. 
Mass Spectrometry 
In all cases the molecular ion was observed corresponding to the proposed structures, whereby 
one 4-amino-7-chloroquinoline ligand complexes to a single gold or rhodium centre. 
Structure of Compound 
Throughout this chapter it has been assumed that all the metal complexes of the ferroquine 
compounds have the analogous structure to those of the chloroquine complexes. 2•3 
Figure 7: 
~( 2 N HN 4~ 
I 
~ CI~NJ 
I 
MLn 
Suggested structure of metal complexes of chloroquine 
The structure of the chloroquine complexes 60, 65 and 79 were proposed on the basis of NMR 
spectral data.2,3 In the case of ferroquine, Figure 8, there are similarly three nitrogen donor sites 
which exist in similar chemical environments to the nitrogen donor sites found in chloroquine. 
The changes in chemical shifts on complexation are similar to those found in the analogous 
chloroquine complex, so it is reasonable to suggest that the structures are similar i.e. 
complexation occurs through the quinoline nitrogen. 
2 4 HN~N/ 
~ Fe I CI~NjJ~ 
1 
15 
Figure 8: Possible sites of metal coordination on ferroquine (15) 
However, in the case of 20, there is an additional potential nitrogen donor site (3), Figure g, 
Nitrogens 1, 2 and 4 are analogous to those found in chloroquine and ferroquine, The question 
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arises as to whether nitrogen 3 competes with nitrogen 1 or not. The NMR spectral evidence 
suggests that nitrogen 1 is still the site of coordination, as there are no major changes observed 
in chemical shifts arising from the side chain of 20. 
CI 
Figure 9: Possible sites of metal coordination on 20 
In the case of 37, Figure 10, nitrogens 1, 2 and 4 are again analogous to those in chloroquine. 
Nitrogens 3 and 5 could ostensibly be sites of metal coordination, but this is unlikely as the 
carbonyl moiety of the urea is strongly electron withdrawing, which would result in a lowering of 
electron density on both of these nitrogens. As coordination to a metal is dependent of the 
availability of electron density, it is likely that the quinoline nitrogen will be favoured. The NMR 
spectral data obtained for the metal complexes of this compound supports this proposal. 
~ H 4 
1 N~il \\.......N~~~N/ 
fj~2 I~I HN~O Fe 
CI- 0)5 ~ 
18 
37 
Figure 10: Possible sites of coordination of 37 
Conductivity Measurements 
Table 1: Molar conductivity of selected gold complexes 
Compound Compound K Concentration A 
Number (J.1!1"1) (mol dm"3) (Q"1cm2mor1) 
[ " 55.0 16 17 3 60 
[Au(FQ)pPh3rN03- 61 38.9 I 0.00184 21 
[Au(F2Q)PPh3] N03- 62 33.7 0.00267 13 
[Au(BU)PPh3rN03" 63 23.4 0.00131 18 
[Au(CeF5)CQ] 65 0.425 0.00208 0.2 
[Au(CeF5)F2Q] 67 2.043 0.00227 0.9 
[Au(BU)CeF5J 68 0,703 0,00140 0.4 
Measurements made In nitrobenzene at 20°C. 
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As part of their characterisation, the molar conductivities were measured for the two series of 
gold complexes. A molar conductivity, A, of below 10-1cm2mor1 under the aforementioned 
conditions is consistent with neutral compounds. The molar conductivities of the salts fall within 
the range of salts of unipositive cations and uninegative anions. These values are at the lower 
end of the range, but as the [Au(L)PPh3] cation is large its motion through the solvent is likely to 
be impeded, so such a salt is likely to exhibit a lower conductivity than sodium chloride for 
example. 
The results obtained here are consistent with the proposed structure of the complexes Le. metal 
complexation at the quinoline nitrogen. If one considers the [Au(F20)PPh3]N03 62, there are 
three possible scenarios: 
1. The gold is attached to the quinoline nitrogen 1 via a coordination bond - the complexes will 
be unipositive and will show a molar conductivity greater than 10. 
2. The gold is attached to nitrogen 3 via a coordination bond - the complexes will be 
unipositive and have a similar conductivity as scenario 1. 
3. The gold is attached to nitrogen 3 via a covalent bond having displaced the hydrogen. This 
would result in a neutral complex having a molar conductivity less than 1. 
As the triphenylphosphine gold complexes have all have similar molar conductivities and all are 
greater than 10. The molar conductivities indicate that either a coordination bond nitrogen 1 or a 
coordination bond at nitrogen 3 is the likely structure. However, the aforementioned I\IMR 
spectral evidence suggests that the coordination bond at nitrogen 1 is the correct structure. 
The pentafluorophenyl gold(l) complexes could be similarly bonded. This would result in neutral 
complexes in the first two instances and a uninegative ion in the final scenario. Molar 
conductivity will be able to distinguish between the formation of a coordinate bond or a covalent 
bond, but will not distinguish between the formation of coordination complexes at nitrogen 1 and 
nitrogen 3. The fact that the complexes of this type were found to be neutral suggests 
coordination bonding. Again, the coordination at nitrogen 1 is proposed on the basis of NMR 
evidence. 
Cyclic Voltametry of the Gold Complexes 
The focus of this section was on the cyclic voltametry of the gold triphenylphosphine complexes 
of FO, F20 and BU, 61 - 63. It should be noted that chloroquine exhibits an irreversible 
oxidation at approximately 750mV. This oxidation event results in deposition on the electrode. 
4,7-Dichloroquinoline shows no redox activity which could imply that the redox event observed in 
chloroquine is associated with the side chain. Triphenylphosphinegold(l) nitrate 59 shows no 
redox activity within the solvent window. 
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Table 2: Cyclic voltametry of gold complexes and 4-amino-7-
chloroquinoline ligands 
Compound Cpd No Epa (mV)8 Epc (mV)" E1/2 (mV)c 
FO 15 181 113 147 
[Au(FO)PPh3] N03- 61 252 162 207 
F20 20 150 30 
[Au(F20)pPh3rN03- 62 294 186 
[Au(CsFs)F20] 67 315 210 
BU 37 198 115 158 
[Au(BU)PPh3fN03- 63 219 141 180 
a . 0 . c anodic potential, cathodic potential, half wave potential (Epa + Epc)/2, 
d LlEp = (Epa-Epc) ; 
~Ep (mV)CI 
70 
90 
120 
108 
105 
83 
78 
It is apparent from the results in Table 2 that the coordination of the gold to the ferroquine 
derivatives has an effect on the redox behaviour of the ferrocenyl moiety. This can be seen by 
the marked increase in both anodic and cathodic peak potentials in moving from free ligand to 
metal complex. In all cases, the incorporation of gold into the molecule resulted in an increase in 
half wave potential, E1/2 , which indicates that the gold complexes are more difficult to oxidise. 
The effect was most marked in the case of the F20 complexes. There also appeared to be a 
trend towards reversibility shown by the lowering in peak separation, LlEp. This was also 
observed in the shape of the voltamograms, Figure 11-13, below show that the cathode peak 
currents have a greater magnitude in the gold complexes. In a fully reversible oxidation the 
anodic and cathodic peak currents shoul.d be of equal magnitude. 
,--- -----------------, S.E-06 
O.E+OO 
-S.E.Q6 
-l.E-OS 
-2 E-DS 
-2.E-OS 
-3.E-OS 
f--~---____,.--~--,..._-____r--~---1 -3.E-OS 
1200 1000 800 600 
Figure 11: 
400 
Voltage I mV 
200 o -200 -400 
Cyclic voltamogram of 20 
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-3.E-06 
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Figure 12: 
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Voltage I mV 
200 o -200 -400 
Cyclic voltamogram of 62 
.-;0, ----;0,------------------,- 3.E-06 
* ... -{)-~~~Zg5'( /~ ~::: 
, '>=> ¢ O.E+OO 
a r -1.E-06 
-2.E-06 
-3.E-06 
) 
-4.E-06 
-5.E-06 
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Figure 13: Cyclic voltamogram of 67 
As the general trends observed are the same for all the compounds i.e. E1I2 for the ferrocenyl 
moiety increases on moving from ligand to complex, it is likely that the interaction is a 'through-
space' interaction rather than a 'through-bond' interaction. There is no conjugated link between 
the quinoline and the ferrocenyl moieties that would facilitate a 'through-bond' interaction . If it 
were a 'through-bond' interaction it would follow that the effect of the gold moiety would be most 
marked in 61 as the gold atom is in closest proximity to the iron in this complex. However, 61 
does not exhibit the greatest increase in peak potentials. 
Inhibition of J3-Haematin Formation 
It has been well established that 4-amino-7 -chloroquinolines prevent the formation of ~­
haematin . As the site of coordination of the gold or rhodium appears to be the quinoline 
nitrogen, it could be postulated that the presence of the metal atom at this position could have 
an adverse effect on this mechanism. [Au(CQ)(PPh3))N03 60, [Au(FQ)(PPh3)]N03 61 , 
[Au(F2Q)(PPh3)]N03 62, [Rh(CI)(COO)(CQ)] 79, (Rh(CI)(COO)(FQ)) 80 and [Rh(CI)(COO)(CQ)] 
81 were all tested for ~-haematin inhibition activity. In all cases, the metal complexes inhibited 
the formation of ~-haematin . 
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The assay used to determine the inhibition of j3-haematin in this case uses a three fold excess 
of the drug relative to haemin. The observed results do not give an indication of either kinetic or 
thermodynamic factors which may playa crucial role. 
Conclusions 
Three series of metal complexes of a variety of 4-amino-7-chloroquinoline ligands have been 
successfully synthesised and characterised using standard spectroscopic methods. The 
characterisation data obtained are consistent through the series as far as reasonable 
comparison could be made. It has been proposed that despite there being from three to five 
potential nitrogen donor sites on the various 4-amino-7-chloroquinoline ligands, the quinoline 
nitrogen is the most likely site of coordination in all cases. This has been demonstrated on the 
basis of NMR spectroscopy. In all cases the mass spectral data and the elemental analytical 
data (where available) have served to confirm the presence of the desired coordination 
complexes. Furthermore, the molar conductivity studies indicate that the complexes of the type 
[Au(L)(PPh3)tN03" are ionic and the complexes of the type [Au(CsFs)(L)] are neutral as required 
by their proposed structures. 
The cyclic voltametry of the ferrocene containing gold triphenylphosphine complexes have been 
determined and it was found that the presence of the gold had a significant influence on the 
ferrocene redox curve. In all cases, large increases in both cathodic and anodic peak potentials 
were observed indicating that the ferrocenyl moiety was significantly more difficult to oxidise 
when the gold atom was present. As the molecule is not fully conjugated it is proposed that this 
change is a through-space effect rather than a through-bond effect. This is also consistent with 
the observation that the degree of increase in peak potential is not related to the methylene 
spacer length. 
The presence of the gold or rhodium attached to the quinoline nitrogen had no effect on the 
ability of the 4-amino-7-chloroquinolines to inhibit ~-haematin formation. 
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Chapter 5 
., 
Biological Results and Discussion 
Introduction 
As mentioned earlier, the main aim of this project was to make potential new antiparasitic 
agents. It was therefore of interest to test the efficacy of these compounds in this regard. Before 
discussing the results in detail, it is worthwhile explaining several general points about 
biological testing and to define some terms. 
It must be noted that biological testing is a complicated process and, as a result, there are 
many possible variables. For this reason, most laboratories will run the assays on new 
compounds and use a standard commercially available drug as a reference control. It is 
therefore not always appropriate to compare results from two different laboratories without 
reference to the standard control drug. It should also be noted that small differences in values 
are rarely significant unless observed as part of a general trend. 
The ICso and EDso values used in this chapter to express biological activity give essentially the 
same information, IC means inhibitory concentration and is usually used when the assay is 
, 
carried out by measuring the inhibition of a certain compound. For example, in Plasmodium 
assays, the measurement is of the inhibition of a purine precursor, specifically the reduction in 
uptake of radiolabelled hypoxanthine. ED means effective dose and is used when the actual 
numbers of parasites are counted. The ICso then is the drug concentration required to cause the 
measured parameter to fall to 50% of its original value. The EDso similarly is the dosage of the 
drug required to kill half the parasite population or to inhibit 50% of the enzyme activity. The 
lower the values of the ICso or ED50 the greater the efficacy of the drug. 
The IC or ED values are calculated from the percentage inhibition at varying concentrations. 
Normally the percentage inhibitions are not quoted in the literature. They are included here in 
order to preserve as full a record of this work as possible, as some useful information may 
sometimes be gleaned from these values. 
Testing was carried out at four different facilities as specified in the results given below. 
Toxicity of a drug can refer to toxicity towards the paraSite or toxicity towards mammalian cells. 
The ideal drug has high toxiCity or efficacy towards the paraSite and low or no toxiCity towards 
mammalian cells. The toxicity referred to in this chapter is toxicity towards mammalian cells . ./ 
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In Vitro Testing against Plasmodium falciparum strains 
Ferroquine and urea derivatives 
CI 
n:::: 2; 20 
n:::: 3; 21 
n:::: 4; 22 
n:::: 6; 24 
CI 
NhN~~N/ 
H I ~ I 
!j ~ HN~O Fe 
-ty ~ I '::.: 
~ n:::: 2; 37 
n:::: 3; 38 
n:::: 4; 39 
n:::: 6; 40 
Figure 1: Ferroquine analogues and urea derivatives tested against 
P. falciparum 
Table 1: IC50 values of compounds on chloroquine sensitive (010) 
and chloroquine resistant (K1) strains of P. falciparum (Oept of 
Pharmacology, University of Cape Town) 1 
I Compound , 
! 
n . 010 (COS) I . K1 (COR) 
I I . ICso (nM) ICso (nM) 
I 
CO 
I 
41.86 ± 1.25 125.38 ± 4.53 
! 20 2 41.70 ± 2.60 73.46 ± 6.40 
I I 
21 3 I 51.37± 3.85 ! 36.93 ± 1.70 
I 
22 4 i 61. 16 ± 1.53 
I 
• 111.5±12.9 
24 6 i 86.92 ± 7.30 I 81.39 ± 5.57 
37 2 1 21.35± 1.99 I 37.50 ± 7.35 
38 3 116.20 ± 0.54 47.41 ± 2.41 
39 4 16.74 4.25 75.23 ± 8.49 
I 40 6 19.01 ± 6.24 110.2 ± 9.46 
J 
I 
I 
All compounds tested showed comparable activity to chloroquine against the chloroquine 
sensitive 010 strain, although the general trend in the ferroquine compounds shows a decrease 
in efficacy with increasing methylene spacer length, terminating with 24 showing half as good 
activity as chloroquine. All the urea compounds show comparable efficacy to one another and 
are approximately twice as efficacious as chloroquine. However, their efficacy against K1 varied 
substantially. Compound 21 was the most effective having an activity three times that of 
chloroquine in the resistant strain. In both the ferroquine and urea series it is apparent that the 
methylene spacer length plays a role in the efficacy of the drug against the chloroquine 
resistant strain (Figure 2).1 These results lend further support to previous observations that the 
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length of the methylene spacer between the nitrogens in the side chain of 7 -substituted 4-
aminoquinolines is a major determinant of activity against chloroquine resistant P. falciparum. 2 ,3 
:2 
c 
--0 U') 
U 
130 
120 - K1 (CQ) 
110 
100 
90 
80 
70 
60 
50 
40 - 010 (CQ) 
30 
20 
10 
0 
0 2 
o 
/ 
• 
3 4 
Spacer length n 
• 
o 
-.- 010 (FnQ) 
-A- 010 (Urea) 
-0- K1 (FnQ) 
-6.- K1 (Urea) 
5 6 
Figure 2: Graph showing correlation between methylene spacer 
length and ICso in ferroquine analogues (FnQ) and ureas (UCT) 
7 
In a separate determination carried out at the Department of Infectious and Tropical Disease, 
London School of Hygiene and Tropical Medicine, compound 23, with a methylene spacer of 5, 
showed an EDso of 0.03J!g/ml (58nM) against the chloroquine sensitive 3D7 strain of P. 
falciparum and 0.19J!g/ml (367nM) against the chloroquine resistant K1 strain. 
Compound 20 and ferroquine were tested in a separate determination against choroquine 
resistant strain, W2, and the sensitive D10 strain of P. falciparum. Ferroquine, 15, was 
approximately twice as effective as 20 and three times as effective as the resolved tartrate salt 
of 20 (Dept of Pharmacology, University of Cape Town). 
Coordination Complexes of 4-Amino-7-Chloroquinolines 
The series of gold and rhodium complexes shown in Figure 3 were also submitted for in vitro 
testing against a chloroquine sensitive and a chloroquine resistant strain of Plasmodium 
falciparum. The parent 4-amino-7chloroquinoline ligands were all tested in the same series of 
assays. 
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CQ-MLn 
60 - AuPPh3N03 
65 - AuCeF5 
79 - Rh(COD)CI 
F2Q-MLn 
62 - AuPPh3N03 
67 - AuCeFs 
81 Rh(COD)CI 
Biological Testing 
HN~N/ 
ro-?" I Fe I , ~ £G.\ CI" N 
I 
MLn 
FQ-MLn 
61 - AuPPh3N03 
66 - AuCeFs 
80 - Rh(COD)CI 
BU-MLn 
63 - AuPPh3N03 
68 - AuCeFs 
82 - Rh(COD)CI 
Figure 3: Structures of metal complexes used in in vitro assays 
It should be noted that the tartrate salts of ferroquine4 and [Rh(CI)(COD)(CQ)]5 and 
[Au(CQ)(PPh3)]PF66 have been synthesised and tested previously. The results obtained here 
cannot be directly compared to the reported values, but it worthwhile noting that our results are 
reasonably consistent with those previously reported. 
Several trends can be observed from the results in Table 2. The ferrocenyl 4-amino-7-
chloroquinoline ligands, FQ (15), F2Q (20) and BU (37), all show good activity in both 
chloroquine sensitive and chloroquine resistant strains of P. fa/ciparum. Compounds 20 and 37 
show similar efficacy in both strains, whilst 15 shows improved efficacy in the chloroquine 
resistant strain. However, the results clearly show that the 4-amino-7-chloroquinoline ligands 
are more efficacious than the metal complexes in the D10 chloroquine sensitive strain. The 
exception to this is chloroquine, as the gold and rhodium coordination complexes of chloroquine 
all exhibit a slightly better efficacy than chloroquine. The presence of the coordinated metal only 
has a significant advantageous effect in the case of the chloroquine complex when used 
against the chloroquine resistant K1strain. It can be seen that the presence of the gold moiety is 
in most cases superfluous, whilst in the case of the gold triphenylphosphine salt of 20 and 37 it 
actually serves to reduce the efficacy of the ligand. The rhodium complexes are Significantly 
less active than the gold complexes. They have a moderate to strong antagonistic effect on the 
efficacy of the ferrocenyl containing ligands. 
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Table 2: In vitro activity of metal complexes against P. falciparum 
(Dept of Pharmacology, University of Cape Town) 
1 
D10 (CQ sensitive) K1 (CQ resistant) 
1 Compound No ICso (ng/ml) ICso (nM) ! ICso (ng/ml) ICso (nM) 
CQ 4 11.83 • 37.10 181.76 I 570.0 
[Au(CsFs)(CQ)] 60 I 12.36 118.07 41.78 61.09 
[Au(CQ)(PPh3)]N03 65 ! 17.74 21.09 51.76 • 61.53 
.• [Rh(CI)(COD)(CQ)] 79 12.16 ,.21.50 • 46.03 
I 
81.31 
FQ 15 7.05 16.30 I 2.15 4.96 
[Au(CsFs)(FQ)] • 61 8.05 10.08 3.16 I 3.96 
[Au(FQ)(PPh3)]N03 66 . 10.02 10.50 5.42 5.68 
I 
I [Rh(CI)(COD)(FQ)] 80 10.57 I 15.80 7.05 I 10.55 
F2Q 20 5.38 11.30 ! 5.98 12.56 
I [Au(CsFs)(F2Q)] I 62 11.53 13.70 12.33 ! 14.65 
[Au(PPh3)(F2Q)]N03 67 i 33.19 33.27 • 33.81 33.89 
[Rh(CI)(COD)(F2Q)] ! 81 1 145.88 • 202.00 1431.52 ! 597.59 
i. BU 37 I. 10.09 16.54 • 9.48 15.54 
• 
• [Au(BU)(CsFs)] 63 22.75 i 23.36 12.59 12.92 I 
i [Au(BU)(PPh3)]N03 ·68 32.14 30.32 32.96 I 31.09 -I 
I 
[Rh(BU)(CI)(COD)] 82 1 47.32 56.10 40.27 47.70 I 
Inhibition of Trypanothione Reductase 
Figure 4: Structure of compounds used in enzyme inhibition assays 
It is clear from Table 3 that the ferroquine analogues have enhanced inhibitory activity against 
both trypanothione reductase and glutathione reductase relative to chloroquine. Changing the 
methylene spacer length did appear to have an effect on the potency against trypanothione 
reductase with 21 and 22 being most efficacious in the amine series. This is consistent with 
similar trends shown for acridine, sulfonamide and urea compounds. 7 A similar effect was 
observed with the potency and selectivity against glutathione reductase. Here 21 had the lowest 
potency and the greatest selectivity. However, compared to chloroquine although the potency 
was approximately 20 times greater with 21, it was at best only a third as selective for 
trypanothione reductase. So while the potency indices might indicate that the ferrocenyl 
compounds are promising, the selectivity counts severely against them. 
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Table 3: Inhibition of Trypanothione Reductase and Glutathione 
Reductase by the Ferroquine and Urea Compounds (Wellcome Trust 
Biocentre, University of Dundee) .' 
1 Compound , n I Side chain R i ICso TyrR IICso GR I Selectivity Potency 
I 
i I (~M) I (~M) , Indexesa Indexesb 
; CO , 147.60 ± I > 2000c >42.02 I N/A 1 
3.81 
20 2 H 6.78 ± 1 14.11 ± 2.08 I 7.0 
I I 0.67 1 1.36 i 
i 21 '3 IH ' 2.70 ± ! 39.60 ± 14.6 17.6 
I I I I 0.17 i 2.23 
,22 '3 'H 
1
2
.
11 ± I 19.97 ± 9.5 22.6 
i J 1.84 I 0.08 
24 4 IH 115.00 ± 18.53 ± 0.57 3.17 
I 1 1.96 1 0.78 
37 2 
'Uf ' 3.20 ± • 25.01 ± 7.8 14.9 1 0.27 2.32 i 
1
38 3 I~ 1 3.33 ± 83.80 ± 25.2 14.3 
I ,I , 0 I 0.16 3.11 I~ 
139 14 I~ i 5.39 ± 18.38 ±, 3.41 8.8 i 
0.29 0.90 
I V 0 , 
140 6 2.40 ± 1 16.77 ± i 6.99 j 19.8 Uf # 0 0.093 i 0.86 1 
41 '2 
' 0 6.44 ± I 142.55 • 22.1 17.4 
--Q-{ 1 ± 38.87 I - X ' 0.41 i 
42 2 0 [2.32 ± i 76.30 ±' 32.9 20.5 
I 
-o-G--t: i 0.16 17.77 i 
43 2 CF3 I 10.46 ± I 143.99 13.77 I 4.6 i 
F3C-Crt 
1 i 
1
0
.
20 ± 29.44 
I i 
, 
144 '2 CF3 1 2.02 ±I 15.17 ± 
7.5 23.6 I 
Ct{ I 1 
I 
0.15 0.98 
! 1 CF3 i 
145 '2 0 2.50 ± I 34.43 ± 13.8 , 19.0 f , CI 
"" - i I I I ---0-{ 020 545 i I I 
alCso in GR I ICso in TryR; blC50 of CO (TyrR) I IC50 of FnO (TryR); eno significant inhibition at 
20001lM. 
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The more potent the compound the better as lower concentrations can be used, reducing the 
potential of problems with toxicity towards mammalian cells. In addition, with lower selectivity, 
the likelihood of the compound being toxic towards mammalian cells is greater. Therefore the 
higher the selectivity and potency indices the better. By this reckoning 42 shows the most 
promise. It showed selectivity slightly lower than that of chloroquine but is Significantly more 
potent. Whilst the lower selectivity may count against the compound, the greater potency 
means that lower concentrations of the drug could be used to achieve the same efficacy. 
In Vitro tests against Leishmania and Trypanosoma Parasites 
Following the results of the aforementioned enzyme inhibition assays, three of the urea 
compounds, 37, 42 and 45 and the parent ferroquine derivative 20 (Figure 5) were selected for 
in vitro testing against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei 
rhodesiense. These tests were all carried out at the Department of Infectious and Tropical 
Diseases, London School of Hygiene and Tropical Medicine. 
~H 
NL.# N~N~N/ o H Fe I 
/ ~ 
CI 
20 
H 
N~ /;-N~N~N/ 
/; HNAO Fe I 
CI d Q 
37 
(\ H 
N~/;-N~N~N/ 
~ /; HNAO Fe I 
I Q 
CI ~ 
CI 
45 
Figure 5: Four ferrocenyl compounds tested against a Leishmania 
and Trypanosoma parasites 
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Leishman iasis 
Table 4: In vitro tests against L. donovani 
I EDso (EDgo) EDso (ED90) % Inhibition I 
Compound 119/ml 11M 3Ol1M 10JlM 3JlM 1JlM I 
Pentostam • 8.9 a 144.2 i 
20 9.95 (12.6) 20.9 (26.5) T/100" T/100 T/+ 0 
1
37 I 5.8 (6.6) 9.5 (10.8) T/100 T/100 0 
42 14.0 (16.6) 22.4 (26.5) T/100 i 0 I 
i 45 14.0 (16.6) 22.2 (26.3) T/100 0 
apentostam IS sodium stlbgluconate and the EDso value is expressed as I-Ig 
Sbv/mL or I-IM Sbv 
bT/100 - toxic to macrophages, no parasite present. 
The ED values indicate that these drugs show some potential against Leishmania donovani. All 
the new compounds exhibit an efficacy of 7-fold greater than the standard drug, Pentostam. 
Compound 37 was found to be most active. However, although the drugs are toxic to the 
parasite, they also show toxicity to the macrophages. Since L. donovani parasites exists as 
intracellular amastigotes, the drug must pass through the macrophage to reach the parasite. 
Selective toxicity is thus crucial. 
Chagas' Disease 
Table 5: In vitro studies against T. cruzi 
EDso (ED90) I EDso (EDgo) % Inhibition 
Compound Jl9/ml 11M 30JlM 1Ol1M 3JlM 1JlM 
Benznidazole 12.4 47.7 
20 >30 >63 32.8 7.3 1.2 0 
37 (1)" 3.7 (>30) 6.1 (>49) i 82.5 52.6 48.0 44.1 
I 
! 37 (2) 1.5 (>30) i 2.5 (>49) 80.11 65.53 : 58.71 47.54 I 
r
42 
! 
1>30 >48 41.5 13.9 10.9 '0 i 
! 45 >30 >48 46.7 27.9 !O I 
a 37 tests repeated 
With the exception of 37 these compounds show very little activity against Trypanosoma cruzi. 
The assays of 37 were repeated because they are anomalous with the rest of the series. This 
compound was found to be more active than the standard drug, Benznidazole. T. cruzi 
parasites also exist as intracellular amastigotes. 
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African Sleeping Sickness 
Table 6: In vitro activity against T. b. rhodesiense ST1B900 
ED50 ED50 % Inhibition 
Compound ~g/ml ~M 
i 
30~M 10~M 13~M 1~M 
Pentamidine 0.012 0.025 
20 2.55 5.36 • 99.3 98.8 97.3 0 
1
37 1.55 2.54 98.5 98.0 58.6 46.0 
I 
42 1.71 2.73 98.1 97.4 50.0 47.4 I 
1
45 4.41 7.00 99.6 98.2 22.3 i 9.7 
i 
The results against Trypanosoma brucei rhodesiense show good promise. However, the 
standard drug, Pentamidine, is at worst 1 DO-fold better than any of the new compounds. T. 
brucei exists in the bloodstream as extracellular trypamastigotes, so the problems associated 
with drug penetration of the macrophage are not present and the drug is far more likely to reach 
the site of action intact. 
If the mode of action of these compounds was solely attributed to trypanothione reductase 
inhibition then there is no correlation as 42 and 45 since show superior efficacy as inhibitors of 
trypanothione reductase. However, 37 is conSistently the best candidate from this series, 
having ED50 values for in vitro antiparasitic activity superior to 42 and 45.·As mentioned 
previously, it is possible that other factors such as cell penetration and metabolism could be 
playing a significant role in accounting for the greater efficacy of 37. 
In Vitro tests against a variety of strains of P. falciparum 
Selected compounds were tested against a variety of strains of P. fa/ciparum and their efficacy 
compared to various standard antimalarial drugs. All strains are sensitive to mefloquine, 
artelinic acid, artemisinin and dihydroartemisinin. Strain W2 is resistant to chloroquine. Strains 
W2, TM91-C235 and TM90C2b are all resistant to quinine. 
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Figure 6: Selected compounds tested against a variety of strains of 
P. falciparum 
Table 7: Comparative results of urea, sulfonamide, and acridine 
compounds with standard antimalarial drugs against various strains of P. 
falciparum (Walter Reed Army Institute of Research) 
ICso (ng/ml) 
. Strain D6 I W2 WR87 i TM91-C235 TM90C2b 
• CQ 2.81 153.85 5.96 59.78 76.13 
Mefloquine i 10.71 3.80 9.83 14.48 12.78 
i 
Quinine 17.90 134.28 44.26 197.97 184.08 
Artelinic acid i 4.51 2.63 4.37 5.41 0.5 
i Artemisinin 2.26 1.11 2.7 .2.02 1.9 
Dihydroartemisinin 1.12 0.75 0.77 0.97 0.84 
37 ·4.85 7.30 8.33 6.1 7.59 
42 5.80 13.18 4.25 8.65 12.02 
148 14.12 > 100 13.25 43.58 146.07 
i 104 7.46 9.05 7.06 7.94 9.45 
• 
RCS 
83.33 
1.61 
92.84 
1.3 
0.84 
0.6 
8.79 
7.13 
80 
7.03 
I 
I 
I 
i 
I 
i 
i 
I 
The results in Table 7 show that against the chloroquine sensitive, 06, ureas show comparable 
efficacy to chloroquine. Whilst against the chloroquine resistant strain, W2, they are in general 
at least ten times better than chloroquine. These urea compounds show comparable activity to 
mefloquine, but are not as good as artelinic acid, artemisinin or dihydroartemisinin. Compounds 
77 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 5 Biological Testing 
37 and 42 show fairly consistent efficacy throughout all the strains of P. falciparum. This implies 
that there is little cross-resistance between these compounds and either quinine or chloroquine. 
The sulfonamide compound showed efficacy of a similar magnitude to chloroquine with much 
variation of efficacy between strains of the parasite. Compound 104 is a quinacrine analogue 
and its preparation is discussed in Chapter 6. It shows consistently good activity against all 
strains. 
In Vivo Studies 
It has been mentioned in Chapter 1 that malaria is caused by parasites of the genus 
Plasmodium. Plasmodium falciparum is the main species found in Africa and is the species in 
which chloroquine resistance is most prevalent and is therefore of greatest interest to this study. 
For in vivo studies it is normal to test the potential antimalarial drugs against Plasmodium 
berghei, a species of the parasite that has been developed for use in mice. P. berghei is 
sensitive to chloroquine. All in vivo testing was carried out at the Department of Infectious and 
Tropical Diseases, London School of Hygiene and Tropical Medicine. 
Table 8: In vivo activity of selected compounds against P. berghei 
Group Dose I Dose Schedule Mean St Mean St 
(mg/kg) i (j.lmol/kg) Parasitemia Err Survival Err 
% Time 
(days) 
. Control 
- - 16.99 1.30 I 5.00 0.00 
CO 10 • 31.3 x4 0.00 0.00 28.00 0.00 
120 25 52.4 I x4 10.00 0.00 15.20 1.24 
37 25 41.0 x4 0.00 0.00 >30 N/A i 
142 25 39.9 x4 0.00 0.00 >30 i N/A I 
i 45 25 39.7 • x4 0.42 0.37 23.00 1.30 
I 
Table 8 indicates that in accordance with the in vitro results, all the compounds tested show 
good antimalarial activity in vivo. This is demonstrated by the mean parasitaemia. For all 
compounds, except 45, no parasitaemia could be detected in the blood at the indicated doses. 
This implies that 20, 37 and 42 all kill the parasite in the blood stage of the disease, which is 
consistent with the mode of action of 4-amino-7-chloroquinolines.B The mean survival time of 
the mice is a good indication of the toxicity of the compounds towards the mice, the longer the 
survival time, the lower the drug toxicity, Thus, it would appear that 20 is more toxic than 37 or 
42. 
The functionalisation at the secondary amino group of 20 to form the ureas appears to play an 
important role in reducing the toxicity of the drug candidates towards mice. Within this limited 
series of compounds, 37 and 42 are the most efficacious. 
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Compounds 37 and 42 were carried through to another phase of in vivo trials in a different 
malaria mode. This time P. chabaudi, a chloroquine sensitive strain of the parasite was used. 
The drug was administered orally and as a subcutaneous injection in different groups. The 
determination of the efficacy is therefore particularly important because it sheds some light on 
the stability of the compounds in the harsh environment of the gastro-intestinal tract. 
Table 9: In vivo trials against P. chabaudi 
I Compound I, Route I EDso (range) : EDso (range) I % suppression 
l ' I mg/kg x 4 I mg/kg x 4 i at 10mg/kg 
I CQ I Subcutaneous 1 1.9 (2.3-2.6) i 3.5 (2.3-4.6) I 100 
'-, C::-cQ::-----+-
1 
Oral ' 1.6 (1.0-2.8) 2.9 (1.8-5.3) 100 
77~-+~:~~~~~-r~~--------~ 37 L Subcutaneous 16.0 (13.0-20,0) 20.0 (16.0-25.0) 99.9 I 
37 i Oral 10.0 (5.0-13.0) 16.0 (7.2-17.0) 46.4 
142 I Subcutaneous [2.7 (1.4-4.8) I 6.5 (3.5-12.5) 96.6 
142 I Oral 1 17.5 (12.5-25.0) i 22.5 (16.0-32.0) i Nil 
In the case of chloroquine, it is noted that there is very little difference between the 
subcutaneous and oral results. However, it is clear that the route of administration of the urea 
compounds has a marked effect on their in vivo efficacy. Compound 37 shows similar activity to 
chloroquine in the SUbcutaneous trial. However, oral administration of the drug results in a 
marked decrease in efficacy. Compound 42 also exhibits a similar trend in moving from 
subcutaneous to oral administration. However, the efficacy of chloroquine is still superior. 
Conclusions 
It is quite clear that the incorporation of the ferrocenyl moiety in the side chain of 4-amino-7-
chloroquinolines has a beneficial effect on the efficacy of these compounds against chloroquine 
resistant strains of Plasmodium. As previously demonstrated,2 the length of the methylene 
spacer has an effect on the efficacy of the compounds. In the ferroquine analogues it has been 
demonstrated that the compound with the three-carbon methylene spacer between aniline and 
secondary amine nitrogens was the most efficacious, whilst in the urea derivatives the 
compound with the two-carbon methylene spacer was favoured. 1 
The in vivo studies show that the ferroquine amine analogues appear to be fairly toxic. The 
toxicity can be reduced by the incorporation of a urea moiety. The urea compounds, in 
particular the benzyl urea 37 and the p-methoxyphenyl urea 42 show good activity in vivo 
provided they are administered by subcutaneous injection. 
The coordination of a metal centre to chloroquine showed improved efficacy in chloroquine 
resistant strains of the parasite relative to uncomplexed chloroquine. However, the effect of 
complexing gold or rhodium to the ferroquine analogues and derivatives was, at best, 
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negligible. In some cases the complexation of the second metal resulted in an apparent 
antagonistic effect. 
Overall compounds 37 and 42 appear to be the most promising drug candidates within this 
limited series of compounds. They show good efficacy against a variety of both chloroquine 
sensitive and chloroquine resistant strains of P. fafciparum in in vitro tests. Compound 37 in 
particular shows a broad spectrum of in vitro activity against the causative agents of several 
tropical diseases. They also show good inhibition of trypanothione reductase whilst maintaining 
a high selectivity for the same enzyme relative to glutathione reductase. Finally, they show 
similar activity to chloroquine against chloroquine sensitive P. berghei in an in vivo study, but 
display a better mean survival time. 
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Preliminary Structure - Activity Relationships 
Introduction 
The synthesis, characterisation and biological evaluation of ferroquine analogues has been 
detailed in previous chapters. The formation of organometallic derivatives and coordination 
complexes between the ferroquine compounds have also been studied. The aim of this chapter 
is to explore the relationship of the chemical structure and the biological activity with a view to 
determining those sub structural motifs which may be important for biological activity either on 
their own or in combination with others. It should be noted that the intention of this study was 
not to determine the necessary features for the activity of 4-aminoquinolines, as this arena has 
been looked at carefully and the results of such studies have been established. 1 Rather, the 
focus here is to conduct preliminary studies into the structure-activity relationships of ferroquine 
analogues. Whatever the mode of action of the compounds under study, structure-activity 
relationships could arise from the specificity or non-specificity of these compounds. 
This chapter deals with the synthesis and characterisation of some new compounds and the 
biological activity thereof. From these results some conclusions can be drawn as to the relative 
importance of several component parts of the molecules in question. As the emphasiS of this 
section is on structure-activity relationships within this series of compounds, the synthetic 
routes employed to make the required compounds were, as far as possible, analogous to those 
previously used. 
The characterisation data is detailed in the general experimental section (Chapter 8). 
Rationale 
The principle question arising from the study of ferroquine derivatives and related compounds is 
to establish the role of the ferrocenyl moiety in the efficacy of these compounds. Ferroquine 15 
is indisputably a remarkable compound. It is more efficacious than chloroquine in both sensitive 
and resistant strains of the parasite, it has low toxicity, both enantiomers are equipotent and it 
appears that there is no sustained build-up of resistance to the drug so far.2 The development 
of ferroquine followed a 'bait and hook' rationale. It is known that P. falciparum has an avidity 
for iron.3 The presence of the iron in the ferrocenyl moiety in the side chain of chloroquine could 
provide the 'bait' whilst the presence of the chloroquine framework I.e. the 4-amino-7-
chloroquinoline and terminal tertiary amine groups provides the 'hook'.2 
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M = Fe: 15 
M = Ru: 83 
M = Fe: 20 
M = Ru: 84 
Figure 1: Ruthenocene and ferrocene analogues 
Results from our laboratory suggest that there is no significant difference in in vitro efficacy 
between analogous compounds containing ruthenocene, Figure 1.4 On this basis, it could 
therefore be suggested that the efficacy of these compounds could be attributed to the large 
hydrophobic group present in the ferroquine or ruthenoquine molecules rather than the effect of 
the metal centre: It was then postulated that replacing ferrocene with phenylene could result in 
a compound which showed similar efficacy to ferroquine. 
Table 1: In vitro activity of ferrocene and ruthenocene analogues against 
P. falciparum (Dept of Pharmacology, University of Cape Town)4 
010 (CQS) K1 (CQR) 
Compound Metal IC50 nM IC50 nM 
CO 37.0 568 
15 Fe 16.3 5.0 
83 Ru 23.8 6.3 
20 Fe 26.3 30.6 
84 Ru 20.2 20.8 
! 
In Chapter 5, the biological activity of a number of ferrocenyl compounds is reported. On the 
basis of the variation in efficacy of those compounds and the efficacy of the ruthenocene 
compounds it was thought that various structural motifs in these compounds could contribute to 
the overall efficacy of these molecules in an additive or synergistic manner. The envisaged 
structure-activity relationships are summarised in Figure 2 . 
• Note that ruthenoquine (83) has also been synthesised independently in the laboratory of Prof 
JS Brocard. 
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, , 
~'/ HN : c::=>: N ,...:-----t-: : I 
-;:::r M 
:.Q.: M==FeorRu ; : <= phenylene 
.... ______ i 
n == 2 - 6 
chloroacridine y-, , -------_, 
~ ____ H+N~_:'~-~db~l/ 
-;:::r : M : fr' I Q. I M = Fe or Ru II ~, ________ j<= phenylene 
tertiary amine 
amide 
urea 
sulfonamide 
Figure 2: Preliminary structure-activity relationships 
The variation in the length of the methylene spacer, n, has already been discussed in Chapter 
5. Here three basic structural motifs are used: one motif based on ferroquine, a second motif, 
based on 20, in which there is a reactive secondary amine centre and a third motif based on 37 
in which an organic substituent has been introduced at the reactive secondary amine centre. 
The compounds synthesised for this series of preliminary structure-activity studies are 
summarised in below. 
H~~~/ 
CI-CO U-
85 
Figure 3: Substituting metaliocene with phenylene moiety 
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'I ~ H 
N N~N~N/ 
I~ 
b 
89 
Figure 4: Substitution of 7-chloroquinoline by qUinoline 
90 
H 
~/N~N~N/ ~~ H Fe I 
Q 
91 
Figure 5: Substitution of quinoline by pyridine 
Figure 6: Substitution of quinoline by chloroacridine 
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n 
Figure 7: Importance of components of 37 
H 
II-N~N~N/ 
II HNAO Fe I (iQ 
37 
H 
N~N~N/ 
~o Fe I V ~ 
96 
H 
N~N~N/ 
~ Fe I V LQ.\ 
97 
Figure 8: Importance of urea linkage 
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Synthesis of Structure-Activity Compounds 
Substitution of Ferrocenyl Moiety by Phenylene Moiety 
The synthesis of 'benzoquine' 85 and corresponding analogue 86 could be carried out in the 
same manner as ferroquine 15 and 20 respectively. Compound 85 bears some resemblance to 
amodiaquine 98. However, as amodiaquine is a Mannich base the in vivo chemistry of 
benzoquine is likely to be different to that of amodiaquine. 
(l(0H( 
HN/~~N--...../ 
Cld) 
98 
Figure 9: Amodiaquine 
Synthesis of Benzoquine Analogues 
Dimethylaminomethylbenzene 99 is commercially available, and as the chemistry of ferrocene 
and benzene is known to be very similar, it was decided that a similar method of preparation 
would be used for making intermediates leading to benzoquine if possible. 
_t_-B_u_L_i ---'I ....... L() 
Et20 
~ !J 
DMF 
99 100 101 
Scheme 1: Synthesis of 101 
The first step in the synthetic scheme requires the synthesis of 2-
dimethylaminomethylbenzaldehyde 101, Scheme 1. This compound is known, but was 
previously prepared using n-butyllithium in hexane and isolated using vacuum distillation after 
work-up (yield 53%).5 As indicated in Scheme 1, tert-butyllithium was used in the synthesis and 
silica gel chromatography used to isolate the product after work-up (yield 60%). 
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° H~ fN/ ~!J I 
101 
86 
(i) 32, MeOH, 
2SoC, 18h 
(ii) NaBH4, 6h 
4,7 -dichloroquinoline, 
K2C03, Et3N, NMP, 
heat under reflux, 4h 
Scheme 2: Preparation of 85 and 86 
85 
Compounds 102 and 103 are known. 6,1 The synthetic route employed to prepare 103 is quite 
different to that used to prepare the compound previously.7 As shown in Scheme 2, 103 was 
made via the benzyl oxime 102. It is possible to make 103 from the benzonitrile 104, Scheme 3, 
but as 101 was required for the synthesis of 86, it was decided to use a similar methodology to 
that used for a related ferrocenyl compound (Chapter 2). 
Ni 
104 
Scheme 3: Alternative synthetic methodology to 921 
As mentioned earlier, the synthesis of 85 and 86, Scheme 2, followed the same methodology 
as that described in Chapter 2 for the synthesis of ferroquine and the ferroquine analogues. No 
significant difference was found in the reactivity between analogous phenylene and ferrocene 
compounds. 
Substitution of the 7-Chloroquinoline Moiety 
Synthesis of Quinoline Compounds 
As would be expected these compounds are synthesised in exactly the same manner as 7-
chloroquinoline compounds. The absence of the chlorine in the 7-position has no noticeable 
effect on the reactivity of these compounds. Reaction conditions are not given in Scheme 4 as 
these have been detailed in Chapter 2. 
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CI 
cO~1 ~ ::-.. N 
105 
.. 
HN ~NH2 
cO 
106 
0 
H¥~/ 
Fe 30 
.0-
.. 91 
O-o-N02 ~N-i 
"==1- 0 53 
90 92 
Conditions for all reactions have been described previously 
Scheme 4: Synthesis of 90, 91 and 92 
Synthesis of Pyridyl Compounds 
The reactivity of 4-chloropyridine is similar to that of 4,7-dichloroquinoline because in both 
molecules, the reactive chlorine lies para to the nitrogen in an aromatic system. This facilitates 
a nucleophilic substitution reaction. The pyridyl compounds were then synthesised in a manner 
similar to the chloroquinoline compounds. The only significant difference here was that 4-
chloropyridine hydrochloride as used as a starting material. This meant that the hydrogen 
chloride had to be removed from the reaction mixture. This was achieved by stirring the starting 
material with triethylamine for a few minutes prior to addition of the other reagents. The 
synthesis of compounds 93, 94 and 95 is detailed in Scheme 5, but only amendments to the 
previously described synthetic methodologies are noted. 
CI 
6·HC1 N 
107 
93 
Conditions for all reactions have been described previously 
Scheme 5:Synthesis of 93,94 and 95 
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The other point to note is that the pyridine derivatives appear to be significantly more basic than 
the quinoline analogues. The pyridine compounds all had lower Rf values than the analogous 
quinoline compounds on silica gel TLC plates. 
Synthesis of acridine derivative 
This compound was synthesised in similar manner to that described for 20. The only difference 
was in the synthesis of the tricyclic diaminoethane 109, starting material. This was carried out in 
high yield according to a literature procedure. s This was then reacted with the ferrocene 
carboxaldehyde 30 under the reactions conditions used for 20. There was no significant 
difference in yield or Rf value of 109 when compared to 20. 
o 
H~( 
Fe 
~ 
(i) MeOH 
93 
+ (ii) NaBH4 
CI 
30 
Scheme 6: Synthesis of 93 
Effect and Nature of the Urea Moiety 
Much study was carried out on the benzyl urea ferroquine derivative 37. It was therefore 
deemed appropriate to try and ascertain which components are most necessary for high 
efficacy and low toxicity. The benzyl urea is essentially a trisubstituted urea, the substituents 
being N1_(7 -Chloro-q uinolin-4-yl)-ethane-1 ,2-diamine, (2-dimethylaminomethylferrocenyl)-
methylamine and benzylamine, Figure 7. 
By synthesising and testing the efficacy of the three basic components indicated in Figure 7 
separately, it may be possible to elucidate which components are necessary for the activity. 
Synthesis of Urea Compounds 
The urea compounds were synthesised in much the same manner as described in Chapter 3. In 
all cases, the urea moiety was introduced using nitrophenylbenzylcarbamate 53 (described as 
method 4 of urea preparation in the general experimental) and reacting it with the appropriate 
primary or secondary amine. 
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OD-N02 ~N-{ 
~- 0 
53 
U-~~NH ~ § HN~O 
Gil d 95 
Conditions of reactions have been detailed 
previously 
Scheme 7: Synthesis of 94 and 95 
Comparison of Amide, Amine and Urea Moieties 
Synthesis of Benzyl Compounds 
Whilst looking at the compounds described above is of importance, it is also necessary to look 
at the significance of the urea moiety in the efficacy of the compounds. This was achieved by 
looking at three different benzyl derivatives, Figure 7. 
22 
Et3N 
.. 96 + CI CH2CI2, 0:0 2SoC,2h 
o 110 
Scheme 8: Synthesis of 96 
The urea compound was synthesised as previously discussed (Chapter 3). The amide 
derivative 96 was synthesised by condensation of 20 and benzoyl chloride in the presence of 
triethylamine. 
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97 
Scheme 9: Synthesis of 97 
The amine 97 was synthesised, using an adapted literature procedure,9 from 20 and 
benzaldehyde in the presence of sodium borohydride and trifluoroacetic acid. 
Introduction of amide linkage into 20 
The introduction of a carbonyl group in position 3' could be expected to have an influence on 
the reactivity of the adjacent secondary amine centre. The compound was made by 
condensation of the ferrocene carboxylic acid chloride with 20 in the presence of triethylamine . 
... 
112 113 
Scheme 10: Synthesis of amide 114 
The ICso value in the D10 chloroquine sensitive strain was determined for this compound at the 
Department of Pharmacology, University of Cape Town. It was determined to be 623 nM (306 
ng/ml) whilst the original amine compound 20 was determined to have an efficacy of 26.3 nM 
(5.38 ng/ml) in the series of assays (Chloroquine 37.0nM, 11.83ng/ml). The efficacy in the 
chloroquine resistant K1 strain was not determined. It is surprising that such a small difference 
in structural change could result in such a significant difference in in vitro efficacy against P 
falciparum. This result is anomalous with the rest of the structure activity results reported below 
and is therefore, probably worth repeating before any major conclusions could be drawn. 
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Structu re-Activity Relatio ns hips 
All the biological results detailed below were obtained from the Department of Infectious and 
Tropical Diseases, London School of Hygiene and Tropical Medicine. In vitro assays were 
carried out against 3D7, a chloroquine sensitive strain, and K1, a chloroquine resistant strain of 
Plasmodium falciparum. Toxicity was determined against mammalian cells. The standard 
control drug used for this assay is podophyllotoxin 115. 
~HH 
<:XXP 
:: H 
() 
H3CO~OCH3 
OCH3 
115 
Figure 10: Structure of podophyllotoxin 
Comparison of Ferroquine, 8enzoquine analogues and advanced 
intermediates 
Ferroquine 15 was not tested in the same series of assays. Both 15 and 20 have been tested 
against the K1 chloroquine resistant strain of P. faiciparum previously at the Department of 
Pharmacology, University of Cape Town. The results of these assays are given in Table 1 
above. It is apparent in those assays, that 15 showed a three fold improvement in efficacy in the 
K1 chloroquine resistant strain, whilst 20 showed similar efficacy in both the 010 chloroquine 
sensitive strain and in the K1 chloroquine resistant strain. The intermediates 30, 31, 32, 101 
and 102 were screened in the same series of assays. This was deemed worthwhile as the 
intention of the study is structure-activity relationships and the activity of the phenylene or 
ferrocenyl moieties in the quinoline system was of particular interest. Whilst it is apparent that 
the 4-amino-7-chloroquinoline moiety is necessary for an efficacy against P. falciparum in the 
above assays, there appears to be little difference in the efficacy between phenylene and 
ferrocene analogues. Perhaps the oxime compounds demonstrate this most effectively. It is 
noteworthy that both phenylene and ferrocene oximes exhibit no activity against the chloroquine 
sensitive 307 strain, but show efficacy, albeit modest, towards the chloroquine resistant K1 
strain. Both 85 and 86 exhibit similar efficacy to chloroquine in the chloroquine sensitive 307 
strain. On the other hand, both 86 and 20 showed significantly diminished efficacy in the 
chloroquine resistant K1 strain. This would suggest that there is a degree of cross resistance. 
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Table 2: In vitro studies on phenylene and ferrocenyl analogues 
I Compound 
Podophyllotoxin 
Chloroquine 
101 
F 
! 
1
31 
i 
I 
132 
i 
r 
! 
86 
20 
i Structure 1307 (COS) 1 K1 (COR) I Toxicity 
· IlM (Ilg/ml) ! IlM (Ilg/ml) i IlM (Ilg/ml) 
I 
0.00024 
HN~r:./ 0.00138 0.47 (0.0044) (0.15) lro . CI :".. 'N 
-+,184 0 >184 
1
160 
HJ.J....= N" 
IH~~' 
. Fe 
, .0-
HO.
NgN
" 
:\ /, I 
HO'N~~" 
Fe 
.0-
H2N~~" 
Fe 
i .0-
I HN:6'N" I '/ '\ I «'0 -CI :".. 'N 1 
{)-~./'NON' o H '/'\ I 
:\/, -
CI 
I N::=>-~./'N~N' 
i (>30) 
134 
(28.9) 
1 >168 
· (>30) 
>130 
· (>30) 
>139 
(>30) 
0.0014 
(0.00047) 
0.0068 
(0.0025) 
i 
<0.2 
«0.1 ) 
• (>30) 
>139 
(>30) 
36.5 
(6.5) 
46 
(10.8) 
76.7 
! 
(16.6) 
0.0031 
(0.010) 
0.461 
(0.170) 
0.650 
(0.310) 
. 26.1 
450 
(96.8) 
i 773 
(137.6) 
17 
(4) 
11.6 
• (2.5) 
70 
(22.9) 
14 
(5.1 ) 
133 
(63.6) I· 0 H Fe I 
'--_____ -l....-C_I _____ 'O-__ ~ ____ ."'_I _____ '--___ ......J 
Although the exact mode of action of phenylene and ferrocene derivatives is unknown as yet, 
these results do suggest that the ferrocenyl mOiety might simply be acting as a hydrophobic 
group. If that is the case, the phenylene derivatives offer a promising new avenue of research. 
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Effect of substitution of the 7-chloroquinoline moiety 
7 ·Chloroquinoline versus Quinoline 
It well known that the presence of the chlorine atom in the 7 position of the qUinoline ring plays 
an important role in the binding of quinoline compounds to haematin and hence influences the 
ability of the compounds to inhibit ~~haematin formation. This has a significant effect on the 
efficacy of analogous compounds against a chloroquine sensitive strain of P. fa/ciparum, Figure 
11. 
HN~NH2 
~ 
UN) 
Does not inhibit r..-haematin formation 
IC50 in D10 strain of P. fa/ciparum = 3 800 ± 500nM 
106 
Does inhibit r..-haematin formation 
IC50 in 010 strain of P. fa/ciparum = 92 ± 12nM 
Figure 11: Effect of presence of chlorine atom in the 7 position 10 
The results shown in Figure 11 indicate that there is a 40 fold difference in efficacy between the 
two compounds shown. The only difference between them is the presence of the chlorine atom 
in the 7 position. Presuming inhibition of ~-haematin formation to be the mode of action of these 
antimalarials and the ferrocenyl mOiety to have no influence on the inhibition of ~~haematin 
formation, it could be postulated that the compounds shown in Figure 4 would show a similar 
decrease in efficacy as antimalarial agents with respect to 15, 20 and 31. If, however, the 
ferrocenyl unit enhances the antimalarial activity and/or ~-haematin inhibition in some way, the 
efficacy may not be so severely affected. 
7 ·Chloroquinoline versus Pyridine 
There have been various reports on the use of pyridine derivatives in antimalarial 
compounds. 11 .12 A brief perusal of the results reported indicate that 4-aminopyridines show no 
antimalarial activity. 
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Figure 12: Pyridine analogue of chloroquine (inactive against P. 
relictum)12 
If the pyridine analogues of 15, 20 and 37 show activity, it could indicate that the ferrocenyl 
mOiety itself is playing some role in the antimalarial activity of these compounds. 
7 -Chloroquinoline versus Acridine derivatives 
Quinacrine 3,13 also known as mepacrine, was the antimalarial drug of choice before 
chloroquine. 14•15 Again, the incorporation of ferrocene in the side chain of this compound was 
deemed worthy of investigation to ascertain whether the beneficial influence of the ferrocenyl 
moiety exhibited in the ferroquine analogues is also observed in acridine derivatives. 
CI 
3 
Figure 13: Quinacrine (3) 
There are several points to note from the results reported in Table 3. The efficacies of 87 and 
89 are superior to those of chloroquine in the chloroquine sensitive 3D7 strain despite the lack 
of the chlorine atom in the 7- position of the quinoline ring. There is a slight decrease in activity 
in moving from the 7-chloroquinoline to the quinoline but the effect is not as marked as would 
be expected when compared to previous studies e.g. Figure 11. This suggests these results 
may be strain specific. The pyridine derivatives show limited efficacy while the acridine 
derivative shows good efficacy, albeit they display high toxicity towards mammalian cells. It 
should be noted that neither the pyridine derivatives 92 nor the quinoline derivatives 87 and 88 
inhibit l3-haematin formation, but the acridine derivative 93 does. It would appear that the 
presence of the ferrocene in the side chain does have a positive influence on the efficacy of 
these compounds, indicated by the good efficacy of the quinoline compounds. However, the 
quinoline moiety is still necessary for activity. This may suggest that there is an additive or 
synergistic effect arising from the incorporation of the ferrocenyl moiety. 
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Table 3: Effect of modifications to 7 -chloroquinoline on in vitro 
efficacy 
,compound I Structure -:1--~ ~~(CQS) K1 (CQR) Toxicity 
11M (Ilg/ml) 11M (Ilg/ml) 11M (Ilg/ml) . 
___ L-. 
0.00024 "I IOdOPhY~~ 
Chloroquine 
I I ~ 
120 [~" N. /, N-""'~~~~ ~ !. Fe 
I 'CI Q. 
37 S-" N. /, N-""'N~~~ ~ /, HN...l;:.O Fe 
CI cr Q. 
I /. 
I 
'--._-
87 HN~N~ 00 Fe I 
" "N Q. 
88 
89 
92 
0.0137 
(0.0044) 
<0.2 
«0.1 ) 
0.007 
(0.004) 
0.0083 
(0.0033) 
0.837 
(0.44) 
·0A7 
(0.15) 
0.65 
(0.31) 
0.29 
(0.18) 
0.125 
(0.050) 
.~~. 0.927 
(0.410) 
0.59 
(0.33) 
21.7 
(11.4) 
._-_. 
133 
(63.6) 
24 
(14.5) 
13 
(5.2) 
13.8 
(6.1) 
8.0 
(4.5) 
42.0 
(21.9) 
.-
93 --l-0::-.""'00-::-1:-::3---l-0::-.~00=77::---·-I-O:-. 9:-C:O-~· 
(0.0007) (0.0043) (0.50) 
96 
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Effect of urea moiety 
Table 4: Efficacy of the components of the urea 
Compound ! Structure 3D7 (COS) I K1 (COR) . Toxicity ! 
I 
11M (Ilg/ml ) • /lM (/lg/ml) 
I 
/lM (/lg/ml) 
Podophyllotoxin 0.00024 
Chloroquine r 0.0137 0.47 HN~N./ (0.0044) (0.15) I 
ro CI ~ 'N 
i h7 ..... S-H 1 0.007 0.29 24.0 N, I. N~N~N~ • 
• (0.18) (14.5) k I. (0.004) 
:.. I. HN 0 Fe . 
I 
CI cr Q 
I 
.22 g-H <0.20 0.65 133 N, I. N~~~~~ 
«0.1 ) • (0.31) (63.6) 
:-.. I. Fe 
I 
CII Q 
94 g-H 0.113 3.4 73.0 N, I. N~NH (0.04) (1.2) • (25.9) 
:-.. I. HNkO 
CII cr 
I 
.95 I HN~N~ 170.6 29.9 7.2 I 
HNkO Fe I I (28.6) (12.1 ) (2.9) 
I
·. 32 H2N~~' I ~,1')3~ 76.7 ·11.6 
'---_____ LQ_e __ .. ~._--,-(_16_.6_) __ ..J....1 _(2_.5_) __ -" 
It is quite clear that the most efficacious of the benzyl ureas are those containing the 7-
chloroquinoline moiety. Those molecules lacking the 7-chloroquinoline show significantly higher 
ED values. However, it does appear that incorporation of benzyl urea unit is also advantageous 
in that there is a moderate to good improvement in both efficacy and toxicity observed in 
moving from 32 to 95 and 20 to 37. 
Comparison of amide, amine and urea moieties 
It is clear from Table 5 that the nature of substitution at the secondary amine group of 20 does 
have an effect on the efficacy of the benzyl derivatives. Compound 97 shows the greatest 
efficacy in both strains of the paraSite. This is most significant in the chloroquine resistant K1 
strain. The toxicity of all the compounds is moderate. 
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Table 5: Effect of nature of substituent on reactive secondary amine 
centre on in vitro efficacy of benzyl derivatives 
I Compound I Structure 
i 
! 
I Podophyllotoxin ! 
Chloroquine I HN~[-/ 
i 1m I CI '" 'N 
37 S-" I N,,, N..,/"'N~~; I ~" HNkO Fe 
i 
I CI cr .Q 
I 
1
96 g-" N, /, N..,/"'N~~; 
\ ~ /, ~o Fe 
I CI I .....: .Q 
J3-Haematin Inhibition Studies 
1307 (CQS) 
I 
• JlM (!lg/ml) 
0.0137 
(0.0044) 
0.007 
(0.004) 
<0.17 
«0.1 ) 
0.006 
(0.0034) 
! K1 (CQR) I Toxicity 
JlM (!lg/ml) • JlM (Jlg/ml) 
! 
0.00024 
0.47 
(0.15) 
I 
0.29 
1
24
.
0 
. (0.18) i (14.5) 
0.10 9.7 
(0.06) ! (5.6) 
(0.0098) 
~-Haematin inhibition can be determined by carrying out a simple assay and monitoring the 
product by infrared spectroscopy. ~-haematin has characteristic bands at 1660 and 1210 cm·1. 
These bands are not observed if the synthesis of ~-haematin is attempted in the presence of 
chloroquine. This assay has been well documented and has been used to screen many 
potential antimalarial compounds. In general, in 4-aminoquinolines there is a correlation 
between the in vitro efficacy of a given compound against chloroquine sensitive P. fa/ciparum 
and its ability to inhibit ~-haematin formation. 1o 
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Table 6: Inhibition of ~-haematin formation 
I Compound . Structure 
[CQ]diphosphate 
HN~( 
c.)-P' Fe .~ 
CI "'" "'N 
20 
185 
CI 
87 
• 88 
92 
28 
! Inhibition of 
I 
haematin formation 
Yes 
Yes 
Yes 
No 
No 
No 
No 
13-
I 
! 
It is clearly demonstrated from Table 6 that the only compounds that are capable of inhibiting 
the formation of ~-haematin are those compounds which contain the 7-chloroquinoline moiety. 
The acridine compound, 93, is capable of this inhibition because it contains the necessary 
substituent. 
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Conclusions 
The presence of a hydrophobic group in the side chain of chloroquine derivatives has a 
beneficial effect on the efficacy of these compounds particularly in chloroquine resistant strains 
of the P. falciparum. The nature of this hydrophobic group does not appear to be important in in 
vitro studies but it remains to be seen whether there is a difference in in vivo activity between 
phenylene, ferrocene and ruthenocene analogues. 
The presence of the ferrocenyl moiety in the side chain of quinoline derivatives shows a marked 
increase in in vitro efficacy compared with those compounds with an aliphatic organic side 
chain. Moving from quinoline to pyridine results in a large decrease in efficacy, but the pyridine 
derivatives have a greater efficacy than expected. This suggests that the presence of the 
ferrocenyl moiety is important, and that it does have a beneficial influence on the efficacy of the 
compounds. It remains to be seen whether the phenylene or ruthenocene analogues would 
have a similar effect. 
The presence of the benzyl urea results in a lowering of toxicity particularly in the ferroquine 
compounds. Whilst it is acknowledged that the lower the molecular mass of drugs the better, 
the addition of the benzyl urea is justified because it does appear to have a significant influence 
on the toxicity. There also seems to have a beneficial influence on the efficacy of these 
compounds. However, the benzyl amine derivative appears to have a similar efficacy although it 
does exhibit an increased toxicity 
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Conclusions and Future Work 
Conclusions 
The aim of this project was to synthesise new monometallic and heterobimetallic compounds as 
antiparasitic agents. A number of ferroquine type compounds have been synthesised. The 
incorporation of a reactive secondary amine centre in the side chain facilitated the derivatisation 
to form urea and sulfonamide compounds. Two of the new compounds together with ferroquine 
and chloroquine were used to make a series of coordination complexes with gold and rhodium. 
All these compounds were characterised using 1H and 13C NMR spectroscopy. infrared 
spectroscopy, mass spectrometry and elemental analysis (where possible). In addition. 19F and 
31p NMR spectroscopy. molar conductivity and cyclic voltametry were used for further 
characterisation of selected compounds. The x-ray crystal structure of one of the ferroquine 
compounds was determined. 
These compounds were then tested for in vitro antiparaSitic activity with some being tested 
against the antioxidative enzyme trypanothione reductase. In particular most compounds were 
tested against Plasmodium falciparum, the causative agent of malaria. The incorporation of 
ferrocene into the side chain of 4-amino-7-chloroquinolines is clearly advantageous. Many of 
the ferroquine compounds and derivatives showed good efficacy both in chloroquine sensitive 
and in chloroquine resistant strains of the parasite. It was noted that in general the longer the 
methylene spacer between 4-amino-7-chloroquinoline and the ferrocenyl moiety the less 
efficacious the compound. It was also found that introducing a urea group at the reactive 
secondary amine centre resulted in a decrease in toxicity towards mammalian cells. 
The incorporation of a gold or rhodium centre into chloroquine shows an improvement in 
efficacy against chloroquine resistant P. falciparum. However, incorporation of the same into 
the ferroquine compounds resulted in, at best, no effect on the efficacy of the compounds in 
either chloroquine sensitive or chloroquine resistant strains of the parasite. However, in some 
cases an antagonistic effect in the heterobimetallic system was apparent. 
The cyclic voltametry of selected complexes was measured. Ferroquine itself gave a fully 
reversible one electron wave, but the ferroquine analogues showed at best quasi-reversible 
behaviour. The urea derivatives showed fully reversible behaviour. The incorporation of gold or 
rhodium resulted in a large increase in both anodic and cathodic potentials indicating that the in 
vitro ferrocenyl moiety is much more difficult to oxidise when the second metal centre is 
Un
ive
rsi
ty 
of 
C
pe
 To
n
Chapter 7: Conclusions 
present. There did not appear to be any real correlation between the half wave potential and the 
antimalarial activity. 
The urea compounds were also tested for enzyme inhibition against trypanothione reductase 
and glutathione reductase. Those compounds which showed good selectivity for trypanothione 
reductase were tested against the causative agents of Leishmaniasis, African Sleeping 
Sickness and Chagas's Disease, all of which require trypanothione reductase to reduce 
peroxides in the parasitic cell. Little correlation was found between antiprotozoal activity and 
inhibition of trypanothione reductase. 
Having established the efficacy of the aforementioned ferroquine compounds and derivatives, it 
was clear that the presence of ferrocenyl moiety in the side chain was advantageous. However, 
the role of the ferrocene was not well defined. As ruthenocene derivatives show similar efficacy 
to the ferrocene analogues of these compounds, it was suggested that the metallocene could 
simply be acting as a large hydrophobic group. A small selection of compounds were made in 
order to glean some understanding of the role of the ferrocenyl moiety in the ferroquine 
compounds. 
Various phenylene derivatives were synthesised and tested against P. falciparum alongside the 
analogous ferrocene compounds. In all cases, there was little difference in efficacy between 
phenylene and ferrocene derivatives. 4-Aminoquinoline derivatives and 4-aminopyridine 
analogues of three 4-amino-7-chloroquinoline derivatives were also made and tested. The 4-
aminoquinolines were significantly more efficacious than the 4-aminopyridines, but both series 
showed that the presence of the ferrocenyl moiety in the side chain gave a significantly greater 
efficacy than would be expected for compounds lacking the 4-amino-7-chloroquinoline moiety 
on the basis of ~-haematin inhibition as the primary mechanism accounting fro antimalarial 
activity in the chloroquine sensitive strain of the parasite. It is therefore suggested that the 
presence of the ferrocenyl moiety enhances the efficacy of these compounds. 
An analysis of the benzyl urea ferroquine analogue showed that whilst the inclusion of the 
benzyl urea had a minor advantageous effect on the efficacy of these compounds, there was a 
significant lowering in toxicity in mammalian cells associated with inclusion of this group. It was 
also shown that the benzyl amine derivative showed similar behaviour but the benzyl amide 
analogue did not. It is therefore concluded that the presence of the reactive secondary amine 
centre is advantageous, for the purpose of improving toxicity. 
Future Work 
Whilst it is apparent that the phenylene and metallocene derivatives show similar behaviour in 
in vitro assays, it remains to be seen whether this correlation is observed in in vivo studies. 
While it is also apparent that 4-aminoquinoline compounds with ferrocene in the side chain 
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exhibit unusually high antiplasmodial efficacy, it would be worth making the phenylene 
analogues and testing their efficacy in a similar assay. 
It is noted that the inclusion of a benzyl urea or benzyl amine in the ferroquine derivatives is 
advantageous, however, this system has not been optimised. It would therefore be important to 
make a large series of urea and amine derivatives in order to find the most suitable compound. 
This would also serve to determine whether or not the urea and amine linkages are, in fact, 
equivalent in the biological system, or whether this is simple coincidental of the benzyl 
derivatives. Again, increasing the study to the phenylene analogues would be useful to provide 
further evidence to support or refute the similarity between phenylene and ferrocene analogues. 
CloSing Remarks 
In 1947, my grandfather, William Kerr Blackie, wrote a book entitled 'Malaria with special 
reference to the African forms'. He was a general practitioner in Harare, Zimbabwe (Salisbury, 
Rhodesia, as it was then). He ended the historical review with these comments: 
"The disease (malaria) continues to be widespread throughout the length and breadth 
of the Tropics and beyond, and in consequence is responsible for a heavy toll on life, both 
amongst the indigenous inhabitants and amongst European settlers. In addition it is responsible 
for much in the way of chronic ill-health and invalidism. 
But recent advances in chemo-therapy have provided the clinician with new powerful 
drugs for the more efficient treatment of the disease in all its phases, and at the same time 
refinements in laboratory technique have enhanced the accuracy of laboratory diagnosis. 
Again, in the sphere of preventative medicine, the hygienist is now in the possession of 
highly potent insecticides by means of which he can strike at the very heart of the malaria 
problem - the malaria vector. 
None the less, the scientific control and elimination of malaria will long remain a task of 
the first magnitude, but the balance is now more definitely weighted in favour of those who a 
grappling with this elusive biological challenge to human life and enterprise." 
Despite the great advances in medical technology in the last 55 years, the problem of malaria 
remains. Its significance is perhaps being overshadowed by the HIV/AIDS pandemic, but the 
poorest countries in the world continue to battle against a problem in which the First World has 
little interest. Much of the development of antimalarial drugs historically has occurred during 
periods such as the two World Wars, when soldiers from the First World countries were being 
directly affected by this disease. In addition to this, it is the children who are most severely 
affected so the economic effect of the disease is not as obvious as the effect of HIV/AIDS. 
Meanwhile the areas where malaria is endemic slowly grow and drug resistance is increasing 
even more rapidly. If the paraSite had not developed resistance to drugs and the mosquito 
resistance to pesticides, I could not have produced this project, as there would have been no 
real need for much further research in this area. However, these problems are real and once 
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again nature is one step ahead of us. The real key to solving the problem of malaria is 
education in the Third World. Prevention is always far superior to a cure, and the only way to 
achieve prevention is through education. In the mean time, it is my fervent hope that this project 
will serve to increase understanding of the mode of action ferrocenyl-quinoline derivatives, 
thereby sheddding some further light on this specialised field of research. 
On a personal note 
Before commencing this section, I acknowledge that this is not usual to include such a section 
in scientific writing, but I feel it is perhaps important to review the process of producing this 
thesis. The chemistry is, of course, important, and I would like to think that I have made some 
small contribution to the field of medicinal chemistry. I have learnt a great deal about the 
chemistry involved in this project but also something of the chemistry in which my fellow 
students have been involved in. I think I have a far better idea of the nature of chemistry and 
chemistry research than I did three years ago. But in some ways this project has been a part of 
me, and in producing this thesis I have put some of myself on paper for review. 
In addition to the chemistry I have learnt, the personal skills that I have developed will be 
invaluable. I would think it impossible to spend three years in such an environment and not 
learn something about interpersonal relationships. It is also impossible not to learn something 
about self-discipline and self-motivation. It has been for the most part a good and fruitful 
experience and I am grateful for having had this marvellous opportunity. 
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General Experimental 
General Procedures 
Unless clearly stated otherwise all manipulations were carried out under an atmosphere of 
nitrogen using common Schlenk techniques. Syringes were stored at 60°C and all other 
glassware was thoroughly dried for at least 4 h at 210°C prior to use. 
Materials 
The solvents used in reactions for the preparation of compounds in the experimental were 
purified, dried and distilled as described in Table 1, according to literature procedures. 1 N,N-
~," 
" , 
Dimethylformamide, 1-methyl-2-pyrrolidinone and triethylamine were stored in dry glass storage 
vessels equipped with Teflon valve closures and stored under nitrogen. All other solvents were 
freshly distilled before use. 
Table 1: Solvent Purification and Drying Procedures 
Solvent Drying Agent Distillation Colour 
Acetonitrile CaH2 Yes -
Dichloromethane ! CaH2 Yes - I 
Diethyl Ether , Sodium/benzophenone Yes Blue 
N, N-Dimethylformamide Drierite at 15-20mm Hg 
Yes -(DMF) 
Methanol b/Mg turnings Yes -
--
1-Methyl-2-pyrrolidinone Azeotropic distillation 
Yes 
-(NMP) with toluene 
Tetrahydrofuran (THF) Sodium/benzophenone 
I Yes Blue I Itetraglyme ! Toluene Sodium Yes -
I Triethylamine ~ over K,CO" Yes 
-
I I distilled from CaH2 I 
I 
The solvents used for work-up procedures and silica gel chromatography were of analytical 
grade and used without further purification. The only exceptions to this were hexane and 
dichloromethane, both of which were obtained as chemically pure grade reagents and distilled 
in air prior to use. 
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n-Butyllithium (1.6M in hexanes) and tert-butyllithium (1.7M in pentane) were purchased from 
Sigma Aldrich and transferred into Teflon valved storage flasks. The storage flasks were 
wrapped in aluminium foil, and stored at room temperature. 
Chloroquine, free base, was obtained from chloroquine diphosphate by the addition of a strong 
ammonia solution, followed by extraction into diethyl ether. The solvent was removed under 
reduced pressure before dissolving in acetonitrile and allowing to stand at -6°C overnight. A 
white precipitate of chloroquine formed which was then filtered and washed with acetonitrile 
before drying in vacuo.2 
Sodium tetrachloroaurate and rhodium trichloride were provided by Johnson-Matthey. 
Dimethylaminomethylferrocene was obtained from Strem. All other commercial reqgents were 
obtained commercially used without further purification. 
Chromatography 
Column chromatography was carried out on silica gel (Particle size: 0.063 mm - 0.200 mm) 
obtained from Merck. The ratio of product to silica used was approximately 1:80. The column 
was packed by making a slurry of silica gel and the starting solvent system. The sample was 
loaded onto the column in a concentrated solution. It was found that gradually increasing 
polarity to the required solvent system provided good separation of all products. 
Table 2: Starting Solvent System and Final Solvent System for Silica 
Gel Chromatography 
Starting Solvent System ! Required Solvent System 
Et20: Hexane (50:50) Et20:Hexane:EhN (70:20:10) 
CH2CI2:MeOH (95:5) CH2CI2:MeOH:Et3N (80:20:1) 
CH2CI2:MeOH (95:5) i CH2CI2:MeOH (80:20) 
Instrumentation 
Melting points were recorded on a Kofler hotstage microscope (Reichart Thermovar). 
Microanalysis data were performed using a Carlo Erba EA 1108 elemental analyser. Infrared 
spectra were recorded on a Perkin-Elmer Paragon 1000 FT-IR spectrometer in the range 400 to 
4000 cm'l. Samples were either prepared neat between NaCI discs for oils, or as KBr discs for 
solids. All data are given in wavenumbers (cm'\ 
NMR spectra were recorded on either a Varian Unity-400 CH: 400 MHz; 13C: 100.6 MHz; 19F: 
376 MHz) spectrometer or a Varian Mercury-300 CH: 300 MHz; 13C: 75.5 MHz; 31p: 121 MHz) 
spectrometer at ambient temperature, 1H NMR spectra were referenced internally using the 
residual protons in the deuterated solvent (COCh: 0 7.27; C0300: 0 5.84; 0 20: 0 4.79; DMSO: 
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2.50) and values are reported relative to tetramethylsilane (0 0.00). 13C NMR spectra were 
either referenced internally to the solvent resonance (COCh: 0 77.0; C0300: 0 49.1; OMSO: 0 
39.4) or sodium 3-(trimethylsilyl)-1-propanesulfonate was used as an external reference and 
values are reported relative to tetramethylsilane (0 0.0). 19F NMR spectra were referenced 
externally to CFCI3. 31p NMR spectra were referenced externally to H3P04. All chemical shifts 
are quoted in 0 (ppm) and coupling constants, J, are given in Hertz (Hz). 
Mass spectra were determined by Dr Boshoff of the mass spectrometry unit at the Cape 
Technikon. In all cases the isotopic distribution pattern was checked against the theoretical 
distribution. 
Cyclic voltametry (CV) was carried out on a BAS-100B electrochemical analyser in a one-
compartment-three-electrode system, comprising Ag/Ag+ (0.01M) as the reference electrode, 
platinum wire as the auxiliary electrode and a platinum disc as the working electrode. The 
'r' 
supporting electrolyte was a solution of 0.1 M tetrabutylammonium perchlorate in anhydrous 
acetonitrile. The potentials E were recorded without IR compensation. All potentials reported 
are relative to the half wave potential (Em) of the ferrocene/ferrocenium couple run under the 
same conditions. The experiments were performed in 1.0mM solutions under an atmosphere of 
argon at room temperature. The solutions were saturated with argon, by bubbling argon through 
the solution for 5 minutes prior to the CV run. The platinum disc electrode was polished after 
every run. 
Conductivity measurements were performed on a Metrohm 660 conductometer in 1.0mM 
nitrobenzene solutions at 20°C. 
X-ray diffraction data was collected at room temperature using a Nonius Kappa CCO with 
1.5kW graphite-monochromated Mo radiation. The strategy for the data collection was 
evaluated using COLLECT. 3 Several sets of data were collected with both 360°C phi and 
omega scans to collect the cusp data. These data were integrated using OENZO-SMN.4 Unit 
cell dimensions were refined on all data. The program SCALEPACK4 was used for the scaling 
and treating the data for absorption. The structure was solved and refined using SHELX97.5 
Note 
It is acknowledged that the characterisation data given below is in excess of that required by 
most journals. For example, all the infrared bands observed are written down whilst only some 
can be assigned unambiguously. The reason for this is to provide as detailed a record of this 
work as possible as only a small part of this work has been published to date. 
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Experimental Details Pertaining to Chapter 2 
Compound 30 
[(N,N-Dimethylamino )methyl]ferrocenecarboxaldehyde 
Method 1:6 
(Dimethylamino)methylferrocene 28 (2ml, 2.43g, 10mmol) was added to 
anhydrous diethyl ether (20ml) in a Schlenk tube. n-Butylilthium (7.5ml, 
12.5mmol) was added and the mixture aI/owed to stir at 25°C for 18 h under nitrogen. A bright 
orange suspension was formed. Anhydrous DMF was added dropwise and the mixture allowed 
to stir for a further 4 h. A deep red solution was formed. The reaction was quenched by adding 
deionised water (20ml). The organic layer was separated off and the aqueous layer washed 
with diethyl ether (3 x 15ml). The organic extracts were collected, combined and dried over 
sodium sulfate. The solution was filtered and the sodium sulfate residue washed with diethyl 
ether. The solvent was removed under reduced pressure. The product was purified by silica gel 
chromatography eluting with diethyl ether: hexane: triethylamine (70:20:10). The product was 
collected and the solvent removed under reduced pressure before drying in vacuo to give the 
required product as a deep red oil. Yield: 1.195g (44%). 
Method 2:7 
(Dimethylamino)methylferrocene 28 (2ml, 2.43g, 10mmol) was added to anhydrous diethyl 
ether (20m I) in a Schlenk tube. tert-Butyllithium (7.5ml, 12.5mmol) was added and the mixture 
allowed to stir at 25°C for 30 min under nitrogen. A bright orange suspension was formed. 
Anhydrous DMF was added dropwise and the mixture allowed to stir for 30 min, after which 
time a deep red solution had formed. Diethyl ether was added slowly to dilute the reaction 
mixture before quenching with deionised water. The reaction was then worked up in the manner 
described above. Yield: 2.278g (84%). 
The products from the two methods were indistinguishable by lH and 13C NMR. 
Rf (silica/diethyl ether: hexane: Et3N = 70:20:10) 0.26; 
OH (300 MHz; CDCIs) 10.09 ('IH, s, CHO), 4.76 (1H, m, CpH-aCHO), 4.60 (1H, m, CpH-~CHO), 
4.54 (1 H, m, CpH-aCH2NMe2), 4.21 (5H, 5, Cp'), 3.81 (1 H, d, 2JHH = 13, 2'a), 3.36 (1 H, d, 2JHH = 
13, 2'b) and 2.20 (6H, 5, 1'); 
OC{H} (75.5 MHz; CDCI3) 193.2 (CHO), 75.9 (IVC, Cp), 71.8 (CpC-aCHO), 72.0 (CpC-~CHO), 
70.2 (5C, Cp'), 68.5 (IVC, Cp), 68.0 (CpC-aCH2NMe2), 56.5 (2') and 44.7 (2C, 1 '); 
IR (thin film) Vmax 3332w, 3095m, 2938s, 28555, 28165, 2770s, 2722m, 1674v5 (v C=O), 14435 
(NCH3), 1411m, 1384m, 1353m, 1289m, 1251m, 1206w, 1173m, 1147m, 1106m (ferrocene), 
1034s, 1013s (ferrocene), 957w, 8425 (aryl CH2N(CH3», 8235 (ferrocene), 791m and 741m; 
= 88 mV. 
lH NMR in agreement with literature.6 ,a 
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Compound 31 
2-[(N,N-Oimethylamino)methyl]ferrocenecarboxaldehyde Oxime6 
30 (2.00g, 7.40mmol) was placed in a 100ml round bottomed flask. 
Absolute ethanol (50ml) was added followed by hydroxylamine 
hydrochloride (0.84g, 12mmol). Sodium hydroxide (0.96g, 
24.4mmol) was dissolved in deionised water (10ml) and the solution added to the reaction 
mixture. The mixture was allowed to heat under reflux for 2 h in an atmosphere of nitrogen. The 
reaction mixture was allowed to cool to room temperature before adding sufficient dry ice to 
neutralise the solution. Oichloromethane was then added and the organic layer separated off. 
The aqueous layer was washed with dichloromethane (3 x 20ml). The organic fractions were 
collected, combined and dried over sodium sulfate. The solution was then filtered and the 
sodium sulfate residue washed with dichloromethane. The solvent was removed under reduced 
pressure before drying in vacuo. The product was a hygroscopic deep orange crystalline solid. 
Yield: 0.737g (98%); 
OH (300 MHz; COCI3) 8.02 (1 H, s, 3'), 4.55 (1 H, m, Cp), 4.38 (1 H, m, Cp), 4.30' (1 H, t, 3 J HH :: 2, 
Cp), 4.13 (5H, s, Cp'), 3.94 (1H, d, 2JHH :: 13, 2'a), 3.45 (1H, d, 2JHH :: 13, 2'b), 2.28 (6H, s, 1') 
and 2.19 (1H, s, OH); 
oC{Hl (75.5 MHz; COCh) 148.0 (3'), 80.9 ('VC) , 72.6 (Cp), 69.8 (5C, Cp'), 69.0 (Cp), 68.0 (Cp), 
56.6 (2') and 44.0 (2C, 1'); 
HRMS (EI) mlz 286.07641 [M+, C14H1SN20Fe requires 286.07685]. 268.1. 241.0 [Fp-CHr 
NMe2], 224.0, 211.0,187.0,163.0,121.0 rCp-Fe], 104.0 and 58.1 [CH2NMe2]' 
1H NMR and mass spectral data in agreement with Iiterature.6 
Compound 32 
2 -[(N, N-Oimethylami no )methyl]ferrocenemethylamine 6 
31 (1.913g, 6.638mmol) was placed in a 1 OOml round bottomed flask. 
Anhydrous THF (50ml) was added followed by lithium aluminium 
hydride (836mg, 21.74mmol). The mixture was heated under reflux in 
HN~N/ 
2  I 
Fe 
Q 
an atmosphere of nitrogen for 15 h. The mixture was allowed to cool to room temperature 
before diluting with diethyl ether (10ml) and adding a saturated brine solution (30ml). The 
product was extracted into the organic phase. The aqueous layer was washed with diethyl ether 
(3 x 50ml). The organic extracts were collected. combined and dried over potassium carbonate. 
The product was filtered to remove potassium carbonate and the solvent was removed under 
reduced pressure. The deep red oil product was dried in vacuo. Yield: 1.802g (95%) 
OH (300 MHz; COCb) 4.10 (1H, m, Cp), 4.08 (1H, m, Cp), 4.02 (5H, s, Cp'), 3.99 (1H, m, Cp), 
3.66 (1 H, d, 2 J HH :: 14, 3'a), 3.61 (1 H, d, 2 J HH :: 13, 2'a), 3.45 (1 H, d, 2 J HH :: 14, 3'b), 2.88 (1 H, d, 
2JHH :: 13, 2'b) and 2.12 (6H, s, 1'); 
oe{Hl (75.5 MHz; COCh) 90.3 ('VC, Cp), 83.1 (IVC, Cp), 70.7 (Cp), 68.7 (5C, Cp'), 68.1 (Cp), 65.7 
(Cp), 58.0 (2'), 44.9 (2C, 1') and 40.4 (3'); 
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IR (thin film) Vmax 33525 (NH), 30935 (NH), 29335,28555,28165,27715, 1641m, 14565 (NCH3), 
1353m, 1286w, 1258m, 1172m, 1105m (ferrocene), 1037m, 10015 (ferrocene), 952w, 8435 
(aryl CHzN(CH 3h) and 8165 (ferrocene); 
1H NMR and mass spectral data in agreement with Iiterature.6 
Compound 15 
(7 -Chloro-quinolin-4-yl)-(2-
dimethylaminomethylferrocenylmethyl)amine, 
(FQ) 
ferroquine 
32 (4.742g, 17.42mmol) was placed in a 50ml round 
HN~N/ 
m"" I Fe I " ~ ~ CI '" N 
bottomed flask together with 4,7-dichloroquinoline (17.42g, 87.1 mmol), anhydrous potassium 
carbonate (10.1 Og, 25.26mmol), anhydrous triethylamine (7ml) and anhydrous NMP (20ml). 
The flask was fitted with a reflux condenser and nitrogen inlet and the mixture heated to 135"C 
for 4 h. The reaction mixture was allowed to cool to room temperature before adding ethyl 
~,f'> 
acetate. The mixture was then transferred to a separating funnel and washed "Nith a saturated 
brine solution (10 x 30ml). The organic layer was then dried over sodium sulfate before 
removing the solvent under reduced pressure. The product was then purified by silica gel 
chromatography. The orange glassy solid obtained was recrystallised from ethyl 
acetate/hexane to give a bright orange crystalline solid. Yield: 3.987g (53%); 
mp: 196-197"C (from ethyl acetate/hexane) 
Rf (silica/ethyl acetate: hexane: EhN = 45:50:5) 0.18; 
OH (400 MHz; COCb) 8.53 (1H, d, 3JHH = 5, ArCz-H), 7.91 (1H, d, 4JHH = 2, ArCa-H), 7.62 (1H, d, 
3JHH = 9, ArCs-H), 7.27 (1H, dd, 4JHH = 2 and 3JHH = 9, ArC6-H), 6.46 (1H, d, 3JHH = 5, ArC3-H), 
4.38 (1H, d, ZJHH = 13, 3'a), 4.26 (1H, m, Cp), 4.16 (1H, m, Cp), 4.14 (1H, m, 3'b), 4.13 (5H, s, 
Cp'), 4.08 (1H, t, 3JHH = 2, Cp), 3.80 (1H, d, zJHH = 13, 2'a), 2.89 (1H, d, ZJHH = 13, 2'b) and 2.21 
(6H, s, 1'); 
OC{H} (100.6 MHz; COCh) 152.3 (ArCz), 150.5 (IVC), 149.5 ('vC), 134.8 (IVC), 128.6 (ArCa), 124.9 
(ArC6), 122.4 (ArCs), 118.1 (IVC) , 102.8 (IVC) , 99.1 (Ar~), 84.2 (2C, IVC), 71.6 (Cp), 70.8 (Cp), 
69.5 (5C, Cp'), 66.2 (Cp), 58.3 (2'), 45.1 (2C, 1') and 42.7 (3'); 
IR (KBr) V max 3425br w (NH), 3192br w (NH), 3091m, 3046m, 2976m, 2944m, 2901m, 2865m, 
2831 m, 2787m, 1609s (7-chloroquinoline), 1578vs (7 -chloroquinoline), 1541 s (7-
chloroquinoline), 1488w, 1463m (NCH3), 1442m, 1426m, 1379w, 1365w, 1348s, 1330s (v C-N 
aromatic), 1280w, 1250w, 1224w, 1195m, 1165m, 1131s, 1105m (ferrocene), 1076m, 1033m, 
1006m (ferrocene), 906m, 879m, 859m (aryl CHzN(CH3)z), 813m (ferrocene), 798s, 765m, 
725w, 694m, 640m, 623w, 614w, 548w, 510m, 490s (ferrocene), 454m, 433m, 418m and 
405m; 
HRMS (EI) mlz 433.09928 [M+, CnHz4N335CIFe requires 433.10081), 388.0 [M+ - N(Melz), 
307.2,255.1 [HC-Fp-CHz-NMe2], 213.0, 167.0, 149.0, 120.1 [Cp-Fe), 91.0 [CHz-Cp-CH21 and 
57.1 [CH-NMez]; 
Found: C, 63.89; H, 5.38; N, 9.40. Calc. for C23H24N3CIFe: C, 63.67; H, 5.58; N, 9.67%. 
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El12 = 147 mV; ferrocene redox: Epa = 181 mV and Epc = 113 mV. 
1H NMR, 13C NMR, IR and MS in agreement with literature values.s 
Tartrate salt of 15 
15 was dissolved in hot methanol. L-tartaric acid was dissolved in hot acetone and then added 
slowly to the solution of ferroquine forming a yellow precipitate. The precipitate was filtered and 
washed with hot acetone. The product was then dried in vacuo. 
DH (300 MHz; D20) 8.12 (1H, d, 3JHH = 7, ArCz-H), 7.82 (1H, d, 3JHH = 9, ArCs-H), 7.50 (1H, d, 
4JHH = 2, ArCs-H), 7.30 (1 H, dd, 4JHH = 2 and 3JHH = 9, ArCs-H), 6.66 (1 H, d, 3 JHH = 7, ArC3-H), 
4.40-4.31 (3H, m, 3'a, 3'b, Cp), 4.28 (4H, m, tartaric acid), 4.22 (1H, d, 3JHH = 3, Cp), 4.13 (3H, 
m, 2'a, 2'b, Cp), 4.03 (5H, s, Cp'), 2.57 (3H, s, 1'a), 2.48 (3H, s, 1'b) and 2.164 (1 H, s, OH); 
De{Hl (75.5 MHz; D20) 176.1 (2C, tartaric acid, COOH), 155.2 (ArC2), 142.4 (IVC) , 139.2 (ArCs), 
137.8 (IVC) , 127.7 (ArCs), 123.7 (ArCs), 119.0 (ArCa), 114.8 (IVC) , 98.7 (ArC3), 82.9 (vC), 73.8 
(Cp), 72.6 (2C, tartaric acid, CHOH) 71.9 (Cp), 70.6 (Cp), 69.9 (SC, Cp'), SS.3 (2'), 41.9 (1 'a), 
~(, 
41.3 (1'b) and 40.7(3'). i 
1H NMR in agreement with literature values.s 
Compounds 33 - 37 
33: N-(7 -ch loro-quinolin-4-yl)-ethane-1,2-diamine9 
34: N-(7 -chloro-quinolin-4-yl)-propane-1,3-diamine 
35: N-(7 -chloro-quinolin-4-yl)-butane-1,4-diamine 
36: N-(7 -chloro-quinolin-4-yl)-pentane-1,S-diamine 
37: N-(7 -chloro-quinolin-4-yl)-hexane-1,6-diamine 
Synthesis of Compound 33 
A mixture of 4,7-dichloroquinoline and 4.S mol equivalents of the appropriate alkyldiamine was 
placed in a round bottomed flask fitted with reflux condenser and nitrogen inlet. The mixture 
was heated to 80°C for 1 h before raising the temperature to 14SoC for a further 3 h. A cream 
preCipitate formed in the bottom of the flask. The reaction mixture was allowed to cool to room 
temperature with stirring. 
Work-up 1: Sodium hydroxide (1 M, 10ml) was added forming an emulsion. The product was 
then extracted into ethyl acetate. The solvent was then removed under reduced pressure giving 
a pale yellow powder. Yield: 1.118g (82%). 
Work-up 2: Sodium hydroxide (1 M, 10ml) was added forming an emulsion. The product was 
then extracted into dichloromethane. The solvent was then removed under reduced pressure 
giving a pale yellow powder. Yield: 1.2S49 (84%). 
Compounds 34 - 37 were prepared in a similar manner starting from 1,3-diaminopropane, 1,4-
diaminobutane, 1,S-diaminopentane and 1,6-diaminohexane respectively. All products were 
pale yellow powders. 
Compound 34 Yield: 44%; 
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Compound 35 Yield: 67%; 
Compound 36 Yield: 80%; 
Compound 37 Yield: 89%. 
Compounds 20 - 24 
Synthesis of Compound 20 
[(N,N-dimethylamino)methyl]ferrocenecarboxaldehyde, 
30 was dissolved in anhydrous methanol in a round 
bottomed flask. 1 mol equivalent of the appropriate 7-
chloroquinoline-4-alkyldiamine (33 - 37) was added 
Chapter 8: General Experimental 
and the mixture allowed to shake for 16 h at 200rpm at 20°C. 2 mol equivalents of Amberlite, 
IRA 400, borohydride exchange resin (2.5g mmor1) was added and the mixture allowed to 
shake for a further 6 h. The mixture was filtered and the resin washed with methanol. The 
solvent was removed under reduced pressure and the product purified using silica gel 
./ 
chromatography eluting with dichloromethane: methanol: triethylamine (80:20': 1) to give the 
product amine. Yield: 1.498g (64%). 
Method 2: [(N,N-dimethylamino)methyl]ferrocenecarboxaldehyde, 30, was dissolved in 
anhydrous methanol in a round bottomed flask. 1 mol equivalent of the appropriate 7-
chloroquinoline-4-alkyldiamine was then added and the mixture allowed to stir for 16 h at 20°C. 
Sodium borohydride (10 mol equivalents) was added and the mixture stirred for a further 6 h. 
Residual sodium borohydride was destroyed by the slow addition of deionised water. The 
product was extracted into dichloromethane and dried over sodium sulfate before removing the 
solvent under reduced pressure. The purification procedure used followed that detailed in 
method 1. Yield: 1.356g (61 %). 
Similar reaction procedures were used to make 21, 22, 23 and 24 from 34, 35, 36 and 37 
respectively. 
Compound 20 
N-(7 -C hloro-quinolin-4-yl)-N'-[2-( N", N"-
dimethylaminomethyl)ferrocenylmethyl]-ethane-1,2-
diamine, F2Q 
Bright orange crystalline solid; Yield: 5.067g (74%); 
mp: 118-120oC (from acetonitrile/diethyl ether); 
Rf (silica/CHzCb: MeOH: EhN = 80:20:1) 0.27; 
OH (400 MHz; CDCI3) 8.50 (1H, d, 3JHH = 5, ArCz-H), 7.93 (1H, d, 4JHH = 2, ArCa-H), 7.73 (1H, d, 
aJHH = 9, ArCs-H), 7.33 (1H, dd, 4JHH = 2 and 3JHH = 9, ArC6-H), 6.27 (1H, d, aJHH = 5, ArCa-H), 
4.14 (1H, m, Cp), 4.10 (1H, m, Cp), 4.04 (6H, m, Cp, 5Cp'), 3.83 (1H, d, 2JHH = 13, 3'a), 3.67 
(1 H, d, 2 JHH = 13, 2'a), 3.38 (1 H, d, 2JHH = 13, 3'b), 3.48-3.40 (2H, m, 5'), 2.98-2.92 (2H, m, 4'), 
2.79 (1H, d, ZJHH = 13, 2'b) and 1.95 (6H, s, 1'); 
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OC{H} (100.6 IVIHz; CDCb) 152.0 (ArC2), 149.9 tc), 149.2 (IVC) , 134.7 evC), 128.6 (ArCa), 125.0 
(ArC6), 121.5 (ArCs), 117.4 ('VC) , 99.1 (ArC3), 86.0 (IVC, Cp), 83.8 (IVC, Cp), 71.1 (Cp), 69.9 
(Cp), 68.9 (5C, Cp'), 65.8 (Cp), 58.2 (2'), 47.3 (4'), 46.4 (3'), 45.0 (2C, 1 ') and 42.0 (5'); 
IR (KBr) Vmax 3314br w, (N-H), 3090s (N-H), 2970s, 2939s, 2853s, 2825s, 2780s, 1608m (7-
chloroquinoline), 1579vs (7-chloroquinoline), 1538s (7-chloroquinoline), 1487m, 1471m, 1452s 
(NCH3), 1434m (6-as (NCH3», 1370m, 1354m, 1327m (v C-N aromatic), 1287m, 1254m, 
1211w, 1198w, 1172w, 1159w, 1140s, 1113w, 1103m (ferrocene), 1087m, 1076m, 1032m, 
1008m (ferrocene), 970w, 954w, 872s, 854s, 845s (aryl CH2N(CH3h), 824s (ferrocene), 804s, 
771 m, 742w, 647m, 613m, 562m, 528w, 508m, 488m (ferrocene), 474m (ferrocene) and 429w; 
HRMS (EI) mlz 476.14119 [M+, C2sH2sN43sCIFe requires 476.0891],431.1 [M+ - (NMe2)], 366.0 
[M+ - (Cp + NMe2)], 255.1 [HC-Fp-CH2-NMe2J, 240.0 [Fp-CH2-NMe2J, 213.0, 191.0 [CICgNHs-
NH-CH2], 163.0 [CICsNHs], 155.0 [CgNHs-NH-CH2] 121.0 [Cp-Fel, 91.0 [CH2-Cp-CH2], 58.1 
[CH2-NMe2] and 55.9 [Fe]; 
Found: C, 63.11; H, 5.97; 1\1,11.61. Calc. forC2sH2sN4CIFe: C, 62.97; H, 6.130; N, 11.75%; 
~/ 
E1I2 = not found, ferrocene redox: Epa = 150 mV, Epc = ± 30 mV; second redox~'Epa = ± 300 mV 
and Epc = ± 250 mV; 
A = 0.6 Q.lcm2morl; 
Crystal Data: C2sH2sN4CIFe, M = 476.82, monoclinic, a = 10.7013(3), b = 16.2573(4), c = 
13.7853(3) A, f3 = 92.727(1t, U = 2395.55 N, T = 173(2) K, space group P2 1/c, Z = 4, J1 = 
0.760 mm,l, 10265 reflections collected, 5429 unique (Rint = 0.0240), final R, = 0.0552 and WR2 
= 0.0843 (all data). 
Tartrate salt of 20 
20 was dissolved in hot methanol. L-tartaric acid was dissolved in hot acetone and then added 
slowly to the solution of 20 forming a yellow precipitate. The precipitate was filtered and washed 
with hot acetone. The product was then dried in vacuo. 
OH (300 MHz; 0 20) 8.16 (1H, d, 3JHH = 6, ArC2-H), 7.92 (1H, d, 3JHH = 9, ArCs-H), 7.65 (1H, d, 
4JHH = 2, ArCa-H), 7.42 (1H, dd, 4JHH = 2 and 3JHH = 9, ArC6-H), 6.62 (1H, d, 3JHH = 7, ArC3-H), 
4.28 (4H, m, tartaric acid), 4.21-4.15 (5H, m, 2'a, 2'b, Cp), 4.04 (5H, s, Cp'), 3.94 (1 H, d, 2 JHH = 
13 Hz, 3'a), 3.74 (2H, m, 5'), 3.29 (3H, m, 3'b, 4'), 2.66 (3H, s, 1'a) and 2.50 (3H, 5, 1'b); 
OC{H} (75.5 IVIHz; 020) 177.1 (2C, tartaric acid, COOH), 156.1 (IVC), 142.7 (ArC2), 139.5 (ArC6), 
138.0 (IVC) , 127.8 (ArCa), 124.0 ('VC), 119.2 (ArCs), 115.4 (tVC) , 98.4 (ArC3), 74.5 (Cp), 73.5 
(Cp), 73.1 (2C, tartaric acid, CHOH), 71.0 (Cp), 70.3 (5C, Cp'), 57.2 (2'), 45.4 (4'), 44.8 (1'a), 
43.5 (1'b), 40.8 (3') and 39.3 (5'). 
114 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Compound 21 
N-(7 -Chloro-q uinolin-4-yl)-N' -[2 -( N", N"-
dimethylaminomethyl)ferrocenylmethyl]-propane-
1,3-diamine, F3Q 
Red glassy solid; Yield: 1.204g (61%); CI 
mp: 108-11 DoC; 
Rdsifica/CH2Cl2: MeOH: EhN = 80:20:1) 0.2; 
Chapter 8: General Experimental 
N~N~~N/ 
H H ~ I 
Fe 
~ 
OH (400 MHz; COCI3) 8.44 (1H, d, 3JHH = 6, ArC2-H), 7.86 (1H, d, 4JHH = 2, ArCs-H), 7.50 (1H, d, 
3JHH = 9, ArC5-H), 7.11 (1H, dd, 4JHH = 2 and 3JHH = 9, ArCs-H), 6.22 (1H, d, 3JHH = 6, ArC3-H), 
4.19-4.15 (2H, m, Cp), 4.12 (1H, t, 3JHHH = 2, Cp), 4.05 (5H, s, Cp), 3.79 (1H, d, 2JHH = 12, 2'a), 
3.74 (1H, d, 2JHH = 12, 3'a), 3.42 (1H, d, 2JHH = 12, 3'b), 3.36-3.31 (2H, m, 6'), 2.99-2.92 (2H, m, 
4'),2.79 (1H, d, 2JHH = 12, 2'b), 2.11 (6H, s, 1') and 1.94-1.72 (2H, m, 5'); 
OC{H} (100.6 MHz; COCh) 152.1 (ArCz), 150.7 (IVC) , 149.1 (IVC), 134.4 (IVC), 128.2 (ArCa), 124.8 
(ArCs), 122.9 (ArC5), 117.7 (IVC), 97.9 (ArC3), 85.9 (IVC, Cp), 84.1 (IVC, Cp)~r71.2 (Cp), 70.3 
(Cp), 68.0 (5C, Cp'), 65.8 (Cp), 58.3 (2'), 49.3 (4'), 48.3 (3'), 44.9 (2C, 1'), 44.3 (6') and 26.9 
(5'); 
IR (KBr) Vmax 3249br w (NH), 2970s, 2940s, 2850s, 2816s, 2766s, 1610s (7-chloroquinoline), 
1586vs (7 -chloroquinoline), 1544s (7 -chloroquinoline), 1491 m, 1457s (NCH3), 1439s, 1386m, 
1367s, 1329m (v C-N aromatic), 1285m, 1253m, 1236w, 1203m, 1174m, 1156w, 1138m, 
1104m (ferrocene), 1079m, 1034w, 1016m, 999m (ferrocene), 954w, 908m, 878m, 856s (aryl 
CHzN(CH3h), 819m (ferrocene), 809m, 798m, 768m, 646m, 613m, 598w, 558w, 528w, 489m 
(ferrocene), 458w, 438w and 426w; 
HRMS (EI) mlz 490.15824 [M+, CzsH31N435CIFe requires 490.11590],445.1 [M+ - (HNMez)], 
380.0 [M+ - (Cp + NMe2)], 255.1 [HC-Fp-CH2-NMe2], 241.1, 227.0 (Fp-CHz-NMe], 213.0,191.0 
[CICgNH5-NH-CH2], 154.0 [CgNHs-NH-CH2J. 134.0 [Fe-Cp-CH2], 121.0 [CpFeJ, 91.0 [CHz-Cp-
CH 2], 58.1 [CH 2-NMezl and 55.9 [Fe]; 
E1/Z = not found; ferrocene redox: Epa = ± 120 mV, Epc = 13 mV; second redox: Epa = 318 mV 
and Epc = 210 mV; 
Found: C, 63.89; H, 6.39; N, 11.15. Calc. forCZ6H31N4CIFe: C, 63.62; H, 6.365; N, 11.41%. 
Compound 22 
N-(7 -Chloro-quinolin-4-yl)-N'-[2-(N",N"-dimethyl-
aminomethyl)ferrocenylmethyl]-butane-1,4-
diamine, F4Q 
Red glassy solid; Yield: 1.337g (65%); 
mp: 103-104°C; 
Rr(silica/CHzCIz: MeOH: Et3N = 80:20:1) 0.17; 
OH (400 MHz; COCh) 8.44 (1H, d, 3JHH = 6, ArCz-H), 8.14 (1H, d, 3JHH = 9, ArCs-H), 7.88 (1H, d, 
4JHH = 2, ArCa-H), 7.31 (1H, dd, 4JHH = 2 and 3JHH = 9, ArC6-H), 6.29 (1H, d, 3JHH = 6, ArC3-H), 
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4.20-4.07 (3H, m, Cp), 4.06 (5H, 5, Cp), 3.77 (1H, d, 2JHH = 13, 2'a), 3.53 (1H, d, 2JHH = 13, 3'a), 
3.33-3.29 (3H, m, 3'b, 7'), 2.83 (1 H, d, 2 JHH = 13, 2'b), 2.69-2.66 (2H, m, 4'), 2.10 (6H, 5, 1'), 
1.85-1.80 (2H, m, 5' or6') and 1.75-1.70 (2H, m, 5' or6'); 
OC{H} (100.6 MHz; COCI3) 151.8 (ArC2), 150.4 ('vC), 149.2 (IVC), 134.7 (IVC), 128.2 (ArCa), 125.0 
(ArCs), 123.0 (ArC5), 117.7 (IVC) , 98.5 (IVC), 83.7 (IVC), 71.6 (Cp), 71.0 (Cp), 69.4 (5C, Cp'), 
66.6 (Cp), 57.9 (2'), 47.0 (4'), 46.0 (3'), 44.4 (2C, 1 '), 42.3 (7'), 25.4 (5' or 6') and 25.3 (5' or 6'); 
IR (KBr) V max 3285br 5, 30875, 29395, 28575, 28195, 27745, 2362m, 1653m, 1610m (7-
chloroquinoline), 1581vs (7 -chloroquinoline), 1540m (7 -chloroquinoline), 1451 m (NCH3), 
1367m, 1331m, 1282m, 1252m, 1170w, 1137m, 1105m (ferrocene), 1080w, 1033w, 1000m 
(ferrocene), 877w, 851m (aryl CH2N(CH3)), 809m (ferrocene), 768w, 645w and 489w 
(ferrocene); 
HRMS (EI) mlz 504.1746 [M+, C27H33N43SCIFe requires 504.1427],460.1 [M+ - (HI\JMe2)], 394.1 
[M+ - (Cp + NMedl, 255.1 [HC-Fp-CH2-NMe2], 240.0, 213.0, 134.0 [Fe-Cp-CH21, 121.0 [CpFel, 
,/ 
E112 = not found; ferrocene redox: Epa = 106 mV, Epc = 14 mV; second redox: E~~ = 328 mV, Epe 
= 220 mV. 
Compound 23 
N-(7 -Chloro-quinolin-4-yl)-N' -[2-(N", N"-
dimethyl-aminomethyl)ferrocenylmethyl]-
pentane-1,5-diamine 
Red glassy solid; Yield: 541mg (60%); 
mp: 74-75°C; 
Rf (5i1ica/CH2CI2: MeOH: Et3N = 80:20:1) 0.1; 
CI 
N~N~N/ 
H H ~ I 
Fe 
~ 
OH (400 MHz, COCh) 8.50 (1H, d, 3JHH = 5, ArC2-H), 7.93 (1H, d, 4JHH = 2, ArCa-H), 7.76 (1H, d, 
3 JHH = 9, ArCs-H), 7.32 (1 H, dd, 4JHH = 2 and 3JHH = 9, ArCs-H), 6.37 (1 H, d, 3 JHH = 5, ArC3-H), 
4.16-4.15 (1 H, m, Cp), 4.10-4.09 (1 H, m, Cp), 4.03 (5H, 5, Cp), 3.80 (1 H, d, 2JHH = 13, 2'a), 3.67 
(1H, d, 2JHH = 13, 3'a), 3.38 (1H, d, 2JHH = 13, 2'b), 3.32 (2H, m, 8'), 2.82 (1H, d, 2JHH = 13, 3'b), 
2.67-2.65 (2H, m, 4'), 2.10 (6H, 5, 1') and 1.78-1.40 (6H, m, 5',6',7'); 
OC{H} (100.6 MHz, COCh) 151.9 (ArC2), 150.0 (IVC) , 149.1 (IVC) , 134.7 (IVC), 128.5 (ArCa), 125.0 
(ArCs), 121.7 (ArCs), 117.3 (IVC), 98.8 (IVC), 84.9 ('VC, Cp), 83.6 (IVC, Cp), 71.1 (Cp), 70.1 (Cp), 
69.0 (5C, Cp'), 66.1 (Cp), 57.9 (2'), 48.1 (4'),47.7 (3'), 44.8 (2C, 1'),42.9 (8'), 28.9 (5' or 7'), 
28.1 (5' or 7') and 24.4 (6'); 
IR (KBr) Vmax 3244br 5, 3092m, 2939m, 2856m, 2819m, 2772m, 1610m (7-chloroquinoline), 
1580vs (7-chloroquinoline), 1534m (7-chloroquinoline), 1457m (NCH3), 1367m, 1352m, 1329m, 
1283w, 1255w, 1201w, 1174w, 1136m, 1104m (ferrocene), 1082w, 1001w (ferrocene), 880w, 
855m (aryl CH2N(CH3», 805m (ferrocene), 770w, 649w, 598w, 533w, 487w, 458w and 426w; 
HRMS (El) mlz 518.1886 [M+, C2sH3SN43SCIFe requires 518.1655], 473.1 [M+ - (HNMe2)], 408.1 
[M+ - (Cp + NMe2)l, 255.1 [HC-Fp-CH2-NMe2], 240.0, 213.0, 134.0 [Fe-Cp-CHzl, 121.0 [CpFe], 
91.0 [CH2-Cp-CHzl, 58.1 [CHz-NMe21 and 55.9 [Fel; 
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Em = not found; ferrocene redox: Epa = 92 mV, Epe = 12 mV, second redox: Epa = 332 mVand 
Epe = 210 mV. 
Compound 24 
N-(7 -Chloro-q uinolin-4-yl)-N -[2 -(Nil, N"-
dimethyl-aminomethyl)ferrocenylmethyl]-
hexane-1,6-diamine, F6Q 
Red glassy solid; Yield: 1.729g (60%); CI 
mp: 92-95°C; 
Rf (silica/CHzClz: MeOH: EhN = 80:20:1) 0.07; 
OH (400 MHz; CDCb) 8.46 (1H, d, 3JHH = 6, ArCz-H), 8.16 (1H, d, 3JHH = 9, ArCs-H), 7.90 (1H, d, 
4JHH = 2, ArCa-H), 7.24 (1 H, dd, 4JHH = 2 and 3 JHH = 9, ArC6-H), 6.34 ('I H, d, S JHH = 6, ArCs-H), 
4.28-4.15 (3H, m, Cp), 4.09 (5H, s, Cp), 3.81 (1 H, d, 2 JHH = 13, 2'a), 3.53 (1 H, d, z JHH = 13, 
3'a), 3.55-3.50 (2H, m, 9'), 3.33 (1H, d, zJHH = 13, 3'b), 2.86 (1H, d, 2JHH = 13, 2'b), 2.64 (2H, m, 
./ 
4'),2.14 (6H, 5,1'),1.76-1.73 (2H, m, 5' or 8'),1.60-1.54 (2H, m, 5' or 8') and 1;145-1.38 (4H, m, 
6' and 7'); 
OC{H} (100.6 MHz, CDCls) 151.8 (ArC2), 150.3 (IVC), 149.2 evC), 134.7 (IVC), 128.3 (ArCa), 125.0 
(ArC6), 122.6 (ArCs), 117.5 (IVC), 98.7 (ArCs), 83.8 ('vC), 71.6 (Cp), 71.2 (Cp), 69.5 (5C, Cp'), 
66.8 (Cp), 57.8 (2'), 46.7 (4'), 45.5 (3'), 44.3 (2C, 1'),42.5 (9'), 27.9 (5' 8'r, 27.0 (5' - 8'),26.2 
(5' - 8') and 25.9 (5' - 8'); 
IR (KBr) Vmax 3300br m (NH), 3084m, 2934m, 2857m, 1610s (7-chloroquinoline), 1580vs (7-
chloroquinoline), 1540s (7-chloroquinoline), 14535 (NCHs), 1425m, 13675, 1331m (v C-N 
aromatic), 1282m, 1250m, 1205w, 1175w, 1137m, 1105m (ferrocene), 1080w, 1033w, 1000m 
(ferrocene), 900w, 877w, 850m (aryl CHzN(CH3», 8105 (ferrocene), 769w, 726w, 646w, 600w, 
547w, 489m (ferrocene) and 424w; 
HRMS (EI) mlz 532.20585 [M+, C29H37N43SCIFe requires 532.20561], 515.2, 487.1 [M+-
(HNMez)], 422.1 [M+ - (Cp + NMe2)], 255.1 [HC-Fp-CH2-NMezl, 240.0, 213.0, 121.0, [CpFej, 
91.0 [CHz-Cp-CHz], 58.1 [CH2-NMez] and 55.9 [Fe]; 
ElIz = not found; ferrocene redox: Epa = indistinct, Epe = 12 mV, second redox: Epa = 330 mV, Epe 
= 210 mV. 
Experimental Details Pertaining to Chapter 3 
Compound 52 
Phenylbenzylcarbamate 
Anhydrous DMF (O.77ml, 10mmol) was placed in a centrifuge 
tube fitted with nitrogen inlet and dropping funnel, followed by 
anhydrous dichloromethane (10rnl). The mixture was cooled to 
• (5' - 8') indicates that these proton or carbon signals could be the 5', 6', 7' or 8' signals. 
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O°C and allowed to stir for 10 min. Phenylchloroformate 50 (1.26ml, 10mmol) was added 
dropwise and the mixture allowed to stir for 40 min. Benzylamine 49 (1.2ml, 11 mmol) was then 
added dropwise and the mixture allowed to stir for 4 h. The mixture was allowed to warm to 
room temperature before removing the solvent under reduced pressure. The product was used 
without further purification. (TLC checked; 20:80; ethyl acetate: hexane). 
Compound 53 o-o-IJ N02 
Nitrophenylbenzylcarbamate F\ ~N-{ 
Nitrophenylchloroformate 51, (2.016g, 10mmol) was ~ 0 
placed in a 2-necked 100ml round bottomed flask fitted with nitrogen inlet and dropping funnel, 
followed by anhydrous acetonitrile (10ml). Benzylamine 49 (1.09ml, 10mmol) and anhydrous 
triethylamine (1.40ml, 10mmol) were mixed and placed in a pressure-compensated dropping 
funnel followed by anhydrous acetonitrile (10ml). The mixture was added dropwise to the 
reaction vessel. A white suspension (ammonium salt) formed immediately. The mixture was 
allowed to stir at 25°C for 30 min, after which time a bright yellow precipit~te had formed. 
Dichloromethane (30ml) was added followed by deionised water (30ml). The mixture was 
extracted into dichloromethane and dried over magnesium sulfate. The organic extract was 
then filtered and the residual magnesium sulfate washed with dichloromethane. The solvent 
was removed under reduced pressure leaving a yellow solid. The product was used without 
further purification. (TLC checked: ethyl acetate: hexane; 20:80). 
Synthesis of Urea Compounds 
Method 1: 
20 was dissolved in anhydrous dichloromethane in a 
small sample vial. 1.2 mol equivalents of the required 
isocyanate was added and the sample vial was placed 
on a shaker at 200 rpm for 2 h at 25°C. 1 mol 
N~N~N~N/ H ~N~O Fe I U- R Q / 
CI 
equivalent of aminomethylpolystyrene (polymer loading: 1.1 g morl ) was added, followed by 
anhydrous dichloromethane and the mixture allowed to shake for a further hour. The mixture 
was then filtered and washed with 10% methanol in dichloromethane. The product was then 
purified by silica gel chromatography eluting with 10% methanol in dichloromethane. The 
product was isolated as a yellow crystalline solid. Yield: 143mg (75%). 
Method 2: 
As for method 1, but use of aminomethylpolystyrene omitted. The reaction mixture was placed 
directly onto the column. Yield: 452mg (90%). 
Method 3: 
Phenylbenzylcarbamate 52 was placed in a 50ml round bottomed flask. Anhydrous THF was 
added followed by 0.9 mol equivalents of 20. The mixture was allowed to stir at 50°C for 16 h. 
The reaction progress was monitored by TLC (20% methanol in dichloromethane). Only a small 
amount of product was observed so the reaction was allowed to heat under reflux for a further 
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24 h. The solvent was then removed under reduced pressure and the mixture purified by silica 
gel chromatography (20% methanol in dichloromethane) without further workup. Yield: 58mg 
(35%). 
Method 4: 
Nitrophenylbenzylcarbamate 53 and 1 mol equivalent of 20 were placed in a 100ml round 
bottomed flask and anhydrous THF was added. The mixture was heated to 50°C and the 
reaction allowed to proceed for 16 h before allowing to cool to room temperature. The solvent 
was then removed under reduced pressure and the product purified using silica gel 
chromatography as described in previous methods. Yield: 531mg (83%). 
Compound 37 
3-Benzyl-1-[2-(7 -chloro-quinolin-4-ylamino )-ethyl]-1-
[2 -( Nil, N"-dimethylaminomethyl)-
ferrocenylmethyl)urea 
Yellow crystalline solid; Yield: 345mg (90%); 
mp: 95-96°C; 
Rf (silica/CH2CI2: MeOH = 80:20) 0.51; 
OH (400 MHz; CDCb) 8A5 (1 H, d, 3JHH = 6, ArC2-H), 8.12 (1 H, t, 3 JHH = 6, ArCH2NHCO), 7.96 
(1 H, d, 4JHH = 2, ArCa-H), 7.75 (1 H, d, 3 JHH = 9, ArC5-H), 7.15 (1 H, dd, 4JHH = 2 and 3 JHH = 9, 
ArCe-H), 7.13-7.07 (5H, m, U2 , U3, U4), 6.32 (1H, d, 3JHH = 6, ArC3-H), 4.24-4.16 (7H, m, Cp, 1", 
3'a, 3b'), 4.08 (5H, s, Cp'), 3.82 (1H, d, 2JHH = 13, 2'a), 3.73-3.68 (2H, m, 4'), 3.58-3AO (2H, m, 
5'),2.82 (1H, d, 2JHH = 13, 2'b) and 1.98 (6H, s, 1'); 
OC(H} (100.6 MHz; CDCI3) 160A ('VC, CO), 151.7 ('vC), 149.7 (ArC2), 146.7 (IVC), 140.2 (IVC) , 
135.7 evC), 128.2 (2C, U), 126.6 (ArCe), 126.5 (2C, U), 126.2 (U4), 125.7 (ArCs), 123.1 (ArCa), 
116.9 (IVC), 97.5 (ArC3), 83.9 (IVC, Cp), 70.6 (Cp), 69.5 (5C, Cp'), 69.0 (Cp), 67.7 (Cp), 57.8 (2'), 
47.0 (3'), 45.6 (4'), 44.6 (1"), 44A (2C, 1') and 43.7 (5'); 
IR (KBr) Vrnax 3268br w (NH), 3061m, 3027m, 2940m, 2858m, 2821m, 2777m, 1611s (7-
chloroquinoline), 1582vs (7-chloroquinoline), 1539s (7-chloroquinoline), 1452m (NCH3), 1430m, 
1405m, 1365m, 1332m (v C-N aromatic), 1302m, 1270m, 1241m, 1205m, 1170m, 1135m, 
1105m (ferrocene), 1079m, 1038m, 1005m (ferrocene), 960w, 917w, 874m, 842m (aryl 
CH2N(CH3», 808m (ferrocene), 768m, 731m, 698m, 608w, 526m, 487m (ferrocene), 454w and 
424w; 
HRMS (FAB) mlz 610.2030 [M+ + H, C33H3eNsCIOFe + H requires 610.2034], 565.1 [M+-
(HNMe2)], 432.2 [M+ - (HNMe2 + CeHsCH2NHCO)], 409.1 [M+ - (Cp + CeH5CH2NHCO)], 304.0, 
255.1 [HC-Fp-CH2-NMez]' 213.1, 191.0 [CICgNHs-NH-CHz], 154.0 [CgNHs-NH-CHzJ, 134.1 [Fe-
Cp-CHz] and 91.1 [CHz-Cp-CHz]; 
E1I2 = 157 mV; ferrocene redox: Epa = 198 mV, Epc = 115 mV; second redox: barely noticeable; 
Found: C, 65.01; H, 5.83; N, 11.50. Calc. for C23H24N3CIFe: C, 64.98; H, 5.95; N, 11A8%. 
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Compound 38 
3-Benzyl-1-[3-(7 -chloro-quinolin-4-ylamino)-
propyl]-1-[2 -( Nil, N"-dimethylaminomethyl)-
ferrocenylmethyl]urea 
Yellow crystalline solid; Yield: 33mg (34%); 
mp: 88-89°C; 
Rf (silica/CH2Clz: MeOH = 80:20) 0.46; 
Chapter 8: General Experimental 
N~-N~N~~N/ )---(H I ~ I Y dHN~OQ 
CI I 
~ 
OH (400 MHz; CDCb) 8.47 (1 H, d, 3JHH = 6, ArCz-H), 8.05 (1 H, d, 3JHH = 9, ArCs-H), 7.95 (1 H, d, 
4JHH = 2, ArCa-H), 7.30 (1 H, dd, 3 JHH = 2 and 4JHH = 9 Hz, ArC6-H), 7.25-7.13 (5H, m, Uz, U3, 
U4), 6.39 (1H, d, 3JHH = 6, ArC3-H), 4.48 (1H, m, Cp), 4.39-4.38 (1H, m, Cp), 4.33 (1H, d, zJHH = 
16, 3'a), 4.26-4.21 (1H, m, Cp), 4.22 (1H, d, ZJHH = 16, 3'b), 4.14 (1H, t, SJHHH = 3, Cp), 4.03 (5H, 
5, Cp'), 4.07 (2H, m, 1"),3.91-3.82 (1H, m, 4'),3.80 (1H, d, 2JHH = 13, 2'a), 3.48-3.43 (2H, m, 
6'), 3.36-3.27 (2H, m, 4'), 2.77 (1 H, d, Z JHH = 13, 2'b), 1.97 (6H, 5, 1') and 1.91-1.85 (2H, m, 5'); 
OC(H} (100.6 MHz; CDCls) 159.1 ('VC, CO), 151.2 (IVC) , 150.7 (ArCz), 140.7 (~v£), 135.8 ('VC) , 
~ I 
! IV 128.2 (2C, U), 127.2 (ArC6 ), 126.7 (2C, U), 126.6 (U4), 125.4 (ArCs), 122.9 (ArCs), 117.6 ( C), 
97.8 (ArCs), 84.3 ('VC, Cp), 70.4 (Cp), 69.5 (5C, Cp'), 69.0 (Cp), 67.4 (Cp), 58.0 (2'), 45.4 (3'), 
45.2 (4' or 6'),44.7 (4' or 6'),44.6 (2C, 1'), 39.4 (1") and 26.7 (5'); 
IR (KBr) Ymax 3437br s (NH), 3322br s (NH), 3087m, 3027m, 2936m, 2857m, 2820m, 2761m, 
16115 (7-chloroquinoline), 1578vs (7-chloroquinoline), 1538s (7-chloroquinoline), 1494w, 
1455m (NCHs), 1428w, 1369m, 1331w, 1272m, 1242w, 1169w, 1139w, 1106w (ferrocene), 
1078w, 1037w, 1005w (ferrocene), 903w, 878w, 850m (aryl CH 2N(CH3», 809m (ferrocene), 
770w, 731w, 702m, 647w, 625w, 604w, 530w, 511w and 487w; 
HRMS (FAB) mlz 624.1890 [M+ + H, C34H38NsCIOFe + H requires 624.1908], 579.1 (M+-
(HNMe2)], 446.1 [M+ - (HNMez + C6HsCHzNHCO)], 423:1 [M+ - (Cp + CsHsCH2NHCO)], 318.0, 
255.1 [HC-Fp-CHz-NMe2]' 213.1,191.0 [CICgNHs-NH-CHz], 154.0 [CgNHs-NH-CH2], 134.1 [Fe-
Cp-CH 2] and 91.1 [CHz-Cp-CHz]; 
E112 = 131 mV; ferrocene redox: Epa = 171 mV, Epc = 91 mV; second redox: Epa = ± 300 mVand 
Epc = 240 mV. 
Compound 39 
3-Benzyl-1-[ 4-(7 -chloro-quinolin-4-ylamino)-
butyl]-1-[2-(N", N"-dimethylaminomethyl)-
ferrocenylmethyl]urea 
Yellow crystalline solid; Yield: 75mg (58%); 
mp: 84-86°C; 
Rf (silica/CHzCI2: MeOH = 80:20) 0.4; 
OH (400 MHz; CDCI3) 8.47 (1H, d, 3JHH = 5, ArC2-H), 8.07 (1H, d, 3JHH = 9, ArCs-H), 7.91 (1H, d, 
4JHH = 2, ArCa-H), 7.38-7.09 (6H, m, ArC6-H, Uz, U3, U4), 6.35 (1H, d, 3JHH = 6, ArC3-H), 4.42-
4.09 (5H, m, 3Cp, 3'a, 3'b), 4.06 (5H, s, Cp'), 4.05-4.04 (2H, m, 1"),3.79 (1 H, d, zJHH = 13, 2'a), 
3.43 (4H, m,4', 7'), 2.77 (1H, d, zJHH = 13, 2'b), 1.96 (6H, 5,1') and 1.79-1.65 (4H, m, 5', 6'); 
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bC{H} (100.6 MHz; CDCI3) 158.7 <,VC, CO), 151.3 (IVC), 150.6 (ArC2), 144.2 (IVC), 140.8 (IVC) , 
134.9 (IVC), 126.2 (2C, U), 127.8 (U4), 126.6 (2C, U), 126.5 (ArCs), 125.1 (ArCs), 122.9 (ArCs), 
117.6 (IVC), 98.5 (ArC3), 64.6 (IVC), 70.3 (Cp), 69.4 (5C, Cp'), 69.2 (Cp), 67.3 (Cp), 57.9 (2'), 
47.8 (3'), 45.2 (4'),44.7 (2C, 1 '), 44.5 (7'), 43.1 (1 "),26.7 (5' or 6') and 24.3 (5' or 6'); 
IR (KBr) Vmax 3437br s (NH). 3322br s (NH). 3087m, 3027m, 2936m, 2657m, 2620m, 2761m, 
1611s (7-chloroquinoline), 1578vs (7-chloroquinoline), 1538s (7-chloroquinoline), 1494w, 
1455m (NCH3), 1428w, 1369m, 1331w, 1272m, 1242w, 1169w, 1139w, 1106w (ferrocene), 
1078w, 1037w, 1005w (ferrocene), 903w, 878w, 850m (aryl CH2N(CH3)), 809m (ferrocene), 
770w, 731w, 702m, 647w, 625w, 604w, 530w, 511w and 487w; 
HRMS (FAB) mlz 638.2333 [M+ + H, C3sH40NsCIOFe + H requires 638.2347], 593.0 [M+ -
(HNMe2)], 505.2 [M+ (CsHsCH2NHCO)], 460.0 [M+ - (HNMe2 + CsHsCH2NHCO)], 437.0 [M+ -
(Cp + CsHsNHCO)], 255.1 [HC-Fp-CH2-NMe2], 213.0,191.0 [CICgNHs-NH-CHzl. 154.0 [CgNHs-
NH-CH2], 134.1 [Fe-Cp-CHzl and 91.1 [CH2-Cp-CH21; 
E112 = 116 mV; ferrocene redox: Epa = 149 mV, Epc:: 82 mV; second redox: Epa = 303 mV and 
~/ 
Epc = 240 mV. ..1 
Compound 40 
3-Benzyl-1-[6-(7 -chloro-quinolin-4-
ylamino )-hexyl]-1-[2-(N",N"-
dimethylaminomethyl)-
ferrocenylmethyllurea 
Yellow crystalline solid; Yield: 78mg 
(57%); mp: 85-8rC; 
Rf (silica/CH2CIz: MeOH = 60:20) 0.46; 
bH (400 MHz; CDCI3) 8.39 (1H, d, 3JHH = 6, ArCz-H), 8.14 (1H, d, 3JHH = 9, ArCs-H), 8.02 (1H, d, 
4JHH = 2, ArCa-H), 7.16-7.12 (5H, m, U2, U3 , U4), 7.04 (1H, d, 3JHH = 9, ArCs-H), 6.32 (1H, d, 3JHH 
= 6, ArC3-H), 4.41-4.17 (4H, m, 2Cp, 3'a, 3'b), 4.16 (1H, t, 3JHHH = 3, Cp), 4.09 (5H, s, Cp'), 
4.08-4.07 (2H, m, 1"), 3.77 (1H, m, 2'a), 3.31-3.21 (2H, m, 4'), 3.19 (2H, m, 9'), 2.89 (1 H, d, 
2JHH = 13, 2'b), 2.05 (6H, s, 1') and 1.74-1.33 (8H, m, 5', 6', 7', 8'); 
bC{H} (100.6 MHz; CDCI3) 158.5 (IVC, CO), 151.9 (IVC) , 149.1 (ArC2), 140.7 (IVC), 135.6 (IVC) , 
128.2 (2C, U), 126.5 (2C, U), 126.5 (U4), 125.6 (ArC5), 123.0 (ArCa), 117.1 ('VC) , 96.0 (ArC3), 
84.7 (IVC, Cp), 70.4 (Cp), 69.5 (5C, Cp'), 69.4 (Cp), 67.5 (Cp), 57.8 (2'), 46.6 (3'), 44.6 (2C, 1'), 
44.3 (4'), 41.6 (9'), 27.7 (5' - 8')*, 27.6 (5' - 6'), 25.0 (5' - 8') and 24.6 (5' - 8'); 
IR (KBr) Vmax 3306br s (NH), 3095m, 3027m, 2931s, 2859m, 2822m, 2780m, 1612s (7-
chloroquinoline), 1582vs (7-chloroquinoline), 1540s (7-chloroquinoline), 1492w, 1457m (NCH3), 
1425w, 1407w, 1367m, 1333w, 1281m, 1266m, 1209w, 1171w, 1135w, 1106w (ferrocene), 
1076w, 1036w, 1005w (ferrocene), 933w, 903w, 879w, 852m (aryl CH2N(CH3)), 813m 
(ferrocene), 770w, 734w, 701m, 606w, 530w, 512w, 490m (ferrocene), 453w and 437w; 
* As for 24, 5' - 8' indicates that signals could correspond to 5',6',7' or 8' carbon atoms 
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HRMS (FAB) mlz 666.2648 [M+ + H. C37H44NsCIOFe + H requires 666.2660]. 621.1 [M+-
(HNMe2)], 547.4, 502.2 [M+ - (HNMe + CeHsCH2NHCO)], 488.0 [M+ - (HNMe2 + 
CeHsCH2NHCO)], 465.0 [M+ - (Cp + CeHsCH2NHCO)], 422.1, 360.0 [C9NHs-NH-(CHzkN-CH2-
CsH3-CHzNMel. 304.0, 255.1 [HC-Fp-CHz-NMez], 213.1, 191.0 [CIC9NHs-NH-CHz]' 154.0 
[C9NHs-NH-CHz], 134.1 [Fe-Cp-CH2] and 91.1 [CH2-Cp-CH2]; 
E1/z = 123 mV; ferrocene redox: Epa = 164 mV. Epc = 81 mV, second redox: Epa = 317 mV and 
Epc = 260 mV. 
Compound 41 
1-[2-(7 -Chloro-quinolin-4-ylamino)-ethyl]-1-[2-
(N",N"-dimethylaminomethyl)-ferrocenylmethyl]-3-
p-tolyl-urea 
Yellow crystalline solid; Yield: 145mg (75%); 
mp: 81-84°C; 
Rf (silica/CHzClz: MeOH = 80:20) 0.51; 
8H (400 MHz; CDC!;;) 8.51 (1 H, d, 3JHH = 6, ArCz-H), 
7.91 (1 H, d, 4JHH = 2, ArCs-H), 7.69 (1 H, d, 3 J HH = 9, ArCs-H), 7.15-7.08 (5H, m, Uz, U3, ArCs-H). 
6.31 (1H, d, 3JHH = 6, ArC3-H), 4.43 (1H, d, ZJHH = 16, 3'a), 4.40-4.39 (1H, m, Cp), 4.36-4.34 
(1H, m, Cp), 4.28 (1H, d, ZJHH = 16, 3'b), 4.15 (1H, t, 3JHHH = 3, Cp), 4.10 (5H, s, Cp'), 3.80 (1H, 
d, z J HH = 13, 2'a), 3.71-3.68 (2H, m, 5'), 3.55-3.40 (2H, m, 4'), 2.77 (1 H, d, 2 J HH = 13, 2'b) and 
1.98 (9H, s, 1', ArCH3); 
8C{HJ (100.6 MHz; CDCI3) 160.5 ('VC, CO), 151.5 ('VC), 150.8 (ArCz), 140.3 ('VC), 134.9 ('VC), 
128.3 (2C, U), 127.7 ('VC) , 126.6 (ArCe) 126.5 (2C, U), 125.3 (ArCs), 122.7 (ArCa), 117.3 ('vC), 
97.6 (ArC3), 85.0 ('VC, Cp), 82.1 (lVC, Cp), 70.5 (Cp), 69.5 (5C, Cp'), 68.9 (Cp), 67.6 (Cp), 57.9 
(2'),47.2 (3'), 45.6 (4'), 44.7 (2C, 1'),44.7 (3') and 43.7 (5'); 
IR (KBr) Vmax 3266br m (NH), 3061m, 3027m, 2827m, 2940m, 2821m, 2777m, 1610s (7-
chloroquinoline), 1582vs (7-chloroquinoline), 1537s (7-chloroquinoline), 1452m (NCH3), 1430m, 
1404w, 1365m, 1332m (v C-N aromatic), 1302m, 1270s, 1241s, 1204m, 1170m, 1135m, 
1105m (ferrocene), 1079m, 1029m, 1005s (ferrocene), 960w, 917w, 873m, 841m (aryl 
CHzN(CH3», 808s (ferrocene) , 768m, 730m, 698m, 644w, 608w, 526m, 488m (ferrocene), 
456w and 426w; 
HRMS (FAB) mlz 610.2025 [M+ + H, C33H3SNsCIFeO + H requires 610.2034]. 565.1 [M+-
(HNMez)], 432.1 [M+ - (HNMez + CH3CsH4NHCO)], 409.0 [M+ - (Cp + CH3CeH4CH2NHCO)], 
304.0 [C9NHs-NH-(CH2h-N-CHz-CsH3-CHzNMe], 255.1 [HC-Fp-CHz-NMez], 213.1, 134.1 [Fe-
Cp-CH21 and 91.0 [CHz-Cp-CHz or CSH4CH3]; 
E1/z = 155 mV; ferrocene redox: Epa = 195 mV, Epc = 115 mV; second redox: not observed. 
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Compound 42 
1-[2-(7 -Chloro-quino!in-4-ylamino )-ethyl]-1-[2-(N", N"-
dimethylaminomethy!)-ferrocenylmethyl]-3-p-
methoxyphenyl-urea 
Yellow crystalline solid; Yield: 101mg (51%); 
mp: 99-100°C; 
Rf (silica/CH2Ch: MeOH = 80:20) 0.49; 
OH (400 MHz; CDCb) 8.53 (1 H, d, 3 JHH = 5, ArC2-H), 
7.94 (1 H, d, 4JHH = 2, ArCs-H), 7.81 (1 H, d, 3 JHH = 9, 
Chapter 8: General Experimental 
ArCs-H), 7.29 (1 H, dd, 4JHH = 2 Hz and 3JHH = 9 Hz, ArC6-H), 6.99 (2H, d, 3JHH = 9, U), 6.84 (2H, 
d, 3JHH = 9, U), 6.31 (1 H, d, 3 JHH = 5, ArC3-H), 4.48 (1 H, d, 2 JHH = 16, 3'a), 4.43 (1 H, m, Cp), 
4.34 (1H, d, 2JHH = 16, 3'b), 4.17 (1H, t, 3JHH = 2, Cp), 4.13-4.12 (1H, m, Cp), 4.11 (5H, s, Cp'), 
3.87 (1H, d, 2JHH = 13, 2'a), 3.81 (3H, s, OCH3), 3.71-3.67 (2H, m, 5'), 3.60-3.40 (2H, m, 4'), 
2.82 (1H, d, 2JHH = 13, 2'b) and 2.05 (6H, s, 1'); 
I~, 
OC(H} (100.6 MHz; CDCb) 159.8 (IVC, CO), 157.1 (IVC, U4), 151.5 (ArC2), 150.8 (IVC), 132.2 (IVC) , 
127.8 (IVC), 126.8 (2C, U2), 125.3 (ArCs), 122.9 (ArCs), 117.4 (IVC), 113.9 (2C, U3), 98.0 (ArC3), 
83.8 ('VC, Cp), 82.1 (IVC, Cp), 70.7 (Cp), 69.5 (5C, Cp'), 69.0 (Cp), 67.6 (Cp), 58.0 (2'), 55.5 
(OCH3), 46.7 (4'), 45.7 (3'),45.0 (2C, 1') and 43.4 (5'); 
IR (KBr) Vmax 3284br m (NH), 3087m, 2950m, 2858m, 2823m, 2780m, 1636m (v C=O), 1610m 
(7-chloroquinoline), 1583vs (7-chloroquinoline), 1510vs (OCH3), 1481m, 1458m (NCH3), 
1416m, 1391m, 1365m, 1332m (v CoN aromatic), 1295m, 1277m, 1232s (v-as R-O-R'), 1169m, 
1149m, 1136m, 1105m (ferrocene), 1089w, 1075w, 1032m (v-s R-O-R'), 1006m (ferrocene), 
916w, 875m, 824s (ferrocene), 767w, 736w, 645w, 576w, 524m, 492m (ferrocene), 456w and 
436w; 
HRMS (FAB) mlz 626.1995 [M+ + H, C33H36NsCIFe02 + H requires 626.1983}, 581.1 [M+-
(HNMe2)], 530.9, 477.0 [M+ - (CH30C6H3NHCO)], 432.0 [M+ - (HNMe2 + CH30C6H3NHCO)]. 
365.9,334.0, 270.1,213.0, 191.0 [CICgNHs-NH-CH2], 134.1 [Fe-Cp-CH2J and 91.0 [CH2-Cp-
CH2J; 
E1I2 == not found; ferrocene redox: Epa == 170 mY, Epc = ± 30 mY; second redox: Epa == 342 mV 
and Epc = 205 mY. 
Compound 43 
'1-[2-(7 -Chloro-quinolin-4-ylamino )-ethyl]-1-[2-(N", N"-
dimethylaminomethyl)-ferrocenylmethyl]-3-[2,4-bis-
(trifluoromethyl)-phenyl]-urea 
Yellow crystalline solid; Yield: 138mg (65%); 
mp: 94-96°C; 
Rf (silical CH2Cb: MeOH = 80:20) 0.63; 
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OH (400 MHz; COCI3) 8.52 (1 H, d, 3JHH = 5, ArC2-H), 7.91 (1 H, d, 4JHH = 2, ArCa-H), 7.63 (1 H, d, 
3JHH = 9, ArC5-H), 7.38 (1H, dd, 4JHH = 2 and 3JHH = 9, ArCs-H), 7.24-7.14 (3H, m, U3, Us, Us), 
6.33 (1H, d, 3JHH = 5, ArC3-H), 4.52 (1H, d, zJHH = 16, 3a'), 4.42-4.40 ('IH, m, Cp), 4.34 (1H, d, 
2JHH = 16, 3b'), 4.20 (1H, t, 3JHHH = 3, Cp), 4.14 (1H, m, Cp), 4.13 (5H, s, Cp'), 3.85 (1H, d, 2JHH 
= 13, 2a'), 3.76-3.70 (2H, m, 5'), 3.61-3.39 (2H, m, 4'), 2.80 (1H, d, 2JHH = 13, 2b') and 1.94 (6H, 
s, 1'); 
OC{H) (100.6 MHz; COCh) 159.8 (/VC, CO), 151.6 (ArCz), 150.6 (IVC), 133.3 (U), 133.2 (U), 127.9 
(ArCs), 125.0 (U), 122.6 (ArCa), 119.5 ('vC), 117.3 (IVC) , 114.3 (IVC, U4), 114.0 ('VC, Uz), 97.8 
(ArC3), 83.5 (IVC, Cp), 82.0 (IVC, Cp), 71.0 (Cp), 69.5 (5C, Cp'), 69.3 (Cp), 67.7 (Cp), 57.7 (2'), 
46.2 (4'),45.6 (3'), 44.6 (2C, 1') and 43.1 (5'); 
IR (KBr) Vmax 3312br W, 3013m, 2949s, 2823w, 2779m, 1636m (v C=O), 1612m (7-
chloroquinoline), 1583vs (7-chloroquinoline), 1505s, 1470m (NCH3), 1431s, 1405m, 1368m, 
1319s (v-as CF3), 1280s (v-as CF3), 1250m, 1202m, 1163s (v-s CF3), 1136s (v-s CF3), 1047m 
(v C-F), 1005m (ferrocene), 956w, 918m, 876m, 820m (ferrocene), 767w, 745w, 668w, 647w, 
'/ 
.'> 
608w, 530m and 488m (ferrocene); J 
HRMS (FAB) mlz 682.1669 [M+ + H, C33H3zN5CIF4FeO + H requires 682.1658], 636.9 [M+-
(HNMe2)], 597.0, 531.0,477.0,431.9, 367.0,321.9,256.1 [HC-Fp-CHz-NMe21, 213.0, 191.0 
[CIC9NHs-NH-CH2]. 134.1 [Fe-Cp-CH2] and 91.0 [CHz-Cp-CH2]; 
E1/2 = 165 mV; ferrocene redox: Epa = 204 mV, Epc = 125 mV; second redox: not observed. 
Compound 44 
1-[2-(7 -Chloro-quinolin-4-ylamino )-ethyl]-1-[2-( N", N"-
dimethyl-aminomethyl)-ferrocenylmethyl]-3-[2,6-bis-
(trifluoromethyl)-phenyl]-urea 
Yellow crystalline solid; Yield: 96mg (43%); 
mp: 113-115°C; 
Rf (silica/CHzCI2: MeOH = 80:20) 0.79; 
OH (400 MHz; COCI3) 8.50 (1H, d, 3JHH = 6, ArC2-H), 7.98 (1H, d, 4JHH = 2, ArCa-H), 7.65 (1H, d, 
3JHH = 9, ArCs-H), 7.51-7.32 (3H, m, U3• U4), 7.17 (1H, dd, 4JHH = 2 and 3JHH = 9, ArCs-H), 6.35 
(1H, d, 3JHH = 6, ArC3-H), 4.64 (1H, d, 2JHH = 16, 3'a), 4.45-4.44 (1H, m, Cp), 4.38 (1H, d, 2JHH = 
16, 3'b), 4.21 (1H, t, 3JHHH = 2, Cp), 4.15 (1H, m, Cp), 4.13 (5H, s, Cp'), 3.91 (1H, d, 2JHH = 13, 
2'a), 3.74-3.72 (2H, m, 5'),3.66-3.41 (2H, m, 4'), 2.81 (1H, d, 2JHH = 13, 2'b) and 1.95 (6H, s, 
1 '); 
De{Hl (100.6 MHz; COCh) 159.9 evc, CO), 151.6 (IVC), 149.8 (ArC2), 146.9 evC), 135.6 (IVC) , 
128.5 (U), 126.3 (ArCs), 125.3 (ArC5), 123.1 (ArCs), 122.0 (U), 119.8 (U), 119.6 (U), 116.9 (IVC), 
97.7 (ArC3), 83.3 evC, Cp), 81.8 (IVC, Cp), 71.1 (Cp), 69.7 (5C, Cp'), 67.8 (Cp), 66.1 (Cp), 57.6 
(2'),53.0 (2C, CF3), 46.0 (4'), 45.8 (3'),44.1 (2C, 1') and 43.0 (5'); 
IR (KBr) Vmax 3296br w (NH), 3092m, 2950m, 2861m, 2824m, 2780m, 1637m (v C=O), 1616m 
(7-chloroquinoline), 1582vs (7-chloroquinoline), 1522s (7-chloroquinoline), 14765 (NCH3), 
1406m, 1368m, 1323vs (v-as CF3), 1276m (v-as CF3), 1203w, 11665 (v-s CF3), 11365 (V-5 
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CF3), 1076w, 1039w (v C-F), 1005m (ferrocene), 904m, 876w, 844m (aryl CH2N(CH3», 804m 
(ferrocene), 766w, 729w, 668w, 507w, 488w (ferrocene) and 422w; 
HRMS (FAB) mlz 682.1666 [M+ + H, C33H32NsCIF4FeO + H requires 682.1658], 637.0 [M+ -
(HNMe2)], 477.1 [M+ - (CF3C6H3NHCO)], 432.1 [M+ - (HNMe2 + CF3CsH3NHCO)}, 367.1, 322.0, 
213.1, 205.0, 134.1 [Fe-Cp-CH2} and 91.0 [CH2-Cp-CH2]; 
E1I2 = 179 mV, ferrocene redox: Epa = 218 mV, Epc = 138 mV, second redox: not observed. 
Compound 45 
1-[2-(7 -Chloro-quinolin-4-ylamino)-ethylj-1-[2-(N",N"- ~ ~~ ~ N ~ NI ./ 
dimethyl-aminomethyl)-ferrocenylmethyl}-3-p-chloro- I ~;/ HN~O Fe 
phenyl-urea ¢ Q 
Yellow crystalline solid; Yield: 115mg (56%); CII : I 
mp:115-116°C; ........ ,
Rf (silica/CH2Cb: MeOH = 80:20) 0.62; CI . 
3 4'~ 
OH (400 MHz; CDCI3) 8.52 (1 H, d, JHH = 6, ArC2-H), 7.95 (1 H, d, JHH = 2, ArC&-H), 7.79 (1 H, d, 
3JHH = 9, ArC5-H), 7.31 (1 H, dd, 3JHH = 2 and 3JHH = 9, ArC6-H), 7.28-7.24 (4H, m, U), 6.35 (1 H, 
d, 3 JHH = 6, ArC3-H), 4.54 (1 H, d, 2 JHH = 16, 3a'), 4.42-4.41 (1 H, m, Cp), 4.38 (1 H, d, 2 JHH = 16, 
3b'), 4.19 (1H, t, 3JHH = 3, Cp), 4.16-4.14 (1H, m, Cp), 4.12 (5H, s, Cp'), 3.89 (1H, d, 2JHH = 13, 
2a'), 3.74-3.72 (2H, m, 5'), 3.66-3.41 (2H, m, 4'),2.80 (1H, d, 2JHH = 13, 2b') and 1.97 (6H, s, 
1 '); 
OC(H} (100.6 MHz; CDCI3) 159.1 (IVC, CO), 151.5 ('vC), 150.7 (ArC2), 138.0 (IVC), 135.5 (IVC) , 
128.7 (2C, U), 127.9 (2C, U), 125.9 (ArC6), 125.4 (ArCs), 122.6 (ArCa), 117.3 (IVC), 97.9 (ArC3), 
83.4 (IVC, Cp), 82.0 (IVC, Cp), 70.8 (Cp), 69.6 (5C, Cp'), 69.0 (Cp), 67.7 (Cp), 58.1 (2'),46.7 (4'), 
45.8 (3'), 45.3 (2C, 1 ') and 43.2 (5'); 
IR (KBr) Vmax 3306s (NH), 3089m, 2980m, 2934m, 2853m, 2820m, 2771m, 1634s (v C=O), 
1608m (7 -chloroquinoline), 1579vs (7 -chloroquinoline), 1528s (7 -chloroquinoline), 1482s 
(NCH3 ), 1413m, 1364m, 1329m, 1310m, 1288m, 1259m, 1237m, 1176m, 1150w, 1137m, 
1098m, 1087m, 997m, 912w, 874m, 844m (aryl CH2N(CH3», 820m (ferrocene), 809m, 766w, 
742w, 644w, 593w, 507m and 460w; 
HRMS (FAB) m/z 630.1479 [M+ + H, C32H33N5CI2FeO + H requires 630.1489}, 585.0 [M+ -
(HNMe2)], 477.1 [M+ - (CICsH3NHCO)], 432.0,366.0, 307.1, 274.1, 256.1 [HC-Fp-CH2-NMe2J, 
213.0 and 91.0 [CH2-Cp-CH2]; 
E1I2 = not found; ferrocene redox: Epa = 214 mV, Epc = 111 mV; second redox: Epa = 300 mV 
and = ± 210 mV; 
Synthesis of Sulfonamide Derivatives 
Method l' 
20 was placed in a large sample vial followed by 
anhydrous dichloromethane. 5 mol equivalents of poly(4-
vinyl pyridine) (2% cross-linked) was added followed by 3 
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mol equivalents the appropriate sulfonyl chloride resulting in a vigorous, exothermic reaction. 
The sample vial was placed on the shaker overnight at 200 rpm at 20°C. 
Pentaethylenehexamine (3 mol equivalents) was added followed by a further anhydrous 
dichloromethane, and the sample vial was returned to the shaker for 1 h. 1,4-phenylene 
diisocyanate (3 mol equivalents) was added followed by anhydrous dichloromethane and 
returned to the shaker for 1 h. The mixture was then filtered under gravity. The solvent was 
removed from the filtrate under reduced pressure. The product was then purified using silica gel 
chromatography eluting with 20% methanol in dichloromethane. The product sulfonamide was 
isolated as a yellow crystalline solid. 
Method 2: 
20 was placed in a large sample vial followed by anhydrous dichloromethane. 5 mol equivalents 
of poly(4-vinylpyridine) (2% cross-linked) was added followed by 3 mol equivalents the 
appropriate sulfonyl chloride resulting in a vigorous, exothermic reaction. The sample vial was 
placed on the shaker overnight at 200 rpm at 20°C. The reaction mixture was filtered and the 
>/ 
filtrate concentrated under reduced pressure. The product then purified Using silica gel 
chromatography eluting with 20% methanol in dichloromethane. The product sulfonamide was 
isolated as a yellow crystalline solid. 
Compound 46 
3-Benzyl-sulfonic aCid-1-[2-(7 -chloro-quinolin-4-
ylamino )-ethyl]-1-[2-( NU, N"-dimethylaminomethyl)-
ferrocenylmethyl]am ide 
Yellow crystalline solid; Yield: 38mg (40%); mp: 114-
116°C; 
Rr (silica/CH2CI2: MeOH = 80:20) 0.60; 
8H (400 MHz; CDCI3) 8.41 (1 H, d, 3JHH = 6, ArC2-H), 7.90 (1 H, d, 4JHH = 2, ArCa-H), 7.79 (1 H, d, 
3JHH = 9, ArCs-H), 7.38-7.27 (6H, m, ArC6-H, 52, 53,54),6.27 (1 H, br s, NH), 6.10 (1 H, d, 3JHH = 
6, ArC3-H), 4.51 (1 H, d, 2JHH = 14, 3a'), 4.36-4.09 (7H, m, Cp, 1 ",4', 3b'), 4.04 (5H, s, Cp'), 3.62 
(1 H, d, 2 J HH = 13, 2'a), 3.43-3.27 (2H, m, 5'), 2.95 (1 H, d, 2JHH = 13, 2'b) and 2.17 (6H, s, 1 '); 
bC(H) (100.6 MHz; CDCb) 151.2 (IVC) , 150.2 (ArC2), 135.2 (IVC) , 130.8 (2C, 5),130.7 evC), 128.9 
(54)' 128.8 (2C, 5), 128.1 (IVC) , 127.8 (ArC6), 125.5 (ArCs), 122.3 (ArCa), 117.2 (IVC) , 98.2 
(ArC3), 83.7 (IVC , Cp), 81.9 (IVC , Cp), 72.1 (Cp), 70.7 (Cp), 69.4 (5C, Cp'), 67.9 (Cp), 58.3 (2'), 
57.4 (1"), 46.4 (2C, 3',4'),45.0 (2C, 1') and 41.4 (5'); 
IR (KBr) V max 3392m (NH), 3078m, 3035m, 2932m, 2856m, 2813m, 2771m, 1610m (7-
chloroquinoline), 1582vs (7-chloroquinoline), 1538m (7-chloroquinoline), 1494m, 1456m 
(NCH3), 1367m, 1329s, 1231m, 1184m, 1146s, 1124m, 1106m (ferrocene), 1076m, 1040m, 
1014w (ferrocene), 992m, 913w, 895w, 800m, 732w, 694m, 624w, 602w, 563w, 535m, 511m 
and 491 m (ferrocene); 
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HRMS (EI) mlz 630.1520 [M+, C32H3SN4CIFe02S requires 630.1519J, 585.1 [M+ - NMe2], 475.1 
[M+ - S02CH2C6HS], 430.1, 375.0, 311.0, 255.1 [HC-Fp-CH2-NMe21, 240.0 [Fp-CH2-NMe2]. 
213.0, 191.0 [CIC9NHs-NH-CH2], 121.0 [Cp-Fe], 91.0 [CH2-Cp-CH2] and 58.1 [CH2-NMe2]. 
Compound 47 
1-[2-(7 -Chloro-quinolin-4-ylamino )-ethyl]-1-[2-(N",N"-
dimethyl-aminomethyl)-ferrocenylmethyl]-3-p-chloro-
phenyl-sulphonamide 
Yellow crystalline solid; Yield: 63mg (51%); mp: 119- CI 
121°C; 
Rf (silica/CH2Cb: MeOH = 80:20) 0.57; 
8H (400 MHz; CDCI3) 8.42 (1H, d, 3JHH = 5, ArC2-H), 7.90 (1H, d, 4JHH = 2, ArCa-H), 7.88 (1H, d, 
3JHH = 9, ArCs-H), 7.78 (4H, m, S2, S3), 7.24 (1H, dd, 4JHH = 2 and 3JHH = 9, ArC6-H), 6.25 (1H, 
brs, NH), 6.11 (1H, d, 3JHH = 5, ArC3-H), 4.30-4.19 (4H, m, Cp, 3a', 3b'), 4.10-4.06 (1H, m, Cp), 
.. / 
4.05 (5H, 5, Cp'), 3.60 (1H, d, 2JHH ::: 13, 2a'), 3.38-3.32 (2H, m, 5'), 3.01-2.98 (2H, m, 4'), 2.89 
(1H, d, 2JHH = 13, 2b') and 2.09 (6H, s, 1'); 
OC{H) (100.6 MHz; CDCI3) 151.4 (ArC2), 150.2 (IVC) , 139.4 (IVC), 135.1 evC), 129.6 (2C, S), 129.3 
(IVC), 128.5 (2C, S), 128.6 (ArCs), 128.4 evC) 125.4 (ArC6), 122.1 (ArCa), 117.4 (IVC), 98.4 
(ArC3), 81.3 ('VC, Cp), 72.0 (Cp), 70.6 (Cp), 69.4 (5C, Cp'), 67.8 (Cp), 57.4 (2'), 47.6 (4'), 46.3 
(3'),45.2 (2C, 1') and 42.0 (5'); 
IR (KBr) V max 3393m (NH), 3091m, 2931m, 2858m, 2816m, 2776m, 1611s (7-chloroquinoline), 
1582vs (7-chloroquinoline), 1540m (7-chloroquinoline), 1476m, 1453m (NCH3), 1336s, 1281m, 
1216m, 11585, 1123m, 1088m, 1035m, 1004m (ferrocene), 910w, 872w, 828m (aryl 
CH2N(CH3)), 767m, 729m, 650w, 615m, 561w and 483m (ferrocene); 
HRMS (EI) m/z 650.10164 [M+ + H, C31H32N4CI2Fe02S requires 650.09724], 475.1 [M+ -
SOzC6H4CI], 430.1,395.0,311.0,240.0 [Fp-CH2-NMe2], 213.0,191.0 [CIC9NH5-NH-CH2], 156.0, 
91.0 [CH 2-Cp-CHz] and 57.1 [CH-NMe2]' 
Compound 48 
Quinoline-8-sulphonic acid [2-(7-chloro-quinolin-4-yl)-
ethyl]-(2-dimethylaminomethyl-ferrocenylmethyl)-
amide 
Deep orange crystalline solid; Yield: 204mg (90%); 
mp: 108-110°C; 
Rf (silica/CH2C1z: MeOH = 80:20) 0.23; 
OH (400 MHz; CD30D) 8.82 (1H, d, 3JHH ::: 4,87),8.43 (1H, 3JHH ::: 7,82),8.33 (1H, d, 3JHH 6, 
ArC2-H), 8.24 (1 H, dd, 4JHH ::: 2 and 3 JHH = 8, 85), 7.98 (1 H, dd, 4JHH = 2 and 3 JHH = 8, 84), 7.83 
(1H, d, 3JHH = 9, ArC5-H), 7.66 (1H, d, 3JHH ::: 2, ArCs-H), 7.63 (1H, dd, 3JHH = 7 and 3JHH = 8, 
S3), 7.38 (1H, d, 3JHH = 4 and 3JHH = 8, Ss), 6.92 (1H, dd, 3JHH ::: 2 and 3JHH ::: 9, ArCs-H), 6.66 
(1H, d, 3JHH = 6, ArC3-H), 4.50 (1H, m, Cp), 4.46 (1H, d, 2JHH = 13, 3a'), 4.36 (1H, m, Cp), 4.35 
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(1H, d, 2JHH = 13, 2a'), 4.33 (1H, t, 3JHH = 2, Cp), 4.16 (5H, s, Cp'), 4.00 (1H, d, 2JHH = 13, 3b'), 
3.85-3.64 (2H, m, 4'),3.43 (1H, d, 2JHH = 13, 2b'), 3.37-3.23 (2H, m, 5') and 2.45 (6H, s, 1'); 
OC{H} (100.6 MHz; CD30D) 152.5 (IVC), 150.5 (87),148.5 (ArC2), 145.1 (vC), 144.0 (IVC), 140.8 
IV 6 IVC IV ( C), 137.0 (85), 13 .4 ( ), 131.7 (84), 129.5 (82), 129.3 ( C), 125.5 (8s), 125.1 (ArCs), 123.8 
(ArC5), 123.6 (ArCs), 122.4 (8s), 116.6 (IVC), 98.6 (ArC3), 79.8 (IVC, Cp), 78.0 (IVC, Cp), 72.2 
(2C, Cp), 69.8 (5C, Cp'), 68.1 (Cp), 56.6 (2'), 46.2 (3'),45.0 (5'), 42.4 (2C, 1') and 40.4 (4'); 
IR (KBr) Y max 3448br s, 2973s, 2938s, 2739s, 2676s, 2489m, 1615s (7-chloroquinoline), 1582s 
(7-chloroquinoline), 1495m, 1455m (NCH3), 1398m, 1384m, 1366m, 1334m, 1311w, 1208br vs, 
1105m (ferrocene), 1048s, 980w, 900w, 832m (aryl CH2N(CH3)), 784m, 689m, 618s, 576m, 
519m and 432m; 
M8 (FAB) m/z 686.1 [M+ + Hl, 477.1 [M+ - 802CgHsNl, 432.1, 312.1, 253.9, 213.0, 191.0 
[CICgNH5-NH-CH2l. 102.1 and 91.0. [CHz-Cp-CH21. 
Experimental Details Pertaining to Chapter 4 
Preparation of Ionic Gold Complexes 
Compound 58 
Preparation of Chlorogoldtriphenylphosphine 10 
Compound 59 
Preparation of Triphenylphosphinegold(l) nitrate 11 
Compounds 60 - 63 
Coordination of gold triphenylphosphine to 4-amino-7-chloroquinoline derivatives 
The 4-amino-7-chloroquinoline derivative was added to anhydrous dichloromethane in a 
centrifuge tube fitted with nitrogen inlet. 1 mol equivalent of triphenylphosphinegold(l) nitrate 59 
was added. Light was excluded from the flask and the mixture was allowed to stir at 25°C for 
3h. The reaction vessel was then cooled to -72°C in an ethanol/dry ice slurry. The volume of 
solvent was reduced to about 10% of the original volume in vacuo. The concentrated solution 
was transferred to a sample vial. Diethyl ether was added giving a precipitate. The slurry was 
allowed to stand at 4°C for 1 h before filtering and washing with diethyl ether. 
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Compound 60 
(Chloroquine )(triphenylphosphine )gold 
nitrate; [Au(CO)PPh3]N03 
Cream crystalline solid; Yield: 134mg (82%); 
mp: 89-90°C (from diethyl ether); 
OH (300 MHz; CDCI3) 8.44 (1 H, d, 3JHH = 9, I 
~:~;;~:::~y~~:~:~~:'::-::::::H::~ Q6tp 
ArCs-H), 6.48 (1 H, d, 3 JHH = 6, ArC3-H), 3.76 ::::::-.... 
(1H, m, 6'),2.79-2.56 (6H, m, 2', 3'),1.78-1.57 (4H, m, 5', 4'),1.35 (3H, d, 3JHH = 6,1") and 1.09 
(6H, t, 3 JHH = 6, 1'); 
OC{H} (75.5 MHz; CDCI3) 152.3 (ArCz), 151.8 (IVC) , 147.5 (IVC), 136.3 (IVC) , 134.1 (Ph), 134.0 
·r 
.' IV (Ph), 132.5 (Ph), 129.7 (Ph), 129.5 (Ph), 126.1 (ArCs), 125.3 (ArCs), 124.7 (ArCa), 117.9 ( C), 
99.1 (ArC3), 52.6 (2'),49.3 (6'), 47.0 (3'),33.5 (5'),23.1 (4'), 19.7 (1 ") and 10.6 (1'); 
Op{H} (121 MHz, CDCI3) 30.81 (PPh3); 
IR (KBr) Vmax 3404br m (v N-H), 3070m, 2966m, 1579s (7-chloroquinoline), 1534m (7-
chloroquinoline), 1478m, 1436m, 1382vs (v N-O), 1200w (NCHzCH3), 1152m, 1100m, 1025w, 
996w (v P-C), 807w, 749m, 711 m, 693s, 546s and 503s; 
MS (FAB) m/z 779.142 [M+, C3sH40N3Au3SCIP+ requires 779.198], 747.9, 720.9, 662.9, 578.8, 
458.8 [AuPPh3], 320.0 [CO], 249.0 [(CI37 _ CO - 2(CH2CH3)], 247.0 [CI35_ CO - 2 
(CH2CH3)], 183.0, 165.0, 152.0, 140.1, 136.0, 128.0, 115.0, 105.0,91.0,89.0,86.0,76.9,64.8, 
and 62.8; 
Found: C, 51.72; H, 5.01; N, 6.50. Calc. for [C3sH4oN3AuCIPt[N03r: C, 51.47; H, 4.80; N, 
6.67%; 
A (C6HsN02' 20°C) = 17 Q"1cm2mor1. 
Compound 61 
(Ferroquine)(triphenylphosphine)gold nitrate 
[Au(FO)PPh3]N03 
Orange crystalline solid; Yield: 185mg (84%); 
mp: 110-112°C; 
OH (400 MHz; CDCI3) 8.68 (1 H, d, 3JHH = 7, 
ArC2-H), 8.26 (1 H, d, 4JHH = 2, ArCs-H), 7.94 
(1H, d, 3JHH = 9, ArCs-H), 7.60 (15H, m, Ph), 
7.39 (1 H, d, 4JHH = 2 and 3JHH = 9, ArC6-H), 
I 
Au 
0:61>::0 :71 
::::::-.... 
6.97 (1H, d, 3JHH = 7, ArC3-H), 4.59 (1H, d, 2JHH = 14, 3'a), 4.48 (1H, d, 2JHH :: 14, 3'b), 4.37 (1H, 
m, Cp), 4.22 (1 H, m, Cp), 4.16 (5H, s, Cp'), 4.09 (1 H, m, Cp), 3.99 (1 H, d, 2 JHH = 12, 2'a), 3.11 
(1H, d, 2JHH :: 12, 2'b) and 2.32 (6H, s, 1'); 
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OC(H} (100.6 IVIHz; CDCla) 154.2 (ArC2), 152.5 (IVC) , 146.8 (vC), 136.7 (IVC), 134.2 (Ph), 134.1 
(Ph), 132.6 (Ph), 128.8 (Ph), 126.7 (Ph), 126.1 (ArCs), 124.6 (ArCs), 124.0 (ArC5), 118.0 (IVC) , 
100.4 (IVC), 95.5 (ArCa), 83.0 (IVC, Cp), 71.4 (Cp), 70.8 (Cp), 69.6 (5C, Cp'), 66.7 (Cp), 57.8 (2'), 
44.7 (2C, 1 ') and 42.5 (3'); 
OP{H} (121 MHz, CDCb) 30.60 (PPh3); 
IR (KBr) Vmax 3430br 5 (v N-H), 30795, 29415, 28265, 2776s, 1592vs (7-chloroquinoline, v 
C=N), 1480m, 1434m (15-as NCH3 ), 1384vs (v N-O), 1332s, 1209w, 1141w, 1102s (ferrocene), 
1032w, 996m (v P-C), 815m (ferrocene), 749m (15 C-H aromatic, 5 adjacent hydrogens), 711m 
(15 C-H aromatic, 5 adjacent hydrogens), 544s, 505m and 456w; 
MS (FAB) mlz 892.2 [M", C41Ha9N33sCAuFeP requires 892.15851], 848.1 [M+ - (NMe2)], 757.1, 
721.2,637.1,492.2,432.2 [M+ - (AuPPh3)], 388.1, 262.2 [PPh3], 213.1,185.1,183.1,134.1 and 
91.0 [CH2-Cp-CH2]; 
E1/2 = 147 mV; ferrocene redox: Epa = 252 mV and Epc = 162 mV; 
A (CsHsN02, 20°C) = 21 n-1cm2mor1.· 
Compound 62 
N-(7 -Chloro-q uinolin-4-yl)-
N'-[2-[(N",N"-
dimethylaminomethyl) 
ferrocenylmethyl-ethane-
1,2-diamine] 
(triphenylphosphine)gold 
nitrate 
[Au(F2Q)PPhs]NOs 
o 
< }-~-AU'NJ-~~N~~N/ fA O~ H Ye I 
V /- ~ 
CI 
Deep orange crystalline solid; Yield: 343mg (90%); mp: 106-108°C; 
OH (300 MHz; CDCI3) 8.41 (1H, d, 3JHH = 6, ArC2-H), 8.14 (1H, d, 3JHH = 9, ArCs-H), 7.85 (1H, d, 
4JHH = 2, ArCa-H), 7.53 (15H, m, Ph), 7.12 (1H, dd, 4JHH = 2 and aJHH = 9, ArCe-H), 6.49 (1H, d, 
3JHH = 6, ArC3-H), 4.31 (1H, m, Cp), 4.24 (1H, m, Cp), 4.12 (1H, m, Cp), 4.08 (5H, m, Cp'), 3.90 
(1H, d, 2JHH = 13, 2'a), 3.64 (3H, m, 3'a, 5'), 3.50 (3H, m, 3'b, 4'), 2.82 (1H, d, 2JHH = 13, 2'b) 
and 2.09 (6H, 5, 1'); 
OC{H} (75.5 MHz; CDCls) 152.1 (ArC2), 151.0 ('vC), 148.2 (IVC), 135.4 (IVC) , 134.0 (Ph), 133.9 
(Ph), 132.3 (Ph), 129.5 (Ph), 129.3 (Ph), 128.0 (IVC), 127.1 (IVC) , 126.7 (ArCa), 125.8 (ArCs), 
123.7 (ArCs), 117.7 (IVC) , 99.0 (ArCa), 71.4 (Cp), 69.4 (5C, Cp'), 66.5 (Cp), 65.8 (Cp), 58.0 (2'), 
44.4 (2C, 1 ') and 41.6 (5'); 
15p{H} (121 MHz; CDCls) 30.71 (PPh3); 
IR (KBr) Vmax 333-1 br m (NH), 3054m, 2940m, 15805 (7-chloroquinoline), 1478m (NCH3), 
1436m, 1383vs (v l'l-O), 13295, 1205w, 1139w, 1102m (ferrocene), 1029w, 996m, 811m 
(ferrocene), 747m (0 C-H aromatic), 714m (5 C-H aromatiC), 6955, 618w, 5445 and 506m; 
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HRMS (FAB) mlz 935.20071 [M+, C43H44N4Au3SCIFeP+ requires 935.1396], 841.5, 770.6, 721.5 
[M+ - (3Ph + Me)], 680.5, 649.4, 475.3 [M+ - (AuPPh3)], 459.3 [AuPPh3], 213.1 and 185.1; 
E1/2: not found; ferrocene redox: Epa = 294 mV and Epc = 186 mV; 
A (CsHsN02' 20°C) = 13 0-lcm2mor1. 
Compound 63 
{3-Benzyl-1-[2-(7 -chloro-
quinolin-4-ylamino)-ethyl]-
1-[2-(N",N"-
dimethylaminomethyl)-
ferrocenylmethyljurea} 
(triphenylphosph ine }gold 
nitrate 
[Au(BU}PPh3]N03 
Yellow crystalline solid; 
Yield: 190mg (75%); mp: 102-1 05°C; 
+ N03 
8H (300 MHz; CDCI3) 8.31 (1H, d, 3JHH = 7, ArCz-H), 8.18 (1H, d, 4JHH = 2, ArCa-H), 8.11 (1H, d, 
3JHH = 9, ArCs-H), 7.66-7.50 (15H, m, Ph), 7.28-7.10 (8H, m, 1", ArCs-H, U), 6.81 (1H, d, 3JHH = 
7, ArC3-H), 4.51-4.20 (6H, m, 3Cp, 3'a, 4'), 4.12 (5H, s, Cp'), 4.11-3.61 (5H, m, 2'a, 2'b, 3'b, 5') 
and 2.01 (6H, s, 1'); 
8e{H} (75.5 MHz; CDCb) 159.9 (CO), 153.6 ('vC), 153.3 (ArC2), 146.3 ('vC), 140.5 (IVC) , 136.8 
('vC), 134.2 (Ph), 134.0 (Ph), 132.6 (Ph), 129.8 (Ph), 129.6 (Ph), 128.2 (2C, U), 127.1 (U), 
126.6 (2C, U), 124.9 (ArCa), 123.7 (ArC5) 117.8 (IVC), 99.5 (ArC3), 84.3 (IVC, Cp), 70.6 (Cp), 
69.7 (Cp'), 68.6 (Cp), 67.8 (Cp), 58.7 (2'), 49.7 (3'), 45.5 (4'), 44.6 (1 "), 44.2 (2C, 1') and 43.1 
(5'); 
8p{H} (121 MHz; CDCI3) 30.58 (PPh3); 
IR (KBr) Vmax 3309br m (v N-H), 3057m, 2934m, 2820m, 2775m, 1595vs (7-chloroquinoline), 
1542s (7-chloroquinoline), 1480w, 1452m (NCH3), 1437m (8-as (NCH3», 1381vs (v N-O), 
1336s, 1283m, 1205m, 1101m (ferrocene), 1028m, 999w (v P-C), 814w (8 C-H aromatic), 748m 
(8 C-H aromatic), 695s, 609w, 544s, 51 Om and 454w; 
HRMS (FAB) mlz 1068.2548 [M+ + H, CS1H50NsAu35CIFeOP+ + H requires 1068.2535j, 917.2, 
721.2,610.3 [M+ - (AuPPh3)], 565.2,459.0,213.0,185.1 and 91.0 [CH2-Cp-CH2j; 
Found: C, 54.05; H, 4.14; N, 7.16. Calc. for [C51H50NsAuCIFeOP+]N03-: C, 54.15; H, 4.544; N, 
7.429%; 
El/2 = 180 mV; ferrocene redox: Epa = 219 mVand Epc = 141 mV; 
A (CaH5N02' 20°C) = 31 0-1 cm2mol-1 . 
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Preparation of Neutral Gold Complexes 
Compound 70 
Preparation of (Chloro)( tetrahydrothiophene)gold(l) 12 
Compound 64 
Preparation of (Pentafluorophenyl)(tetrahydrothiophene)gold(l) 13,14 
Compounds 65 - 68 
Complexation of pentafluorophenylgold to 4-amino-7-chloroquinoline derivatives 
Method 1: 
A 1:1 molar ratio of (pentafluorophenyl)(tetrahydrothiophene)gold 64 and the 4-amino-7-
chloroquinoline derivative were placed in a 25ml 2-necked round bottomed flask fitted with 
nitrogen inlet and stopper. Freshly distilled dichloromethane was added and the flask protected 
~ , 
from light. The mixture was allowed to stir at 25°C for 2 h. The solvent was 'then removed in 
vacuo. The solid residue was then purified using preparative TLC, eluting with 10% methanol in 
dichloromethane. 
Method 2: 
A 1:1 molar ratio of (pentafluorophenyl)(tetrahydrothiophene)gold 64 and the 4-amino-7-
chloroquinoline derivative were placed in a centrifuge tube fitted with 2-necked adaptor. Freshly 
distilled dichloromethane was then added. The tube was protected from light and the mixture 
allowed to stir at 25°C for 2 h. The stirrer bar was removed and hexane added. The product 
precipitated out of solution. The suspension was centrifuged and the supematant decanted off. 
The solid product was then dried in vacuo. 
Compound 65 
Chloroquine(pentafluorophenyl)gold 
[Au(CsFs)(CQ)] 
White crystalline solid; Yield: 91 mg (63%); 
mp: 114-116°C; 
OH (400 MHz; CD30D) 8.58 (1H, d, 4JHH = 2, ArCa-H), 8.37 
(1H, d, 3JHH = 6, ArC 2-H), 8.23 (1H, d, 3JHH = 9, ArCs-H), I 
:.44 (1H, dd, 4JHH = 2 and 3J HH = 9, ArCs-H), 6.66 (1H, d, Fy1U, F JHH = 6, ArC3-H), 3.95-3.91 (1H, m, 6'), 3.24-3.12 (6H, m, 2',3'), 1.92-1.74 (4H, m, 4',5'), 1.42 (3H, d, 3JHH = 6, F ~ F 
1") and 1.32 (6H, t, 3JHH = 7, 1'); F 
OC{H} (100.6 MHz; CD30D) 153.5 (ArC2), 151.8 evC), 147.4 evC), 136.2 (IVC) , 125.9 (ArCs), 
125.6 (ArCe), 123.4 (ArCa), 117.8 evC), 99.3 (ArC3), 51.8 (2'), 49.0 (6'), 46.9 (3'), 32.7 (5'), 21.0 
(4'), 18.9 (1 ") and 8.2 (1 '); 
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OF{H} (376 MHz; CD30D) -117.26 to -117.38 (2F, m, a-F), -165.78 (1 F, t, 3 JFF = 19, p-F) and 
-166.80 to -166.97 (2F, m, m-F); 
IR (KBr) Vmax 3431m (NH), 2972m, 2923m, 2874m, 2852m, 2791m, 1594vs (7-chloroquinoline), 
1541m (7-chloroquinoline), 15055 (v C-F), 1455vs (v C-F), 14425, 1381m, 1367m, 1341m, 
1282m, 1263m, 1219w, 1198m, 1068m, 1017m, 956vs (v C-F), 866m, 8035, 754m, 647w, 
514m and 454m; 
MS (FAB) m/z 684.2 [M+, C24H2sN3AuCIFe requires 684.2], 639.5, 595.4, 551.4, 507.3, 462.3, 
332.4, 320.2 [M+ - (AuCsFs)], 247.1 [M+ - (AuCsFs + N(CH2CH3h)], 205.0, 179.0, 142.1, 86.1 
and 58.0; 
A (CsHsN02' 20°C) = 0.2 n-1cm2mol-1. 
Compound 66 
Ferroquine(pentafluorophenyl)gold 
[Au(CsFs)(FQ)] 
Orange crystalline solid; Yield: 79mg (54%); mp: 83-86°C; 
OH (300 MHz; CD30D) 8.37 (1 H, d, 3 JHH = 6, ArCTH), 7.91 
I 
Au 
F I F (1 H, d, 3JHH = 9, ArCs-H), 7.76 (1 H, d, 4JHH = 2, ArCs-H), yy 
7.45 (1 H, dd, 'J" = 2 and' J" = 9, ArC,-H), 6.75 (1 H, d, Y 
3JHH = 6, ArC3-H), 4.58 (1H, d, 2JHH = 14, 3'a), 4.55 (1H, d, F F F 
2JHH = 14, 3'b), 4.37 (1H, m, Cp), 4.31-4.29 (1H, m, Cp) 4.19-4.18 (1H, m, Cp), 4.17 (5H, 5, 
Cp'), 3.92 (1H, d, 2JHH = 13, 2'a), 3.29 (1H, d, 2JHH = 13, 2'b) and 2.34 (6H, 5,1'); 
OC{H} (75.5 MHz; CD30D) 153.3 (ArC2), 150.2 (IVC) , 149.5 (IVC), 126.7 (ArCs), 125.7 (ArCs), 
124.4 (ArCs), 118.2 (IVC), 100.2 (ArCs), 84.9 (IVC, Cp), 82.9 (IVC, Cp), 72.5 (Cp), 71.5 (Cp), 70.6 
(5C, Cp'), 68.2 (Cp), 58.3 (2'), 44.7 (2C, 1') and 42.8 (3'); 
OF{H} (376 MHz; CD30D) -117.25 to -117.45 (2F, m, a-F), -165.88 (1 F, t, 3JFF = 19, p-F) and 
-166.90 to -167.05 (2F, m, m-F); 
IR (KBr) V max 3400br m (NH), 3088m, 2945m, 2826m, 2783m, 15915 (7-chloroquinoline), 
1554m (7 -chloroquinoline), 15025 (v C-F), 14575 (v C-F), 1362m, 1325m, 1285w, 1259w, 
1226w, 1203w, 1141w, 1105w (ferrocene), 1062m, 1003w (ferrocene), 9555 (v C-F), 862m, 
804m, 605w, 527w and 490w (ferrocene); 
HRMS (FAB) m/z 798.0672 [M+ + H, C29H24N3Au3sCIFeFs + H requires 798.3425], 753.0,459.2, 
434.2, 389.0, 256.1 [HC-Fp-CHTNMe2], 213.0, 134.1 [Fe-Cp-CH2l and 91.1 [CHT Cp-CH2l. 
Compound 67 
N-(7 -Chloro-q uinolin-4-yJ)-N'-[2-
[(N",N"-dimethyl-
am i nomethyJ)ferrocenyl methy 1-
ethane-1,2-diaminel 
( pentfluorophenyl)gold 
F F 
'--! H 
F--< ~AU-{)-N~N'2~;;;C'N/ 
l F O~ H Fe I 
/- ~ 
CI 
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[Au(C6Fs)(F2Q)] 
Orange crystalline solid; Yield: 132mg (75%); mp: 76-78°C; 
OH (300 MHz; CDsOD) 8.35 (1H, d, sJHH = 6, ArCz-H), 8.09 (1H, d, 3JHH = 9, ArCs-H), 7.78 (1H, 
d, 4JHH = 2, ArCs-H), 7.40 (1H, dd, 4JHH = 2 and 3JHH = 9, ArC6-H), 6.57 (1H, d, sJHH = 6, ArCs-H), 
4.25-4.23 (1H, m, Cp), 4.15-4.13 (1H, m, Cp), 4.07 (1H, t, sJHHH = 2, Cp), 4.03 (5H, s, Cp'), 3.81 
(1H, d, 2JHH = 13, 3'a), 3.66 (1H, d, 2JHH = 13, 2'a), 3.52 (2H, m, 5'), 3.44 (1H, d, 2JHH = 13, 3'b), 
2.95 (2H, m, 4'),2.88 (1H, d, 2JHH = 13, 2'b) and 1.97 (6H, s, 1'); 
OC{H) (75.5 MHz; CDsOD) 152.7 (IVC), 152.5 (ArC2), 149.7 (IVC) , 136.4 (IVC), 127.7 (ArCs), 126.1 
(ArC6), 124.3 (ArC5), 119.3 (IVC), 99.8 (ArC3), 85.9 (IVC, Cp), 84.0 (IVC, Cp), 72.3 (Cp), 71.3 
(Cp), 70.2 (5C, Cp'), 67.5 (Cp), 58.7 (2'), 44.8 (2C, 1') and 43.3 (5'); 
OF{H) (376 MHz; CDsOD) -117.23 to -117.40 (2F, m, o-F), -165.86 (1 F, t, 3JFF = 19, p-F) and 
-166.86 to -167.03 (2F, m, m-F); 
IR (KBr) Vmax 3411br m (NH), 2955m, 1612m (7-chloroquinoline), 15835 (7-chloroquinoline), 
1536m (7-chloroquinoline), 14995 (v C-F), 1450vs (v C-F), 1384m, 1336m,.,A278w, 1252w, 
." 
1139w, 1105w (ferrocene), 1048m, 1000w (ferrocene) , 952s (v C-F), 811m (ferrocene), 781m, 
489m (ferrocene) and 452w; 
MS (FAB) mlz 841.2 [M+ + H, C31H29N4Au35CIFeFs + H requires 841.2], 796.1, 477.2 [M+ -
AuC6F 4BrJ, 432.2, 312.1, 256.1 [HC-Fp-CH2-NMe2]. 213.0, 134.1 [Fe-Cp-CH2] and 91.0 [CH2-
Cp-CH2]; 
E1/2 : not found; ferrocene redox: Epa = 315 mVand Epc = 210 mV; 
A (C6HSN02' 20°C) = 0.9 O·1cm2mor1. 
Compound 68 
{3-Benzyl-1-[2-(7 -chloro-quinolin-4-
ylamino )-ethyl]-1-[2-( N", N"-
dimethylaminomethyl)-
ferrocenylmethyl]urea} 
(pentafluorophenyl)gold 
[Au(BU)(C6Fs)] 
F F 
F K Au-~1~~ ~ / ~_ N ~ N 
F F fj ~ HN A-o Fe I 
-N ~ 
CI 0 
Yellow crystalline solid; Yield: 130mg (60%); mp: 102-105°C; 
OH (300 MHz; CDCI3 ) 8.81 (1 H, br s), 8.68 (1 H, d, 4JHH = 2, ArCs-H), 8.42 (1 H, 3JHH = 6, ArCz-H), 
8.33 (1H, br 5),7.71 (1H, d, 3JHH = 9, ArCs-H), 7.17-7.02 (6H, m, U, ArC6-H), 6.31 (1H, d, SJHH = 
6, ArC3-H), 4.50-4.15 (8H, m, Cp, 1!1, 3'a, 4'), 4.11 (5H, 5, Cp'), 3.81 (1 H, d, 2 JHH = 13, 2'a), 
3.75-3.66 (1H, m, 3'b), 3.56-3.40 (2H, m, 5'), 2.78 (1H, d, 2JHH = 13, 2'b) and 1.99 (6H, 5,1'); 
OC{H} (75.5 MHz; CDCls) 160.5 ('VC, CO), 153.3 (ArC2), 152.0 (IVC), 146.9 ('vC), 139.7 (IVC) , 
136.4 ('vC), 128.2 (2C, U), 126.7 (ArC6), 126.6 (U4), 126.2 (2C, U), 125.7 (ArCs), 123.0 (ArCs), 
117.4 (IVC), 98.0 (ArC3), 83.5 ('VC, Cp), 70.6 (Cp), 69.9 (Cp), 69.5 (5C, Cp'), 67.6 (Cp), 57.7 (2'), 
46.9 (3'), 45.8 (4'), 44.6 (1"), 44.5 (2C, 1') and 43.8 (5'); 
OF{H} (376 MHz; CDCI3) -120.05 to -120.25 (2F, m, o-F), -164.518 (1 F, t, 3 JFF = 20, p-F) and 
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-167.38 to -167.62 (2F, m, m-F); 
IR (KSr) Vmax 3409br m (NH), 3091 m, 2928m, 2860m, 2823m, 2779m, 1592vs (7-
chloroquinoline), 1548m (7-chloroquinoline), 1502s (v C-F), 1457s (v C-F), 1361m, 1335m, 
1271m, 1204w, 1160w, 1142w, 1104w (ferrocene), 1062m, 1005w (ferrocene), 956s (v C-F), 
858w, 805m, 730w, 698w, 607w, 527w and 487w; 
MS (FAS) 974.1 [M+ + H, C39H37Ns3sCIAuFsFeO + H requires 974.16218L 929.0 [M+ - (HNMe2)], 
806.2, 773.1,610.3 [M> (AuCsFs)], 565.2 [M+ - (AuCsFs + HNMe2)], 499.1, 432.2 [M+ (HNMe2 
+ CsHsCH2NHCO], 409.1, 304.0, 213.0, 134.1 [Fe-Cp-CH21 and 91.0 [CHz-Cp-CH2]; 
A (CsHsN02' 20°C) = 0.7 Q'1cmZmor1. 
Preparation of Rhodium Complexes 
Compound 78 
[RhCI(COD)h was prepared according to literature procedures. 15 
Compounds 79 - 82 
Dichoro(dicyclooctadiene)dirhodium 78 was placed in a Schlenk tube followed by 3 mol 
equivalents of the appropriate 4-amino-7-chloroquinoline compound. Anhydrous 
dichloromethane (5 ml) was added and the mixture allowed to heat under reflux for 4 h. There 
was no visible change in the solution. The solvent volume was reduced to half its original level 
in vacuo. Diethyl ether was then added dropwise until the solution became turbid. The mixture 
was then placed in the freezer overnight. The suspension was then filtered under reduced 
pressure and washed with diethyl ether. The solid product was then dried in vacuo. 
Compound 79 
[RhCI(COD)CQ] 
Pale yellow crystalline solid; Yield: 321mg (45%); 
mp: 171-173°C; 
OH (300 MHz; CDCI3) 9.49 (1 H, br s, ArCa-H), 8.39 (1 H, d, 
3JHH ::: 5, ArCz-H), 7.68 (1 H, d, 3JHH ::: 9 Hz, ArCs-H), 7.09 
(1 H, d, 3JHH ::: 9, ArCs-H), 6.21 (1 H, d, 3JHH = 5, ArC3-H), 
6.04 (1H, br 5, NH), 4.74 (2H, m, COD - CH trans to CI), 
3.66-3.54 (3H, m, 1', COD - CH cis to CI), 2.53 (8H, m, 4', 
I 
Rh-CI 
~ 
5', COD - CHz), 1.81 (6H, m, 2',3'),1.41 (3H, d, 3JHH = 6,1") and 0.98 (4H, br5, COD-CH2); 
0C{H) (75.5 MHz, CDCb) 152.1 (ArC2), 149.6 (IVC, ArCg), 147.3 (IVC, ArC4), 135.1 (IVC, ArC7), 
128.2 (ArCa), 125.3 (ArCe), 122.7 (ArCs), 117.9 (IVC, ArC10), 99.6 (ArC3), 84.2 (2C, CH, COD), 
84.0 (2C, CH, COD), 52.6 (2C, 5'), 48.7 (1'), 46.8 (4'), 34.2 (2'), 31.3 (2C, COD), 30.5 (2C, 
COD), 23.8 (3'), 19.8 (1") and 11.4 (2C, 6'); 
IR (KSr) Vmax 3320s (NH), 3061m, 29725, 29355, 28615, 2833m, 2808m, 1588vs (7-
chloroquinoline), 15405 (7-chloroquinoline), 1492m (v C=C, COD), 1457s, 1423m, 1380m, 
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1368m, 1332m, 1280m, 1258m, 1213w, 1197m, 1143m, 1084m, 996m, 965m, 919m, 859m, 
809s, 765m, 660w, 532m and 484m (v Rh-COD); 
MS (FAB) m/z 566.1 [M+], 530.1799 [(M+ - CI), C2sH3sN3CIRh requires 530.1809], 420.0, 348.9, 
320.1 [M+ - (Rh(COD)CI)], 247.1,211.0,179.1,142.2,136.1,112.1,91.1,86.0 and 77.1; 
Found: C, 55.43; H, 6.71; N, 7.12. Calc. forC2SH38N3ClzRh: C, 55.13; H, 6.76; N, 7.42%. 
1H NMR and IR in agreement with literature values.z 
Compound 80 
[RhCI(COD)FQl 
Orange crystalline solid; Yield: 156mg (60%); 
mp: 212°C (dec); 
HN~N/" 
m"'" Fe I '- ~ ~ bH (300 MHz; CDCI3) 9.58 (1 H, br s, ArCa-H), 8.61 (1 H, d, CI '-" ~ 
3 3 /Rh-CI JHH = 6, ArC2-H) 8.17 (1 H, br s, NH), 7.54 (1 H, d, JHH = 9, /" ........... 
ArCs-H), 7.30 (1H, d, 4JHH = 2 and 3JHH = 9 Hz, ArCs-H), ~ 
,," 3 -., 2 
6.42 (1H, d, JHH = 6, ArC3-H), 4.74 (2H, br s, COD - CH trans to CI), 4.38 (1H, d, JHH = 13, 
3'a), 4.22 (1H, m, Cp), 4.16 (1H, m, Cp), 4.13 (6H, m, Cp', 3'b), 4.08 (1H, t, 3JHH = 2, Cp), 3.79 
(1H, d, 2JHH = 13, 2'a), 3.69 (2H, br s, COD - CH cis to CI), 2.90 (1H, d, 2JHH = 13, 2'b), 2.56 
(4H, m, COD - CH2), 2.21 (6H, s, 1') and 1.85 (4H, m, COD - CH2); 
OC{H} (75.5 MHz; CDCI3) 152.7 (ArC2), 150.7 (ArC4), 128.7 (ArCs), 125.6 (ArCs), 122.4 (ArCs), 
112.4 ('VC, ArC10), 101.4 (IVC) , 99.5 (ArC3), 84.2 (2C, CH, COD), 84.0 (2C, CH, COD), 71.5 
(Cp), 70.5 (Cp), 69.3 (5C, Cp'), 66.1 (Cp), 58.0 (2'), 44.9 (2C, 1'),42.5 (2'), 31.4 (2C, COD, 
CH2) and 30.5 (2C, COD, CH 2); 
IR (KBr) Vmax 3442br m (NH), 3230br m, 3091m, 3077m, 2990m, 2932m, 2878m, 2822m, 
2776m, 1590vs (7-chloroquinoline), 1545m (7-chloroquinoline), 1495m (v C=C, COD), 1451m 
(NCH3), 1427m, 1391w, 1367m, 1350m, 1333m, 1296w, 1282m, 1251m, 1228m, 1201m, 
1170m, 1136m, 1105m (ferrocene), 1067w, 1029m, 1000m (ferrocene), 962w, 923w, 892w, 
861s, 842m, 824s, 807s, 766m, 734m, 701w, 643w, 625w, 615w, 600w, 552w, 523m, 490m 
(ferrocene), 457w, and 434w 
MS (FAB) m/z 680.1 [M+ + H, C31H37N335CI2FeRh requires 680.07690], 644.1 [1\11+ - CI], 599.1, 
491.1, 434:1 [M+ - Rh(COD)CI], 389.1, 359.8, 303.1, 256.1 [HC-Fp-CH2-NMe21, 213.1, 134.1 and 
91.1 [CH2-Cp-CH21. 
Compound 81 
[RhCI(COD)F2Q] 
Orange crystalline solid; Yield: 130mg (57%); 
mp: 213°C (dec); 
OH (300 MHz; CDCI3) 8.50 (1H, d, 3JHH = 5, 
ArC2-H), 8.41 (1H, s, ArCs-H), 7.73 (1H, d, 
3 JHH = 9, ArCs-H), 7.33 (1 H, dd, 4JHH = 2 and 
~' 91 ~ H . Rh-Nd'\-N~  /" '/ N N fj ~ H I Fe 
/- Q 
CI 
3 JHH = 9, ArC6-H), 6.27 (1 H, d, 3 JHH = 5, ArC3-H), 4.70 (2H, br S, COD - CH trans to CI), 4.14 
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(1H, m, Cp), 4.10 (2H. m, Cp), 4.04 (5H, Cp'), 3.83 (1H, d, zJHH = 13. 3'a), 3.67 (3H, m, 2'a, 
COD - CH cis to CI). 3.38 (1H, d, zJHH = 13, 3'b), 3.48-3.40 (2H, m, 5'), 2.98-2.92 (2H, m, 4'), 
2.79 (1H. d, ZJHH = 13, 2'b), 2.52 (4H, m, COD CHz), 1.95 (6H, s, 1') and 1.76 (4H, m, COD-
CHz); 
8C{H} (75.5 MHz; CDCI3) 152.0 (ArCz), 149.9 (ArC4), 149.2 (vC), 134.7 evC), 128.6 (ArCa), 125.0 
(ArCs), 121.5 (ArC5), 117.4 (IVC) , 99.1 (ArC3), 84.5 (2C, CH, COD), 84.2 (2C, CH, COD), 83.8 
(IVC, Cp), 71.1 (Cp), 69.9 (Cp), 68.9 (5C, Cp'), 65.8 (Cp), 58.2 (2'), 47.3 (4'), 46.4 (3'), 45.0 (2C, 
1'),42.0 (5') 31.4 (2C, COD, CHz) and 30.5 (2C, COD, CHz); 
IR (KBr) V max 3311 br m (NH), 3093m, 2940m, 2869m, 2830m, 1611s (7-chloroquinoline), 
1584vs (7-chloroquinoline), 1541m (7-chloroquinoline), 1451m (NCH3), 1424m, 1365m, 1331m, 
1283w, 1251w, 1200w, 1171w, 1140m, 1105w (ferrocene), 1062w, 1035w, 998w, 879w, 854w, 
815m (ferrocene), 766w, 647w and 493w (ferrocene); 
HRMS (FAB) mlz 723.3 [M+ + HJ, 687.1436 [(M+ - CI), C33H41N4CIFeRh requires 687.1424], 
477.2 [M+ - Rh(COD)CI], 432.2,307.1,213.1,179.1,107.1 and 89.1; 
-./ 
Found: C, 57.37; H, 5.28; N, 7.49. Calc. for C33H41N4ClzFeRh: C, 57.61; H, 5.36';' N, 7,26%. 
Compound 82 
[Rh(BU)(CI)(COD)] 
Orange crystalline solid; Yield: 145mg (45%); 
mp: 210°C (dec); 
8H (300 MHz; CDCI3) 9.51 (1 H, br s, ArCa-H), 
8.55 (1 H, d, 3 JHH = 6, ArC2-H), 8.02 (1 H, br s, 
ArCH2NHCO), 7.57 (1H, d, 3JHH = 9, ArC5-H), 
~' CI ~ H . Rh-Nd-N~ ~O /' . I Nf ~ I I HN~O Fe 
- ) ~ CliO 
7.14-7.05 (6H, m, U2, U3, U4, ArCs-H), 6.24 (1 H, d, 3JHH = 6, ArC3-H), 4.72 (2H, br s, COD - CH 
trans to CI), 4.41-4.12 (7H, m, Cp, 1", 3'a, 4'), 4.08 (5H, s, Cp'), 4.05 (1H. m, Cp), 3.77 (1H, d. 
2JHH = 13, 2'a), 3.69-3.25 (5H, m, 3'b, 5', COD - CH cis to CI), 2.74 (1H, d, 2JHH = 13, 2'b), 2.50 
(4H, m, COD -CH2), 1.94 (6H, s, 1 ') and 1.77 (4H, m, COD - CHz); 
8C{H} (75.5 MHz; CDCb) 160.5 (IVC, CO), 152.5 (ArC2), 151.2 (IVC) , 147.3 (IVC), 140.1 ('vC), 
135.5 ('VC) , 128.3 (2C, U), 128.2 (ArCs), 126.7 (U4), 126.4 (2C, U), 126.0 (ArCs), 123.0 (ArCs), 
119.0 (IVC) , 98.7 (ArC3), 84.1 (2C, CH, COD), 83.8 (2C, CH, COD), 82.0 ('VC, Cp), 70.4 (Cp). 
69.5 (5C, Cp'), 68.8 (Cp), 67.6 (Cp), 57.9 (2'), 44.7 (2C, 1 '),44.6 (4'), 43.8 (1"), 31.4 (2C, COD, 
CHz) and 30.5 (2C, COD, CHz); 
IR (KBr) Vmax 3313m, 3084m, 2988m, 2934m, 2878m, 2828m, 2776m, 1590vs (7-
chloroquinoline), 1539s (7-chloroquinoline), 1491m (v C=C, COD), 1452m (NCH3), 1400m, 
1359m, 1331m, 1300m, 1273m, 1256m, 1201m, 1172w, 1139w, 1104w (ferrocene), 1038w, 
1005m (ferrocene), 962w, 856m, 810m (ferrocene), 764w, 742m, 695w, 513m, 492m 
(ferrocene) and 462m; 
MS (FAB) mlz 856.2 [M+ + HJ, 820.3 [M+ - Cll 694.1, 610.2 [M+ - Rh(COD)CI], 565.2, 409.1, 
307.1, 237.9, 213.0, 150.1 and 91.0; 
Found: C, 56.95; H. 5.60; N, 7.61. Calc. forC41H4sN5ClzOFeRh: C, 57.49; H. 5.65; N,8.18%. 
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Experimental Details Pertaining to Chapter 5 
Testing carried out at Department of Pharmacology, University of Cape 
Town 
Cultivation of Malaria Parasites 
Two strains of P. falciparum were used in this study, a chloroquine sensitive strain, D10, and a 
chloroquine resistant strain, K1. The P. falciparum strains were cultured using a modified 
version of the Trager and Jensen method. 16 The parasites were maintained in RPM] 1640 
(BioWhittaker) culture medium, to which was added; 40 mg ml-1 gentamycin (Lennon); 1 % 
sodium bicarbonate; 0.5% Albumax (lipid rich bovine serum) and 0+ human red blood cells 
(Transfusion Services and Haemotology, UCT/Groote Schuur Hospital). The cultures were 
contained in flat bottomed flasks and incubated at 3rC with a controlled atmosphere of 4% 
CO2, 3% O2 and 93% N2. Medium was changed at frequent intervals and paraSite cultures were 
fed to maintain an optimum 3-5% parasitaemia and a 2-4% haemocrit. The parasitaemia was 
determined using Giesma stained blood films of the cultures. Synchronisation of cultures was 
achieved by a brief exposure to 5% O-sorbitol solution. 
Lactacte Dehydrogenase Assay for Parasite Viability 
Sensitive assays are done in 96-well microtitre plates and the parasite lactate dehydrogenase 
(pLDH) assay17 was used to evaluate drug susceptibility. This enzymatic assay is based on the 
ability of pLDH to utilise 3-acetyl pyridine NAD (APAD) as a coenzyme in the conversion of 
lactate to pyruvate. As human red blood cells LDH carry out this reaction at a very slow rate in 
the presence of APAD, pLDH activity is distinguishable from host LDH. The formation of 
APADH by pLDH can be monitored using the Malstat reagent, nitroblue tetrazolium (NBT) and 
phenazine ethosulfate (PES). As APADH is formed the yellow NBT is reduced to a blue 
formazan product, the absorbance of which can be measured at 620nm on a 7520 Microplate 
reader (Cambridge Technology). The amount of blue formazan produced is proportional to the 
pLDH activity and can, thus, be used to assess parasite viability. 
Testing carried out at the Wellcome Trust Biocenter, University of Dundee 
Trypanothione Reductase Inhibition 
Recombinant T. cruzitrypanothione reductase (128 mU) was assayed using a Beckman DU640 
spectrophotometer in 40mM HEPES, pH 7.5, 1mM EDTA and 20011M NADPH at 25°C followed 
by the addition of 10011M Try[SH]2. Human glutathione reductase, purified from human 
erythrocytes (42.3mU), was analysed in a similar manner and under identical conditions 
followed by the addition of glutathione disulfide (10011M). Enzyme mixtures were preincubated 
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with NADPH (10 min at 25°C) before the addition of varying concentrations of the inhibitor 
added in DMSO (1 % vJv final concentration). 
Testing carried out at Department of Infectious and Tropical Diseases, 
London School of Hygiene and Tropical Medicine 
In Vitro Trials against L. donovani, T. cruzi and T. brucei 
L. donovani (MHOMJETJ67JL82) and T. cruzi (MHOMJBRJOOIY): Peritoneal macrophages were 
harvested from female CD1 mice (Charles River Ltd., Margate, UK) by peritoneal lavage 24 h 
after starch (Merck Ltd., Leics, UK) induced recruitment. After two washes in medium the 
exudate cells were dispensed in 16-well Lab-tek™ tissue culture slides (Nunc Inc., IL, USA) at 4 
x 104Jwell in a volume of 200IJL of RPMI-1640 medium (Sigma-Aldrich Company Ltd., Dorset, 
UK) and 10% inactivated foetal calf serum (Harlan-Sea-Lab Ltd., Crawley, UK). After 24 h, 
macrophages were infected at a ratio of 10:1 (4 x 105Jwell) with L. donovani ampstigotes freshly 
isolated from hamster spleen or at a ratio of 5:1 (2 x 105Jwell) with T. cruz/"trypomastigotes 
derived from the overlay of MDCK fibroblasts. Infected macrophages were then maintained in 
the presence of drug in a 3-fold dilution series, with quadruplicate cultures for each 
concentration, for 5 days for L. donovani cultures and for 3 days for T. cruzi cultures. After 
these periods of drug exposure slides were methanol fixed and Giemsa stained and drug 
activity determined by counting the percentage of macrophages cleared of amastigotes in 
treated cultures in comparison to untreated cultures. 18 Sodium stibgluconate (NaSbV) (Glaxo-
Wellcome, Dartford, UK) and nifurtimox (Bayer, UK) or benznidazole were used as the 
respective control drugs. 
T. brucei (S427): Compounds were tested in a triplicate 3-fold dilution series from a top 
concentration of 30~M. Parasites were diluted to 2 x 105Jml and added in equal volumes to the 
test compounds in 96-well, flat bottom Microtest III tissue culture plates (Becton Dickinson and 
Company, NJ, USA). Appropriate controls with pentamidine isothionate (Rhone-Poulenc-Rorer) 
as the standard were set up in parallel. Plates were maintained for 3 days at 3rC in a 5% 
C02Jair mixture. Compound activity was determined by the use of a tetrazolium salt colorimetric 
assay 19 on day 3. 
P. falciparum: All compounds were tested against the chloroquine sensitive strain (3D7) and the 
chloroquine resistant strain (K1). The whole cell growth inhibition assay of P. falciparum growth 
in human red blood cells was carried out in a 48 h [3H]-hypoxanthinine incorporation assay.20,21 
In Vivo Trials 
In vivo testing against Plasmodium berghei 
Day 1: 5 BalbJc mice were inoculated with 1 % (1 x 107 infected RBCs) parasitemia i.v. 
2 h post infection drugs administered as follows 
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Days 2-4: Drugs administered as per above stated dosing and schedule 
Day 5: Tail smears were taken, methanol fixed, stained with 10% Giemsa stain and examined 
under x1 000 and parasitemia calculated. 
Day 6: Mean Survival Time was monitored and scored. 
Experimental Details Pertaining to Chapter 6 
Synthesis of Benzyl Derivatives 
Compound 101 
2-Dimethylaminomethylbenzaldehyde 
N,N-Dimethylaminomethylbenzene 99 (3.0ml, 24.6mmol) was placed in a 
2-necked round bottomed flask followed by 60ml freshly distilled diethyl 
ether. terl-Butyllithium (1.7M in pentane) (20ml) was added slowly. A 
white precipitate of lithiobenzyldimethylamine 100 formed immediately. The mixture was 
allowed to stir at room temperature for 30 min before the dropwise addition of anhydrous DMF 
(1.6ml). The mixture was allowed to stir for a further 30 min before diluting with diethyl ether and 
quenching with deionised water. The mixture was extracted into diethyl ether. The organic 
fractions were collected, combined and dried over sodium sulfate. The solvent was removed 
under reduced pressure. The product, a colourless oil, was then isolated by silica gel 
chromatography. Yield: 2.234g (60%); 
Rf (silica/diethyl ether: hexane: Et3N = 70:20: 10) 0.25; 
OH (300 MHz; CDCb) 10.40 (1H, s, CHO), 7.85 (1H, dd, 3JHH = 1 and 3JHH = 8, Bs), 7.50 (1H, m, 
B), 7.39 (2H, m, B), 3.72 (2H, s, 2') and 2.22 (6H, s, 1'); 
OC{H) (75.5 MHz; CDCI3) 192.1 (CHO), 141.7 (IVC) , 135.1 (IVC) , 133.1 (B), 130.4 (B6), 129.4 (B), 
127.7 (B), 60.9 (2') and 45.1 (2C, 1'); 
IR (thin film) V max 3366w, 3069w, 3028w, 2975s, 2943s, 2859s, 2819s, 2771s, 1690vs (v C=O), 
1599s, 1574w, 1457s (NCH3), 1396m, 1362m, 1309w, 1290m, 1251m, 1213s, 1190m, 1174m, 
1145m, 1097w, 1043m, 1023s, 974w, 954w, 882w, 844s (aryl CH2N(CH3h group), 810m, 756s 
(4 adjacent aromatic H), 657m and 610m; 
HRMS (EI) m/z 163.10011 [M+, C10H13NO requires 163.09971], 148.1 [M+ - CH3], 135.1, 119.0, 
91.1, 77.0, 65.0, 58.0 [CH2NMe2l and 44.0. 
1H NMR in agreement with Iiterature22 
Compound 102 
2-Dimethylaminomethylbenzaldehyde Oxime 
2-Dimethylaminomethylbenzenecarboxaldehyde 
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7.11 mmol) was placed in a 250ml round bottomed flask followed by 75ml absolute ethanol and 
hydroxylamine hydrochloride (1.384g, 19.38mmol). A solution of sodium hydroxide (1.582g, 
40.2mmol) in 20ml deionised water was added. The mixture was allowed to heat under reflux 
under nitrogen for 14 h. The mixture was allowed to cool and dry ice was added until 
neutralisation was achieved. The mixture was diluted with deionised water and extracted into 
dichloromethane. The organic layer was dried over sodium sulfate, filtered and the solvent 
removed under reduced pressure. The product was then dried in vacuo and isolated as a 
colourless oil. Yield: 1.159g (91 %); 
OH (400 MHz; CDCI3) 8.56 (1 H, s, 3'), 7.76 (1 H, m, B6), 7.32 (3H, m, B), 3.56 (2H, s, 2'), 2.28 
(6H, s, 1') and 2.24 (1H, s, OH); 
OC{H} (100.6 MHz; CDCI3) 148.8 (3'), 131.2 (B), 129.3 (B), 128.0 (B), 127.0 (B), 61.8 (2') and 
45.2 (1 '); 
IR (thin film) V max 3224br s (OH), 3063s, 2816s (aliphatic CH), 2779s, 1927w, 1637w, 1600w, 
1573w, 1464s (NCH3), 1364s, 1315m, 1254m, 1222m, 1174m, 1149w, 1096m, 1044s, 1020s, 
f 
970s, 870m, 842s (aryl CH2N(CH3h group), 760s (4 adjacent aromatic H), 138m, 701w and 
638m; 
HRMS (EI) mlz 161.10731 [(M" - OH), C10H13N2 requires 161.10787], 145.1, 132.1, 118.1, 
104.1,89.0,77.0,58.1 and 44.0 (M', 178.1 not observed). 
Infrared data is in agreement with Iiterature23 
Compound 103 
2-Dimethylaminomethylbenzylamine 
2-Dimethylaminomethylbenzaldehyde oxime 102 (1.100g, 6.171 mmol) H2N~N/ 
was placed in a 100ml round bottomed flask. 50ml anhydrous THF was V I 
added followed by lithium aluminium hydride (769mg, 20.00mmol). The 
mixture was heated under reflux under an atmosphere of nitrogen for 15 h. The mixture was 
allowed to cool to room temperature before adding diethyl ether and a saturated brine solution. 
The product was extracted into diethyl ether and dried over potassium carbonate. The solvent 
was removed under reduced pressure before drying the product in vacuo. The product was 
isolated as a colourless oil. Yield: 805mg (79%) 
OH (400 MHz; CDCI3) 7.26 (4H, m, B3, B4, B5, B6), 3.83 (2H, s, 2'), 3.42 (2H, s, 3'),2.23 (2H, s, 
NHz) and 2.20 (6H, s, 1'); 
OC{H} (100.6 MHz; CDCh) 142.4 (IVC, B1), 137.0 evc, B2), 131.0 (8),128.9 (B), 128.1 (B), 126.7 
(B), 62.8 (2'), 45.3 (1') and 45.0 (3'); 
IR (thin film) Vmax 3349m (NH), 3264m (NH), 3063m, 3018m, 2914s, 28565, 2815s, 2769s, 
2714m, 1602m, 14655 (NCH3), 13625, 1311m, 12535, 1215m, 1174s, 1147m, 1097m, 10425, 
10205, 967m, 944m, 910m, 8435 (aryl CHzN(CH3h) and 752s (4 adjacent aromatic H). 
1H NMR and IR spectra in agreement with Iiterature.24 
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Compound 85 
(7 -C h 10 ro-q u i no I i n-4-yl)-( 2 -d imeth yla min ometh yl-benzyl)-
amine 
2-Dimethylaminomethylbenzylamine 103 (0.8059, 
4.9mmol), 4,7-dichloroquinoline (5.09, 25mmol), potassium 
carbonate (1.0g, 7.25mmol), anhydrous triethylamine 
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(5.0ml, 36mmol) and anhydrous NMP (7ml) were placed in a 25m I round bottomed flask and 
allowed to heat under reflux in an atmosphere of nitrogen for 15. h. The mixture was allowed to 
cool to room temperature before diluting with ethyl acetate. The product was washed 10 times 
with brine. The organic layer was dried over sodium sulfate, filtered and the solvent removed 
under reduced pressure. The product was purified using silica gel chromatography and isolated 
as a white crystalline solid. Yield: 819mg (51%); 
Rf (silica/ethyl acetate: hexane: EtsN ::: 45:50:5) 0.24; 
OH (400 MHz; CDCI3) 8.53 (1H, d, 3JHH ::: 5, ArC2-H), 8.31 (1H, br s, NH), 7.90.{1H, d, 4JHH ::: 2, 
ArCa-H), 7.62 (1H, d, 3JHH ::: 9, ArCs-H), 7.40-7.37 (1H, m, B), 7.31-7.22 (4H', m, ArCs-H, B), 
6.52 (1 H, d, 3JHH ::: 5, ArC3-H), 4.42 (2H, s, 3'),3.46 (2H, s, 2') and 2.24 (6H, s, 1'); 
OC{H} (100.6 MHz; CDCh) 152.3 (ArC2), 150.7 (IVC), 149.5 CVC), 137.5 evC), 137.2 (IVC), 134.7 
(IVC) , 132.1 (B), 130.1 (B), 128.6 (ArCa-H), 128.1 (B), 124.9 (ArCs), 122.3 (ArCs), 118.3 CVC), 
99.0 (ArCs), 62.7 (2'),47.4 (3') and 45.1 (2C, 1'); 
IR (KBr) V max 3426br m (NH), 3212br m, 3065m, 3021m, 2968m, 2941m, 2858m, 2817m, 
2790m, 2768m, 1662m, 1610m (7-chloroquinoline), 1575s (7-chloroquinoline), 1485m, 1449m 
(NCHs), 1427m, 1367m, 1350m, 1326m, 1284m, 1237s, 1163m, 1147m, 1136m, 1082m, 
1040w, 1014m, 967w, 901m, 882m, 840m (aryl CH2N(CHsl2), 811s, 771m, 746s (4 adjacent 
aromatic H), 714w, 645m, 590m, 541m, 495w, 463w and 432w; 
HRMS (EI) m/z 325.13380 [M+, C19H20N/sCI requires 325.13458], 280.1 [M+ - (NMez)), 263.0, 
245.1,163.0,146.1,132.1 and 118.1. 
Compound 86 
N-(7 -Chloroquinolin-4-yl)-N'-(2-
dimethylaminomethylbenzyl)-ethane-1,2-diamine 
The compound was prepared in the manner 
described for 20. 
Colourless oil; Yield: 1.881 g (60%); 
Rf (silica/CH2Cb: MeOH: EtsN = 80:20:1) 0.13; 
CI 
OH (400 MHz; CDCls) 8.53 (1H, d, 3JHH ::: 5, ArC2-H), 7.95 (1H, d, 4JHH ::: 2, ArCa-H), 7.76 (1H, d, 
3JHH ::: 9, ArCs-H), 7.38 (1H, dd, 4JHH ::: 2 and 3JHH ::: 9, ArCs-H), 7.33-7.18 (4H, m, Bs, B4, Bs, Bs), 
6.41 (IH, d, 3JHH ::: 5, ArCs-H), 3.85 (2H, s, 3'), 3.43 (2H, s, 2'),3.34-3.29 (2H, m, 5'), 3.00-2.95 
(2H, m, 4') and 2.11 (6H, s, 1 '); 
Oe{H} (100.6 MHz; CDCb) 152.0 (ArC2), 131.1, 130.8, 128.7, 127.8, 125.3, 121.2,99.2 (ArCs), 
62.5 (2'), 51.6 (4'),45.0 (3'), 44.7 (2C, 1') and 40.2 (5'); 
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IR (thin film) Vmax 3265m (NH), 3054m, 2944m, 2858m, 2820m, 2777m, 1611 s (7-
chloroquinoline), 1582vs (7-chloroquinoline), 1535s (7-chloroquinoline), 1450s (I\JCH3), 1428m, 
1367s, 1331s, 1265s, 1204w, 1172w, 1140m, 1081m, 1041w, 1017m, 878m, 843m (aryl 
CHzN(CH3)z), 808m, 738s (4 adjacent aromatic H) and 703m; 
HRMS (EI) m/z 368.17829 [M+, CZ1HzsN43SCI requires 368.17677],323.1 [M+ - NMez], 263.1, 
205.1,191.1 [CICgNHs-NH-CHz], 177.2 [CICgNHs-NH], 156.0, 146.0,132.1,118.1,105.1 and 
58.0. 
Synthesis of Quinoline Derivatives 
Compound 106 
N1-Quinolin-4-yl-ethane-1,2-diamine 
This compound was synthesised according to literature procedures. 9 
The final product was tested on TLC (ethyl acetate: hexane; 1:1) and no 
4-chloroquinoline was observed. 
Compound 87 
(2-Dimethylaminomethyl-ferrocenyl)-quinolin-4-yl-amine 
Compound prepared in the manner described for 15 using 
appropriate starting materials. 
HN~N/ 
~ Fe I ~~J~ 
Deep orange crystalline solid; Yield: 716mg (70%); mp: 148-
150°C; 
Rf (silica/ethyl acetate: hexane: Et3N = 45:50:5) 0.11; 
N 
OH (400 MHz; CDCI3) 8.56 (1H, d, 3JHH = 5, ArCz-H), 7.94 (1H, dd, 4JHH = 1 and 3JHH = 8, ArCs-
H), 7.70 (1 H, dd, 4JHH = 1 and 3JHH = 8, ArCs-H), 7.58 (1 H, m, ArCy-H), 7.33 (1 H, m, ArCs-H), 
6.48 (1H, d, 3JHH = 5, ArC3-H), 4.38 (1H, d, ZJHH = 13, 3'a), 4.27 (1H, m, Cp), 4.20-4.14 (2H, m, 
Cp, 3'b), 4.13 (5H, s, Cp'), 4.07 (1H, t, 3JHHH = 3, Cp), 3.79 (1H, d, zJHH = 13, 2'a), 2.89 (1H, d, 
ZJHH = 13, 2'b) and 2.22 (6H, s, 1'); 
OC{H} (100.6 MHz; CDCI3) 151.2 (ArCz), 150.4 (IVC), 148.8 (IVC), 129.7 (ArCs), 128.9 (ArC?), 
124.2 (ArCs), 120.7 (ArCs), 119.6 (IVC), 98.7 (ArC3), 84.4 ('VC, Cp), 84.2 (IVC, Cp), 71.5 (Cp), 
70.6 (Cp), 69.3 (5C, Cp'), 66.0 (Cp), 58.2 (2'), 45.1 (2C, 1') and 42.5 (3'); 
IR (KBr) Vmax 3185br m (NH), 3078m, 3058m, 2969m, 2943m, 2907m, 2861 m, 2825m, 2781 m, 
1617m (quinoline), 1572vs (quinoline), 1540s (quinoline), 1500m, 1467s (NCH3), 1433m, 
1395m, 1362m, 1340m, 1288m, 1251m, 1221m, 1190m, 1170m, 1151w, 1117s, 1103m 
(ferrocene), 1032m, 1005m (ferrocene), 953w, 900w, 838m (aryl CHzN(CH3)), 822s (ferrocene), 
805s, 780w, 757s, 726m, 694m, 619w, 594w, 550w, 530w, 497m (ferrocene), 480s (ferrocene) 
and 432m; 
HRMS (EI) mlz 399.14058 [M+, Cz3HzsN3Fe requires 399.13979], 354.1 [M+ - NMez], 288.0, 
255.'1 [HC-Fp-CHz-NMez], 213.0,198.0, 121.0[Cp-Fe], 91.1 [CHz-Cp-CHz] and 58.1 [NMez]; 
Found: C, 69.18; H, 6.17; N, 10.10. Calc. forCZ3Hz4N3CIFe: C, 69.18; H, 6.31; N, 10.52%. 
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Compound 88 
N-(2-Dimethylaminomethyl-ferrocenyl)-N-quinolin-4-
yl-ethane-1,2-diamine 
Compound prepared in the manner described for 20 
using appropriate starting materials. 
Chapter 8: General Experimental 
~ H Nd-N~N~N/ (~ HfG>1 
Fe 
- ~ 
Yellow crystalline solid; Yield: 713mg (60%); mp: 128-129°C; 
Rf (silica/CH2CI2: MeOH: EhN = 80:20:1) 0.22; 
bH (400 1111Hz; CDCI3) 8.46 (1H, d, 3JHH = 5, ArC2-H), 7.90 (1H, d, 3JHH = 8, ArCa-H), 7.79 (1H, d, 
3JHH = 8, ArC5-H), 7.52 (1H, t, 3JHHH = 7, ArCrH), 7.30 (1H, t, 3JHH = 8, ArCs-H), 6.29 (1H, d, 
3 JHH = 5, ArC3-H), 6.14 (1 H, s, NH), 4.05 (1 H, m, Cp), 4.00 (1 H, m, Cp), 3.94 (6H, s, Cp, Cp'), 
3.75 (1H, d, 2JHH = 13, 3'a), 3.57 (1H, d, 2JHH = 12, 2'a), 3.31 (1H, d, 2JHH = 13, 3'b), 3.26-3.12 
(2H, m, 5'),2.87-2.77 (2H, m, 4'), 2.69 (1H, d, 2JHH = 12, 2'b) and 1.93 (6H, s, 1'); 
bC{H) (100.6 MHz; CDCI3) 151.1 (ArC2), 150.1 (IVC), 148.6 (IVC), 129.7 (ArCa), 128.9 (ArC7), 
124.5 (ArCs), 120.3 (ArC5), 119.2 (IVC), 98.8 (ArC3), 85.7 (IVC, Cp), 83.9 (IVC,,..,Cp), 71.1 (Cp), 
~ 1 
70.1 (Cp), 69.0 (5C, Cp'), 66.0 (Cp), 58.2 (2'), 47.4 (3'), 46.6 (4'), 45.0 (2C, 1') and 42.2 (5'); 
IR (KBr) Vmax 3235br m (NH), 3070m, 2950m, 2890m, 2839m, 2812m, 2764s, 1619m 
(quinoline), 1577vs (quinoline), 1550s (quinoline), 1500m, 1460s (NCH3), 1435s, 1393s, 
1366m, 1334s, 1276m, 1242m, 1213m, 1167m, 1152m, 1133m, 1104s (ferrocene), 1054m, 
1033m, 1014m, 1000m (ferrocene), 948m, 927m, 878w, 864m, 828m (aryl CH2N(CH3)), 807s 
(ferrocene), 769s, 654m, 61 Ow, 543m, 490m (ferrocene), 456m and 426w; 
HRMS (EI) m/z 442.18181 [M+, C25H30N4Fe requires 442.18199], 397.1, 332.1, 277.0, 255.0 
[HC-Fp-CH2-NMe2l, 240.0 [Fp-CH2-NMe2l, 213.0, 157.1, 120.1, 91.0 [CH2-Cp-CH2l and 58.1 
[NMe2l; 
Found: C, 69.19; H, 6.84; N, 12.33. Calc. for C23H24N3CIFe: C, 67.88; H, 6.84; N, 12.66%. 
Compound 89 
3-Benzyl-1-(2-dimethylaminomethyl-ferrocenyl-1-[2-
(quinolin-4-ylamino)-ethyll-urea 
Compound prepared in the manner described for 37 
(method 4) using appropriate starting materials. 
Bright yellow crystalline solid; Yield: 150mg (80%); 
mp: 88-89°C; 
Rf (silica/CH2CI2: MeOH = 80:20) 0.47; 
bH (300 MHz; CDCI3) 8.52 (1H, d, 3JHH = 5, ArC2-H), 8.03 (1H, t, 3JHH = 5, ArCH 2NHCO), 7.96 
(1 H, d, 3 JHH = 8, ArCa-H), 7.82 (1 H, d, 3 JHH = 8, ArC5-H), 7.63-7.52 (1 H, m, ArCrH), 7.27 (1 H, t, 
3 JHHH = 7, ArCs-H), 7.14-7.09 (5H, m, U2, U3, U4), 6.34 ('I H, d, 3 JHH = 5, ArC3-H), 4.49-4.16 (7H, 
m, Cp, 1", 3'a, 3'b), 4.12 (1H, t, 3JHH = 2, Cp), 4.06 (5H, s, Cp'), 4.05-4.03 (1H, m, Cp), 3.76 
(1H, d, 2JHH = 13, 2'a), 3.71-3.63 (2H, m, 4'),3.58-3.37 (2H, m, 5'), 2.74 (1H, d, 2JHH = 13, 2'b) 
and 1.94 (6H, s, 1'); 
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Chapter 8: General Experimental 
OC(H} (75.5 MHz; COCh) 160.3 (IVC, CO), 150.9 (IVC) , 150.2 (ArC2), 147.6 (IVC), 140.3 (IVC, U1), 
129.0 (ArCa), 128.6 (ArC7), 128.2 (2C, U), 126.6 (2C, U), 126.5 (U4), 124.7 (ArC6), 121.1 (ArCs), 
118.8 (IVC) , 97.4 (ArC3), 84.0 tc, Cp), 82.0 (IVC, Cp), 70.4 (Cp), 69.4 (5C, Cp'), 68.8 (Cp), 67.4 
(Cp), 57.9 (2t 47.0 (3'), 45.4 (4'),44.7 (2C, 1'),44.6 (1") and 43.6 (5'); 
IR (KBr) Vmax 3280br m (NH), 3062m, 2942m, 2858m, 2823m, 2780m, 1618s (quinoline), 
1584vs (quinoline), 1538s (quinoline), 1495m, 1456m (NCH3), 1439m, 1402m, 1352m, 1303m, 
1269m, 1172m, 1126m, 1070w, 1037m, 1004m (ferrocene), 959w, 911w, 810m (ferrocene), 
765m, 731 m, 699m, 607w, 527w and 487w (ferrocene); 
HRMS (EI) mlz 575.23467 [M+, C33H37N50Fe requires 575.234671, 530.2, 442.2, 397.1, 332.0, 
277.0, 255.1 [HC-Fp-CH2-NMe21, 240.0 [Fp-CHz-NMe2], 213.0, 157.1, 133.1, 121.0 [Cp-Fe1, 
91.0 [CH2-Cp-CHz1 and 58.1 [NMezl. 
Synthesis of Pyridine Derivatives 
Compound 108 
N1-Pyridin-4-yl-ethane-1 ,2-diamine 
4-Chloropyridine hydrochloride (2.500g, 15.7mmol) was stirred with 
triethylamine (10.0ml, 72mmol). Ethylene diamine (6.0ml, 8.4mmol) was 
added and the mixture allowed to heat under reflux under nitrogen for 24 h. 
The mixture was allowed to cool and then diluted with dichloromethane. 11V1 sodium hydroxide 
solution was added. The product was extracted into dichloromethane and dried over sodium 
sulfate before removing the solvent under reduced pressure. TLC (ethyl acetate: hexane; 1: 1) 
showed a single spot on the base line, there was no evidence of 4-chloropyridine. 
Yield: 60%. 
Compound 90 
(2-0imethylaminomethyl-ferrocenyO-pyridin-4-yl-amine 
The synthetic route employed was similar to that of ferroquine. 6 
However, the starting material was 4-chloropyridine 
hydrochloride, as opposed to 4-chloropyridine. To compensate for 
this an extra mol equivalent of triethylamine was added. The 4-chloropyridine was allowed to 
stir with the triethylamine for 15 minutes prior to addition of the other reagents. 
Deep red oil; Yield: 60mg (35%); 
Rf (silica/ethyl acetate: hexane: EhN = 45:50:5) 0.05; 
OH (400 MHz; COCh) 8.15 (2H, br 5, ArCz-H), 6.45 (2H, br s, ArC3-H), 4.31-4.13 (5H, m, Cp, 3'a, 
3'b), 4.11 (5H, s, Cp'), 3.80 (1 H, d, 2JHH = 13, 2'a), 3.01 (1 H, d, 2 JHH = 13, 2'b) and 2.25 (6H, 5, 
1 '); 
OC{H} (100.6 MHz; COCh) 155.1 (IVC, ArC4), 145.0 (2C, ArCz) , 107.5 (2C, ArC3), 84.0 (IVC, Cp), 
82.5 evc, Cp), 71.5 (Cp), 70.3 (5C, Cp'), 69.4 (Cp), 66.7 (Cp), 57.6 (2'), 44.3 (2C, 1') and 41.8 
(3'); 
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IR (thin film) Vmax 3267br s (NH), 2925s, 2854m, 2823m, 2777m, 1651s, 1606s (pyridine), 
1573s, 1556s, 1469m (NCH3), 1404m, 1266m, 1204m, 1172w, 1106m (ferrocene), 1038m, 
1003m (ferrocene), 947w, 816m (ferrocene), 740m and 701m; 
HRMS (EI) m/z 349.12487 [M+, C19H23N3Fe requires 349.12414], 304.1, 255.1 [HC-Fp-CH2-
NMe2], 238.0,227.0,213.0,199.1,134.1,121.0 [Cp-Fe], 91.0 [CH2-Cp-CH2] and 58.1 [NMe2]' 
Compound 91 
N-(2-Dimethylaminomethyl-ferrocenyl)-N-pyridin-4-yl-
ethane-1,2-diamine 
The compound was prepared in the same manner 
described for 20 using appropriate starting materials. 
Deep red oil; Yield: 515mg (60%); 
Rr(silica/CH2CIz: MeOH: Et3N :: 80:20:1) 0.22; 
H 
~N~~/ II~~ -I N ~ N 
N /. H I // Fe 
~ 
OH (400 MHz; CDCI3) 8.10 (2H, d, 3JHH = 5, ArC2-H), 6.40 (2H, d, 3JHH :: 6, ArC3-H), 4.12 (1H, m, 
~/ 
Cp), 4.07 (1H, m, Cp), 4.00 (5H, s, Cp'), 3.98 (1H, m, Cp), 3.86 (1H, d, 2JHH :: 1'3, 3'a), 3.66 (1H, 
d, 2JHH :: 12, 2'a), 3.37 (1H, d, 2JHH :: 13, 3'b), 3.24-3.10 (2H, m, 5'),2.79-2.72 (3H, m, 4', 2'b) 
and 2.04 (6H, s, 1 '); 
OC(H} (100.6 MHz; CDCh) 153.6 (IVC, ArC4), 149.9 (2C, ArC2),107.6 (2C, ArC3), 84.1 (IVC, Cp), 
83.8 (IVC, Cp), 71.3 (Cp), 7004 (Cp), 69.2 (5C, Cp'), 66.2 (Cp), 58.2 (2"), 47.3 (3'), 46.6 (5'), 44.6 
(2C, 1 ') and 41.5 (4'); 
IR (thin film) Vmax 3251br m (NH), 3149m, 3094m, 3046m, 2943m, 2855m, 2818m, 2773m, 
1605vs (pyridine), 1545m, 1466m (NCH3), 1402m, 1347m, 1323m, 1265m, 1217m, 1172w, 
1155w, 11 04m (ferrocene), 1034m, 998m, 811 s (ferrocene), 735s and 701 m; 
HRMS (EI) m/z 392.16500 [M+, C21H2SN4Fe requires 392.16634], 373.1, 255.1 [HC-Fp-CH2-
NMe2], 240.0 [Fp-CH2-NMe2J, 213.0, 200.0,163.0 [CICsNH5], 134.1, 121.0 [Cp-Fe], 107.1,91.0 
[CH2-Cp-CH2] and 58.1 [NMe2]. 
Compound 92 
3-Benzyl-1-(2-dimethylaminomethyl-ferrocenyl)-1-[2-
(pyrid ine-4-ylamino )-ethyIJ-urea 
Prepared in the same manner described for 37 (method 
4) using appropriate starting materials. 
Bright yellow crystalline solid; Yield: 236mg (71%); 
mp: 70-72°C; 
Rf (silica/CH2CI2: MeOH = 80:20) 0.05; 
OH (300 MHz; CDCI3) 8.13 (2H, d, 3JHH = 6, ArC2-H), 7.68 (1H, br 5, NH), 7.25-7.08 (5H, m, U2, 
Us, U4), 6.40 (2H, d, 3 JHH = 6, ArC3-H), 6.28 (1 H, br s, NH), 4043 (1 H, d, 2 JHH :: 16, 3'a), 4.35-
4.32 (1H, m, Cp), 4.23 (1H, d, 2JHH = 16, 3'b), 4.23-4.25 (1H, m, Cp), 4.13 (1H, t, 3JHH :: 3, Cp), 
4.06 (5H, 5, Cp'), 4.00-3.89 (2H, m, 1"),3.78 (1H, d, 2JHH :: 13, 2'a), 3.60-3.50 (2H, m, 4'),3.40-
3.20 (2H, m, 5'),2.76 (1H, d, 2JHH :::: 13, 2'a) and 1.96 (6H, 5,1'); 
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OC{H} (75.5 MHz; CDCb) 159.7 (IVC, CO), 154.2 (IVC, ArC4), 148.3 (2C, ArC2), 140.4 ('VC, U1), 
128.3 (2C, U3), 126.7 (2C, U2), 126.6 (U4), 107.2 (ArC3), 84.2 (IVC, Cp), 82.1 (IVC, Cp), 70.5 
(Cp), 69.4 (5C, Cp'), 69.0 (Cp), 67.4 (Cp), 57.9 (2'),47.2 (3'), 45.6 (1"), 44.7 (2C, 1'),44.6 (4') 
and 42.6 (5'); 
IR (KBr) V max 3263m (NH), 3028m, 2941m, 2859m, 2821m, 2776m, 1604vs (pyridine), 15295, 
1455m (NCHs), 1428m, 1404m, 1353m, 1268m, 1240m, 1216m, 1105m (ferrocene), 1036m, 
990m, 813m (ferrocene), 731 m, 699m, 608w, 527m, 510m, 487m (ferrocene) and 457w; 
HRMS (EI) mlz 525.21853 [M+, C2sH3SN50Fe requires 525.21910], 392.2,347.1,282.1,255.1 
[HC-Fp-CHTNMe21, 240.0 [Fp-CHz-NMe2], 213.0, 133.1, 91.1 [CHz-Cp-CH2], 77.0 and 58.1 
[NMezl. 
Compound 109 
N1-(6-Chloro-2-methoxy-acridine-9-yl)-ethane-1 ,2-diamine 
Prepared according to literature procedure25 
Bright yellow crystalline solid; Yield: 90%. 
Compound 93 
N-(6-Chloro-2-methoxy-acridine-9-yl)-N'-[2-(N",N"-
dimethylaminomethyl)ferrocenylmethyl]-ethane-1,2-
diamine 
Prepared in the same manner as that described for 
20 using appropriate starting materials 
Deep orange crystalline solid; Yield: 467mg (74%) 
Rf (silica/CH2Clz:MeOH:Et3N = 80:20:1) 0.25; CI 
/ 
o 
OH (400 MHz; CDCls) 8.14 (1 H, d, 3 JHH = 9, ArCs-H), 8.05 (1 H, d, 4JHH = 2, ArCs-H), 7.99 (1 H, d, 
SJHH = 10, ArC 1-H), 7.41-7.37 (2H, m, ArC3-H, ArC4-H), 7.28 (1H, dd, 4JHH = 2 and SJHH = 9, 
ArC7-H), 4.13-4.12 (2H, m, Cp), 4.05 (5H, S, Cp'), 4.04-4.03 (1H, m, Cp), 3.91 (1H, d, 2JHH = 13, 
3'a), 3.90 (3H, 5, OCH3), 3.79-3.67 (2H, m, 5'), 3.73 (1 H, d, ZJHH = 12, 2'a), 3.42 (1 H, d, zJHH = 
13, 3'b), 2.87-2.84 (2H, m, 4'), 2.83 (1H, d, 2JHH = 12, 2'b) and 2.11 (6H, 5,1'); 
OC{H} (100.6 MHz; CDCh) 131.4 (ArC4), 128.3 (ArCa), 124.9 (ArC7), 124.6 (ArC5), 124.3 (ArC3), 
99.8 (ArC1), 71.3 (Cp), 70.1 (Cp), 69.1 (5C, Cp'), 66.0 (Cp), 58.4 (2'), 55.7 (OCH3), 48.9 (4'), 
48.4 (5'),47.3 (3') and 46.4 (1'); 
IR (KBr) Vmax 3304br m, 3090m, 2938m, 2854m, 2817m, 2772m, 16315 (acridine), 1606m 
(acridine), 15615 (acridine), 1519m (OCH3), 1467s (NCH3), 1436s, 1347m, 12375, 1168m, 
1104m (ferrocene), 1074m, 1030m (v-s R-O-R'), 1001m (ferrocene), 926m, 871w, 826m, 761m, 
670w, 610w, 563w and 488m (ferrocene); 
HRMS (EI) mlz 556.1685 [M+, C30H33N40CIFe requires 556.4647], 511.1 [M+ - (HNMez)], 468.1, 
446.1 [M+ - (Cp + NMez)], 311.0, 255.1 [HC-Fp-CHz-NMezJ, 240.0 [Fp-CHz-NMez], 213.0,J 
191.0,156.1,121.0 [Cp-FeJ, 91.1 [CHz-Cp-CH2], 58.1 [NMezl and 55.9 [FeJ. 
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Preparation of disubstituted ureas 
Compound 94 
1-Benzyl-3-(2 -d i meth ylam i nom ethylferrocen yl meth yl)-
urea 
Prepared in the same manner as described for 37 
(method 4) using appropriate starting materials. 
Deep red oil; 
Yield: 109mg (73%); 
Rf (silica/CHzClz: MeOH = 80:20) 0.41; 
Chapter 8: General Experimental 
OH (400 MHz; CDCb) 7.30-7.22 (5H, m, U), 4.35-4.22 (4H, m, 1", 3'a, Cp), 4.10-4.04 (3H, m, 
Cp, 3'b), 4.06 (5H, Cp'), 3.77 (1H, d, 2JHH = 13, 2'a), 2.86 (1H, d, zJHH = 13, 2'b) and 2.11 (6H, s, 
1'); 
OC(H} (100.6 MHz; CDCI3) 128.5 (2C, U), 127.3 (U4), 127.1 (2C, U), 85.6 (IVC;,Cp), 70.8 (Cp), 
70.1 (Cp), 69.1 (5C, Cp'), 66.3 (Cp), 58.0 (2'), 44.6 (2C, 1'),44.5 (1") and 39.0 (3'); 
IR (thin film) V max 3311br m (NH), 3088m, 3030m, 2941m, 2857m, 2819m, 2775m, 1640s (v 
C=O), 1565s, 1495m, 1454m (NCH3), 1352m, 1265s, 1172w, 1105m (ferrocene), 1080w, 
1029m, 1002m (ferrocene), 819m (ferrocene), 734s (5 adjacent aromatic H) and 700m (5 
adjacent aromatic H); 
HRMS (EI) mlz 405.1497 [M+, C22H27N30Fe requires 405.3151, 360.1 [M+ - (NMe2)], 296.1, 
255.1 [HC-Fp-CH2-NMez1, 254.1, 240.1 [Fp-CHz-NMez]' 225.0, 199.0, 161.1, 134.1, 121.0 [Cp-
Fe], 91.0 [CHz-Cp-CHz] and 58.1 [NllJlez1. 
Compound 95 
1-Benz yl-3-[2-(7 -chloro-quinolin-4-ylam ino )-ethyl]-
urea 
Prepared in the same manner as described for 37 
(method 4) using appropriate starting materials. 
White crystalline solid; Yield: 124mg (45%); 
Rf (silica/CH2Clz: MeOH = 80:20) 0.47; 
OH (400 MHz; DMSO) 8.38 (1H, d, 3JHH = 6, ArCz-H), 8.16 (1H, d, 3JHH = 9, ArC5-H), 7.77 (1H, d, 
4JHH = 2, ArCa-H), 7.52 (1H, br t, NH), 7.43 (1H, dd, 4JHH = 2 and 3JHH = 9, ArCa-H), 7.28-7.15 
(5H, m, B), 6.57 (1 H, t, 3 JHHH = 6, NH), 6.53 (1 H, d, 3 JHH = 5, ArC3-H), 6.26 (1 H, t, 3 JHH = 6, NH), 
4.22 (2H, d, 3 JHH = 6, 1 ") (note - l' and 2' signals are obscured by the presence of the DMSO 
signal); 
OC{H} (100.6 MHz; DMSO) 159.5 (IVe, CO), 152.6 (ArCz), 150.9 ('vC), 149.7 (IVC), 141.4 (IVC) , 
134.1 (IVC) , 128.8 (2C, U), 128.2 (U4), 127.7 (2C, U), 127.2 (ArC6), 124.8 (ArC5), 124.5 (ArCa), 
99.3 (ArC3), 44.5,43.7 and 38.8 (1"); 
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IR (KBr) Ymax 3353s (NH), 1612s (7-chloroquinoline), 1584s (7-chloroquinoline), 1537m (7-
chloroquinoline), 1485m, 1451m, 1371w, 1334w, 1260w, 1198w, 1141m, 1097w, 1080w, 870m, 
803m, 760w, 736m (5 adjacent aromatic H), 700m (5 adjacent aromatic H), 645m and 456w; 
HRMS (EI) mlz 354.12527 [M+, C1sH1SN4035CI requires 354.12474], 248.1 [M+ - (CsH5-CHr 
NH)], 204.0 [M+ - (NHCONH-CH2-CsH5)], 192.0, 164.0, 133.0, 107.1,91.0 [CSH5-CH2J and 51.0. 
Synthesis of other derivatives 
Compound 96 
N-[3-(7 -Ch loro-qui nolin-4-ylamino )-ethyIJ-N-(2-
dimethylaminomethyl-ferrocenyl)-benzamide 
20 (200mg, 0.420mmol) was placed in a 50ml round 
bottomed flask followed by freshly distilled 
dichloromethane (10ml). Anhydrous triethylamine (0.1 ml, 0.756mmol) was then added followed 
·r 
by benzoyl chloride (0.044ml, 0.378mmol). The mixture allowed to stir at 25bC for 2 h. The 
solvent was removed under reduced pressure and the product purified using Silica gel 
chromatography. The product was isolated as yellow crystalline solid. 
Yield: 123mg (67%); mp: 133-135°C; 
Rf (silicalCH2Cb: MeOH = 80:20) 0.5; 
OH (300 MHz; COCI3) 8.35 (1 H, d, 3JHH = 5, ArC2-H), 8.201 (2H, m, A2), 7.87 (1 H, d, 4JHH = 2, 
ArCs-H), 7.48 (3H, m, A3, ArC5-H), 7.39 (1H, d, 3JHH = 10, Av.), 7.33 (1H, m, ArCs-H), 6.19 (1H, 
d, 3 JHH = 5, ArC3-H), 4.72 (1 H, d, 2 JHH = 16, 3'a), 4.34- 4.10 (6H, m, 3'b, 4', Cp), 4.08 (5H, s, 
Cp), 3.56 (1 H, d, 2JHH = 13, 2'a), 3.48-3.40 (2H, m, 5'), 2.97 (1 H, d, 2JHH = 13, 2'b), 2.21 (6H, s, 
1') 
OC{H) (100.6 MHz; COCh) 159.1 (CO), 152.3 (ArC2), 150.5 ('vC), 149.5 (IVC), 134.8 (IVC) , 129.4, 
(Av.) 128.6 (ArCs), 128.8 (A3) , 127.1 (A2) , 124.9 (ArCs), 122.4 (ArCs), 118.1 (IVC) , 102.8 ('vC), 
99.1 (ArC3), 84.2 (2C, IVC), 71.6 (Cp), 70.8 (Cp), 69.5 (5C, Cp'), 66.2 (Cp), 57.2 (2'), 44.7 (2C, 
1') and 42.7 (3'); 
IR (KBr) Ymax 3418br m (NH), 3061m, 2935m, 2765m, 1612s (7-chloroquinoline), 1580s (7-
chloroquinoline), 1453m (NCH3). 1425m, 1370m, 1286m, 1239m, 1210w, 1160m, 1138m, 
1104w (ferrocene), 1022w. 930w, 814m (ferrocene), 703w, 603w and 489w (ferrocene); 
HRMS (EI) m/z 580.16894 [M+, C32H33N403SCIFe requires 580.16923J, 535.1 [M+ - (NMe2)]. 
470.1, 430.1, 380.0, 331.1, 255.1 [HC-Fp-CHrNMe21, 213.1. 191.0 [CICgNH5-NH-CH2]' 105.0, 
91.0 [CH2-Cp-CH2J, 77.0 and 58.1 [CHrNMe21. 
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Compound 97 
N~Benzyl~N~(7 ~chloro-quinolin-4-yl)-N~(2-
dimethylaminomethyl-ferrocenyl)-ethane~1 ,2~diamine 
The compound was prepared by literature 
procedure. 26 The product was purified using silica gel CI 
chromatography. 
Orange glassy solid; Yield: 25mg (30%) 
Rf (silica/CH2CI2: MeOH = 80:20) 0.4; 
Chapter 8: General Experimental 
H 
N~N~N/ N Fe I U ~ 
OH (400 MHz; CDCI3) 8.41 (1H, d, 3JHH := 5, ArC2-H), 7.91 (1H, d, 4JHH := 2, ArCs-H), 7.53 (1H, d, 
3 JHH = 9, ArCs~H), 7.35-7.16 (6H, m, ArC6-H, Ph), 6.19 (1 H, d, 3JHH := 5, ArC3-H), 5.86 (1 H, br, 
NH), 4.35-4.09 (3H, m, Cp), 4.00 (5H, s, Cp'), 3.75 (1 H, d, 2JHH = 13, 3'a), 3.57 (1 H, d, 2JHH = 
12, 2'a), 3.47 (1 H, d, 2JHH = 13, 3'b), 3.35 (2H, s, 1"), 3.20-3.04 (2H, m, 5'), 2.97 (1 H, d, 2JHH = 
12, 2'b), 2.90-2.78 (2H, m, 4') and 2.12 (6H, s, 1'); 
IV IV IV,r" OC{H} (75.5 MHz; CDCb) 151.8 (ArCz), 150.2 ( C), 139.6 ( C), 134.9 ( C), 129.,1 (2C, Ph), 128.5 
(2C, Ph), 128.4 (ArCa), 127.3 (Ph), 124.9 (ArCa), 122.1 (ArCs), 100.0 (ArC3), 84.4 (IVC, Cp), 
83.6 (IVC) , 71.5 (Cp), 70.9 (Cp), 69.4 (5C, Cp'), 69.3 (Cp), 59.4 (1 "), 58.1 (2'), 53.0 (3'), 51.5 
(4'),45.6 (2C, 1') and 40.5 (5'); 
IR (thin film) Vmax 3323br m (NH), 3085m, 3025m, 2941m, 2853m, 2815m, 2772m, 1611m (7-
chloroquinoline), 1581vs (7-chloroquinoline), 1529m (7-chloroquinoline), 1452m (NCH3 ), 
1368m, 1329m, 1262w, 1217w, 1170w, 1136m, 1105m (ferrocene), 1077w, 1035m, 1001m 
(ferrocene), 907w, 877m, 809m (ferrocene), 753s (5 adjacent aromatic H) and 700m (5 
adjacent aromatic H); 
HRMS (El) m/z 566.19074 [M+, C32H3sN/sCIFe requires 566.18996], 521.1 [M+ - (NMe2)], 455.1, 
430.1, 375.1, 344.1, 317.1, 310.1, 255.1 [HC-Fp-CHrNMe21, 213.0, 192.1, 163.0 [CICsNHs], 
121.0 [Cp-Fe], 91.0 [CH2-Cp-CH21 and 58.1 [CHz-NMez]. 
Compound 112 
[(N,N-Dimethylamino)methyl]ferrocenecarboxylic acid 
The work-up procedure follows a literature procedure27 
[(N,N-dimethylamino)methyl]ferrocene 28 (0.5ml, 2.509mmol) was 
placed in a centrifuge tube. Anhydrous diethyl ether (10ml) was added 
and the mixture cooled to -78 cC. tert-Butyllithium (1.5ml, 1.7M solution in pentane, 2.509mmol) 
was then added. The mixture was allowed to stir for 20 minutes before adding crushed dry ice 
(± 19). The mixture was allowed to stir at -78°C for a further 2 h. The mixture was then allowed 
to warm to room temperature. The centrifuge tube was then sealed with a rubber septum and 
centrifuged. The solvent was syringed off and the solid product washed with diethyl ether and 
centrifuged again. This process was repeated three times. The product was dissolved in 
methanol and the solvent removed under reduced pressure. The product was purified using 
silica gel chromatography eluting with 10% diethyl ether in methanol. The product was then 
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Chapter 8: General Experimental 
dissolved in dichloromethane, dried over sodium sulfate and filtered, before removing the 
solvent under reduced pressure. The product was dried in vacuo and isolated as a hygroscopic 
yellow crystalline solid. Yield: 470mg (67%); 
OH (300 MHz; CDCb) 4.96 (1H. m, CpH-aCOOH), 4.35 (1H, d, 2JHH = 13, 2'a), 4.26 (1H, t, 3JHHH 
= 2, CpH-~COOH), 4.20 (1H, m, CpH-aCH2NMe2), 4.17 (5H, s, Cp), 3.21 (1H, d, 2JHH = 13, 2'b) 
and 2.37 (6H, s, 1 '); 
OC{H) (75.5 MHz; CDCI3) 173.6 (COOH), 79.0 (IVC, Cp), 76.4 (IVC, Cp), 74.2 (CpC-aCOOH), 72.0 
(CpC-~COOH), 70.7 (5C, Cp), 68.6 (CpH-aCH2NMe2), 58.0 (2') and 42.4 (2C, 1'). 
Compound 113 
[(N,N-Dimethylamino)methyl]ferrocenecarboxylic acid chloride 
[(N,N-Dimethylamino)methyl]ferrocenecarboxylic acid 112 (0.934g, 
3.256mmol) was placed in a 100 ml round bottomed flask. Anhydrous 
dichloromethane (10ml) was added. The mixture was then degassed 
before sealing with a rubber septum. The mixture was cooled to O°C 
before adding oxalyl chloride (0.56ml, 6.506mmol) dropwise. The mixture was allowed to warm 
slowly to room temperature by stirring in an unlagged ice bath. After 3 h the solvent was 
removed under reduced pressure and the product dried in vacuo. The product was used without 
further purification or characterization. 
Bright red glassy solid. 
Compound 114 
2-Dimethylaminomethyl-ferrocenecarboxylic acid [2-(7-
ch loro-q u i nolin-4-ylam ino )-ethyl]-am ide 
32 (805mg, 3.582mmol) was placed in a 100ml round 
bottomed flask followed by anhydrous dichloromethane 
(15ml). Anhydrous triethylamine (0.85ml, 6.512mmol) 
was then added followed by a solution of 113 (3.256mmol) in anhydrous dichloromethane 
(15ml) and the mixture allowed to stir at 25°C for 2 h. The solvent was removed under reduced 
pressure and the product purified using silica gel chromatography. The product was isolated as 
a red oil. Yield: 756mg (43%); 
Rf (silica/CH2CI2: MeOH: Et3N = 80:20:1) 0.33; 
OH (300 MHz; CD30D) 8.39 (1H, d, 3JHH = 6, ArC2-H), 8.22 (1H, d, 3JHH = 9, ArC5-H), 7.80 (1H, 
d, 4JHH = 2, ArCs-H), 7.56 (1H, dd, 4JHH = 2 and 3JHH = 9, ArC6-H)), 6.73 (1 H, d, 3JHH = 6, ArC3-
H), 5.00-4.99 (1H, m, Cp), 4.72 (1H, d, 2JHH = 13, 2'a), 4.61 (1H, m, Cp), 4.51 (1H, t, 3JHHH = 3, 
Cp), 4.17 (5H, s, Cp'), 3.86 (1H, d, 2JHH = 13, 2'b), 3.82-3.68 (2H, m, 4'),3.44-3.52 (2H, m, 5') 
and 2.71 (6H, s, 1'); 
OC{H) (75.5 MHz; CD30D) 174.6 (3'), 154.2 (ArC2), 150.2 (IVC), 139.5 (IVC), 137.8 (IVC) , 127.7 
(ArCa), 125.7 (ArC6), 124.8 (ArC5), 118.2 ('vC), 99.9 (ArC3), 72.1 (Cp), 71.8 (Cp), 71.7 (Cp), 
69.0 (5C, Cp'), 53.9 (2'), 44.5 (2C, 1'),42.8 (4') and 39.3 (5'); 
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IR (thin film) Vmax 3426br s (NH), 1632s (7-chloroquinoline), 1582m (7-chloroquinoline), 1542m 
(7-chloroquinoline), 1452m (NCH3), 1368w, 1313w, 1265m, 1141w, 1106w (ferrocene), 1004w 
(ferrocene), 896w, 737m and 701w; 
MS (FAB) m/z 491.1 [M+ C2sH27N4CIFeO requires 491.1), 446.2 [M+ - (NMe2)), 371.1, 326.1, 
315.2,270.1 [OC-Fp-CH2-NMe2). 239.3,199.0 and 179.1 
I3-Haematin Inhibition 
Haemin (15mg, 0.023 mmol) was placed in a large sample vial followed by 0.1 M NaOH (3.0m!). 
The solution was placed on a thermostatted hot plate situated on a shaker. This was allowed to 
equilibrate at 60°C. 3 mol equivalents (0.069mmol) of the relevant compound was added. 1.0M 
HCI (0.3ml) and 12.9M acetate buffer solution pH 5 (1.74ml) were also warmed to 60°C. These 
were then added to the haemin solution and the mixture allowed to shake for 30 min. The 
mixture was then cooled on ice. The product was then filtered on an 8IJm cellulose 
acetate/nitrate Millipore filter type SC and extensively washed with water. The black product 
~/ 
was transferred to a sample vial and dried in the presence of phosphorus peliltoxide and silica 
in a vacuum desiccator 5 days.28 The product was then analysed by IR spectroscopy. 
These experiments were carried out on two separate occasions. In both cases a 'blank' 
experiment was performed with no addition of compound to ensure [3-haematin formation was 
occurrIng. In addItion to this, a 'control' was also performed, adding chloroquine diphosphate to 
ensure [3-haematin inhIbition was occurring. 
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Appendix A 
Numbering System for NMR 
Chloroquine 
1" 2' l' 
I 4' ( 
~N~1' 
5 H~ 6' 5' 3' 2' 
6~3 
CI~NjJ2 
8 
In the NMR assignment in Chapter 8, the aromatic protons are labelled as ArC2-H, and the carbons 
are ArC2. This is true for all qUinoline systems. The other protons and carbons are labelled as 
indicated here. 
Ferroquine analogues 
2 3 
N N~N~~N/ b.~ H 4' 3' 2' l' 5' H ~ I 8 If ~ 5 Fe l' /-6 ~ 
CI 
In addition to the above numbering, the substituted Cp ring is denoted as Cp, and the free Cp ring is 
denoted as Cp'. Incremental CH2 groups are placed between 5' and NH and are numbered 
sequentially as 6', 7' etc. 
Substituted Ferroquine Derivatives 
g-~ ~~N~N/ If ~ ~ ~ I 
HN 0 Fe 
/-~111 ~ 
CI I "-'::: U1 
U4 #U2 
U3 
Forthe ureas and sulphonamides and other derivatives, the aromatic protons are labelled as U1 or 51 
etc. from the point of attachment to linker unit i.e urea etc. In cases where unambiguous assignment 
of each proton or carbon is not possible, these are merely indicated as U or 5 etc, in order to 
distinguish them from the signals arising from the ferroquine analogue. 
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Appendix B 
Data for xray crysta.1 structure of 20 
Table 1. Crystal data and structure refmement for 20. 
Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
Z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta = 27.49° 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
20 
Cl Fe C25 H29 N4 0 
476.82 
173(2) K 
0.71073 A 
Monoclinic 
P 21fc 
a= 10.7012(3) A 
b = 16.2573(4) A 
c = 13.7853(3) A 
2395.55(1) A3 
4 
1.322 Mg/m3 
0.760 mm-1 
1000 
0.39 x 0.35 x 0.29 mm3 
1.91 to 27.49°. 
-13<=h<=13, -20<=k<=20, -17<=1<=17 
10265 
5459 [ROnt) 0.0240] 
99.3 % 
0.8097 and 0.7559 
Full-matrix least-squares on F2 
5459/2/290 
1.040 
Rl = 0.0344, wR2 = 0.0768 
Rl = 0.0552, wR2 = 0.0843 
0.255 and -0.295 e.k3 
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Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 103) 
for 181. U( eq) is defined as one third of the trace ofthe orthogonalized UU tensor. 
x y z U(eq) 
Fe 1541(1) 2030(1) 4554(1) 29(1) 
Cl 1423(1) 8834(1) 3377(1) 55(1) 
C(1) 1580(3) 3279(2) 4410(2) 31(1) 
C(18) 2310(3) 7946(2) 3248(2) 32(1) 
N(l) 4464(2) 3902(1) 4152(2) 28(1) 
C(2) 2811(3) 2965(2) 4614(2) 29(1) 
C(l6) 3690(3) 6956(2) 3988(2) 30(1) 
C(6) 1933(3) 1311(2) 3392(2) 41(1) 
C(19) 2416(3) 7598(2) 2358(2) 31(1) 
C(20) 3213(3) 6919(2) 2243(2) 29(1) 
C(15) 3870(3) 6591(2) 3074(2) 26(1) 
N(3) 3324(3) 6623(2) 1321(2) 37(1) 
C(8) 980(3) 840(2) 4741(2) 43(1) 
C(ll) 3897(3) 3080(2) 3988(2) 32(1) 
N(2) 5297(2) 5557(1) 3730(2) 32(1) 
C(14) 4687(3) 5900(2) 2946(2) 29(1) 
C(5) 827(3) 3048(2) 5193(2) 41(1) 
C(3) 2809(3) 2551(2) 5526(2) 40(1) 
C(13) 6128(3) 4852(2) 3682(2) 38(1) 
C(7) 2127(3) 865(2) 4269(3) 45(1) 
C(12) 5461(3) 4037(2) 3483(2) 37(1) 
C(22) 4802(3) 5623(2) 1998(2) 38(1) 
C(21) 4108(3) 6004(2) 1243(2) 41(1) 
C(17) 2935(3) 7625(2) 4080(2) 34(1) 
C(10) 671(3) 1558(2) 3322(2) 39(1) 
C(4) 1590(4) 2598(2) 5872(2) 48(1) 
C(9) 83(3) 1271(2) 4155(2) 40(1) 
N(4) 1779(2) 4556(1) 3455(2) 32(1) 
C(23) 1181(3) 3744(2) 3508(2) 36(1) 
C(25) 1255(3) 5122(2) 4140(3) 50(1) 
C(24) 1604(3) 4876(2) 2465(2) 48(1) 
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Table 3. Bond lengths [AJ and angles [0J for 181. 
Fe-C(4) 2.037(3) 
Fe-C(2) 2.038(3) 
Fe-C(7) 2.040(3) 
Fe-C(1) 2.040(3) 
Fe-C(5) 2.041(3) 
Fe-C(6) 2.042(3) 
Fe-C(9) 2.044(3) 
Fe-C(3) 2.045(3) 
Fe-C(8) 2.046(3) 
Fe-C(IO) 2.046(3) 
CI-C(l8) 1.741(3) 
C(I)-C(2) 1.428(4) 
C(1)-C(5) 1.428(4) 
C(1)-C(23) 1.500(4) 
C(18)-C(19) 1.361(4) 
C(18)-C(17) 1.402(4) 
N(1)-C(12) 1.459(4) 
N(1)-C(1I) 1.481(3) 
C(2)-C(3) 1.427( 4) 
C(2)-C(11 ) 1.491(4) 
C( I 6)-C(l 7) 1.364(4) 
C(16)-C(15) 1.414(4) 
C(6)-C(10) 1.408(5) 
C(6)-C(7) 1.417(5) 
C( 19)-C(20) 1.409(4) 
C(20)-N(3) 1.369(4) 
C(20)-C(l5) 1.419(4) 
C(15)-C(14) 1.439(4) 
N(3)-C(21) 1.317(4) 
C(8)-C(9) 1.411(5) 
C(8)-C(7) 1.417(5) 
N(2)-C(14) 1.356(4) 
N(2)-C(13) 1.454(4) 
C(14)-C(22) 1.394(4) 
C(5)-C(4) 1.416(5) 
C(3)-C(4) 1.412(5) 
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CC I3)-CC 12) 1.523(4) 
C(22)-CC21 ) 1.395(4) 
C(lO)-CC9) 1.414(4) 
N(4)-CC25) 1.450(4) 
N(4)-CC24) 1.465(4) 
N(4)-CC23) 1.469(3) 
CC 4)-Fe-CC2) 68.71(13) 
C(4)-Fe-CC7) 126.68(14) 
C(2)-F e-C(7) 119.34(13) 
CC 4)-Fe-CC1) 68.66(12) 
C(2)-Fe-CCl) 41.01(11) 
C(7)-Fe-CC1) 153.85(14) 
CC 4)-Fe-CC5) 40.63(14) 
C(2)-Fe-CC5) 68.92(13) 
C(7)-Fe-CC5) 163.99(14) 
C(1)-Fe-CC5) 40.98(12) 
C( 4)-Fe-CC 6) 164.03(15) 
C(2)-Fe-CC6) 107.29(13) 
C(7)-Fe-CC6) 40.61(13) 
C(1)-Fe-CC6) 119.18(12) 
C(5)-Fe-CC6) 153.95(14) 
C(4)-Fe-CC9) 120.02(14) 
C(2)-Fe-CC9) 163.79(12) 
C(7)-Fe-CC9) 68.00(14) 
C(1)-Fe-CC9) 126.38(13) 
C(5)-Fe-CC9) 107.99(14) 
C(6)-Fe-CC9) 68.07(13) 
CC 4)-Fe-C(3) 40.47(14) 
C(2)-Fe-CC3) 40.90(11) 
C(7)-Fe-CC3) 108.07(14) 
CC1 )-Fe-CC3) 68.65(12) 
C(5)-Fe-C(3) 68.35(14) 
C(6)-Fe-CC3) 126.60(14) 
C(9)-Fe-CC3) 154.21(13) 
C(4)-Fe-CC8) 108.12(13) 
C(2)-Fe-CC8) 154.07(13) 
C(7)-Fe-CC8) 40.60(14) 
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C(1 )-Fe-C(8) 163.87(14) 
C(5)-Fe-C(8) 126.44(14) 
C(6)-Fe-C(S) 68.30(13) 
C(9)-Fe-C(8) 40.37(13) 
C(3)-Fe-C(S) 119.89(13) 
C(4)-Fe-C(1O) 154.37(15) 
C(2)-Fe-C(lO) 126.14(12) 
C(7)-Fe-C(lO) 67.91(13) 
C(1)-Fe-C(10) 107.65(12) 
C(5)-Fe-C(10) 119.86(14) 
C(6)-Fe-C(10) 40.30(13) 
C(9)-Fe-C(10) 40.46(12) 
C(3)-Fe-C(10) 163.88(14) 
C(8)-Fe-C( 1 0) 68.00(13) 
C(2)-C(1)-C(5) 107.S(3) 
C(2)-C(1)-C(23) 124.5(3) 
C(5)-C(1 )-C(23) 127.7(3) 
C(2)-C(1 )-Fe 69.41(16) 
C(5)-C(1 )-Fe 69.53(16) 
C(23)-C(1 )-Fe 125.22(19) 
C(19)-C(lS)-C(17) 121.8(3) 
C( 19)-C( 18)-CI 120.4(2) 
C( 17)-C( 18)-Cl 117.8(2) 
C(12)-N(1 )-C(lI) 110.2(2) 
C(3)-C(2)-C(1 ) 107.6(3) 
C(3)-C(2)-C(Il) 127.1(3) 
C( I)-C(2 )-C( 11 ) 125.3(3) 
C(3)-C(2)-Fe 69.83(17) 
C(l )-C(2)-Fe 69.58(16) 
C(11 )-C(2)-Fe 127.33(19) 
C(17)-C(16)-C(I5) 121.6(3) 
C(1O)-C(6)-C(7) 107.8(3) 
C(10)-C(6)-Fe 70.01(18) 
C(7)-C(6)-Fe 69.62(18) 
C( 18)-C( 19)-C(20) 120.2(3) 
N(3)-C(20)-C(l9) 117.3(2) 
N(3)-C(20)-C(15) 123.8(3) 
C(l9)-C(20)-C(15) 118.9(3) 
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C(16)-C(15)-C(20) 118.5(3) 
C(l6)-C(15)-C(14 ) 123.1(2) 
C(20)-C(l5)-C(14) 118.4(2) 
C(21)-N(3)-C(20) 115.3(3) 
C(9)-C(8)-C(7) 107.7(3) 
C(9)-C(8)-Fe 69.74(17) 
C(7)-C(8)-Fe 69.48(17) 
N ( 1 )-C( 11 )-C(2) 110.5(2) 
C(14)-N(2)-C(13) 124.1(3) 
N(2)-C(14)-C(22) 123.6(3) 
N(2)-C(14)-C(15) 119.7(2) 
C(22)-C( 14 )-C( 15) 116.6(3) 
C( 4)-C( 5)-C( 1) 107.9(3) 
C(4)-C(5)-Fe 69.56(18) 
C( 1 )-C(5)-Fe 69.49(17) 
C( 4)-C(3)-C(2) 108.2(3) 
C( 4)-C(3)-Fe 69.47(18) 
C(2)-C(3)-Fe 69.27(16) 
N(2)-C(l3)-C(12) 114.3(2) 
C( 6)-C(7)-C(8) 10S.1(3) 
C(6)-C(7)-Fe 69.77(17) 
C(8)-C(7)-Fe 69.92(1S) 
N(1)-C(12)-C(13) 111.5(2) 
C(14)-C(22)-C(21) 119.2(3) 
N(3)-C(21 )-C(22) 126.7(3) 
C(16)-C(17)-C(IS) 11S.S(3) 
C( 6)-C(l 0)-C(9) 10S.2(3) 
C(6)-C(10)-Fe 69.69(18) 
C(9)-C(10)-Fe 69.68(18) 
C(3)-C(4)-C(5) 108.5(3) 
C(3)-C(4)-Fe 70.06(18) 
C(5)-C(4)-Fe 69.81(18) 
C(8)-C(9)-C( 1 0) 108.2(3) 
C(S)-C(9)-Fe 69.S9(18) 
C(10)-C(9)-Fe 69.S6(18) 
C(25)-N(4)-C(24) 110.1(3) 
C(25)-N( 4)-C(23) 110.S(2) 
C(24)-N(4)-C(23) 109.2(2) 
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N(4)-C(23)-C(1) 112.8(2) 
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Table 4. Anisotropic displacement parameters (Alx 103) for 181. The anisotropic 
displacement factor exponent takes the form: _2p2[ h2 a*2U Il + ... + 2 h k a* b* UI2 ] 
UII U22 U33 U23 Ul3 UI2 
Fe 39(1) 21(1) 28(1) -1 
Cl 65(1) 52(1) 48(1) -3(1) -7(1) 26(1) 
C(l) 39(2) 20(1) 33(2) -3(1) 0(1) -4(1 ) 
C(18) 29(2) 31(2) 35(2) 2(1) -2(1) 0(1) 
N(l) 27(1) 21(1) 36(1) .1(1) -3(1) 1(1) 
C(2) 38(2) 21(1) 28(1) -2(1) -5(1) -5(1 ) 
C(16) 35(2) 30(2) 25(1) 4(1) -8(1) -3(1) 
C(6) 50(2) 29(2) 43(2) -11(1) 13(2) -8(1) 
C(19) 30(2) 35(2) 28(2) 7(1) -4(1) -5(1) 
C(20) 31(2) 31(2) 24(1) 2(1) 0(1) -10(1 ) 
C(15) 26(2) 26(1) 26(1) 2(1) -1(1) -7(1) 
N(3) 47(2) 41(2) 23(1) 4(1) 3(1) -2(1) 
C(8) 63(2) 26(2) 41(2) 4(1) 2(2) -15(2) 
C(11) 34(2) 26(1) 36(2) -3(1) -4(1) -2(1) 
N(2) 33(1) 26(1) 37(1) 1(1) -5(1) 0(1) 
C(14) 29(2) 28(1) 31(2) 2(1) 2(1) -9(1) 
C(5) 51(2) 29(2) 44(2) -7(1) 16(2) -2(1) 
C(3) 57(2) 29(2) 32(2) 1(1) -9(2) -8(2) 
C(13) 28(2) 35(2) 49(2) 3(2) 0(1) 1(1) 
C(7) 52(2) 24(2) 59(2) -5(2) -3(2) 2(1) 
C(12) 34(2) 29(2) 47(2) 0(1) 7(1) 5(1) 
C(22) 39(2) 36(2) 39(2) -1(1) 10(1) -1(1) 
C(21) 53(2) 46(2) 26(2) -3(1) 10(1) -6(2) 
C(17) 39(2) 34(2) 27(2) -3(1) -4(1) -2(1) 
C(10) 50(2) 34(2) 33(2) -5(1) 0(1) -9(2) 
C(4) 81(3) 34(2) 28(2) -2(1) 9(2) -8(2) 
C(9) 42(2) 37(2) 41(2) -6(1) 4(2) -13(2) 
N(4) 29(1) 26(1) 39(1) 6(1) -4(1) -3(1 ) 
C(23) 38(2) 27(2) 42(2) 4(1) -8(1) -5(1) 
C(25) 46(2) 33(2) 71(2) -4(2) 7(2) 1(2) 
C(24) 46(2) 44(2) 51(2) 19(2) -15(2) -12(2) 
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Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) 
for 18I. 
x y z U(eq) 
H(l6) 4lO4 6729 4551 36 
H(6) 2546 1423 2934 49 
H(19) 1951 7814 1811 37 
H(8) 840 580 5344 52 
H(llA) 4530 2649 4139 38 
H(1lB) 3614 3023 3297 38 
H(5) -33 3174 5250 49 
H(3) 3507 2289 5846 48 
H(l3A) 6623 4808 4306 45 
H(l3B) 6721 4949 3165 45 
H(7) 2893 623 4501 54 
H(12A) 5lO2 4034 2808 44 
H(l2B) 6074 3582 3549 44 
H(22) 5346 5179 1868 45 
H(21) 4211 5796 608 50 
H(l7) 2836 7869 4698 41 
HOO) 282 1864 2805 47 
H(4) 1326 2367 6461 57 
H(9) -768 1354 4296 48 
H(23A) 1393 3417 2932 43 
H(23B) 262 3817 3488 43 
H(25A) 1698 5648 4120 74 
H(25B) 1345 4891 4796 74 
H(25C) 366 5209 3966 74 
H(24A) 708 4909 2287 72 
H(24B) 2011 4508 2014 72 
H(24C) 1976 5426 2432 72 
H(2) 5230(30) 5844(18) 4434(11) 60(10) 
H(l) 3712(17) 4332(13) 3982(19) 36(8) 
"--" 
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Table 7. Hydrogen bonds for 181 [A and 0]. 
D-H. .. A d(D-H) d(H. .. A) d(D ... A) «DHA) 
-
N(l) -- H(l) .. N(4) [Intra] l.0828 2.1897 3.1691 149.27 
N(2) -- H(2) .. N(l)' [ symm.1] 1.0819 2.0043 3.0481 161.12 
C(l6) -- H(l6) .. N(l)' [symm.l] 0.9500 2.5177 3.4561 169.49 
C(17) -- H(l7) .. N(3)" [symm.2] 0.9500 2.4189 3.3301 160.64 
'= 1-x,1-y,1-z 
" x,3/2-y,1I2+z 
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